{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.10120"}, {"@name": "filename", "#text": "15186_DO_Paula_Oliveira_Original.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE DE S\u00c3O PAULO \nFACULDADE DE ODONTOLOGIA DE RIBEIR\u00c3O PRETO \n\nDepartamento de CTBMF e Periodontia \n\nPrograma de P\u00f3s-Gradua\u00e7\u00e3o em Odontologia (Periodontia) \n\n \n \n \n \n \n \n \n \n \n \n \n\nPAULA GABRIELA FACIOLA PESS\u00d4A DE OLIVIERA  \n \n \n \n \n \n \n \n \nAvalia\u00e7\u00e3o de uma nova superf\u00edcie de implante recoberta por hidroxiapatita \n\nem escala nanom\u00e9trica. Estudo in vivo em ratos \n\n \n \n \n \n \n \n\n \n \n\nRIBEIR\u00c3O PRETO \u2013 SP \n\n2018 \n\n\n\nPAULA GABRIELA FACIOLA PESS\u00d4A DE OLIVIERA  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nAvalia\u00e7\u00e3o de uma nova superf\u00edcie de implante recoberta por hidroxiapatita \n\nem escala nanom\u00e9trica. Estudo in vivo em ratos \n\n \n\n \n\nTese apresentada \u00e0 Faculdade de Odontologia de Ribeir\u00e3o Preto da \n\nUniversidade de S\u00e3o Paulo, para obten\u00e7\u00e3o do titulo de Doutora em \n\nOdontologia (Periodontia). \n\n \n\n\u00c1rea de Concentra\u00e7\u00e3o: Periodontia \n\nOrientador: Prof. Dr. S\u00e9rgio Lu\u00eds Scombatti de Souza  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nRIBEIR\u00c3O PRETO \u2013 SP \n\n2018 \n\n\n\nAutorizo a reprodu\u00e7\u00e3o e divulga\u00e7\u00e3o total ou parcial deste trabalho, por qualquer meio \n\nconvencional ou eletr\u00f4nico, para fins de estudo e pesquisa, desde que citada a fonte. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCataloga\u00e7\u00e3o da Publica\u00e7\u00e3o \n\nBiblioteca Central do Campus USP - Ribeir\u00e3o Preto. \n\nFaculdade de Odontologia de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n  \n\n \nOliveira, Paula Gabriela Faciola Pess\u00f4a de \n \nAvalia\u00e7\u00e3o de uma nova superf\u00edcie de implante recoberta por \n\nhidroxiapatita em escala nanom\u00e9trica. Estudo in vivo em ratos. Ribeir\u00e3o \nPreto, 2018. \n\n \n163 f. : il. ; 30cm \n \nTese de Doutorado apresentada \u00e0 Faculdade de Odontologia de \n\nRibeir\u00e3o Preto/ USP. \u00c1rea de concentra\u00e7\u00e3o: Periodontia. \n \nOrientador: Souza, S\u00e9rgio Lu\u00eds Scombatti de \n \n1. Diabetes Mellitus. 2. Implantes Dent\u00e1rios. 3. Express\u00e3o G\u00eanica.  \n4. Microtomografia por Raio-X. 5. Histologia. \n \n\n\n\nFOLHA DE APROVA\u00c7\u00c3O \n \n \n \n\nOLIVEIRA, Paula Gabriela Faciola Pess\u00f4a de   \n\n \nAvalia\u00e7\u00e3o de uma nova superf\u00edcie de implante recoberta por hidroxiapatita em escala \n\nnanom\u00e9trica. Estudo in vivo em ratos. \n\n \nTese apresentada \u00e0 Faculdade de Odontologia de \nRibeir\u00e3o Preto da Universidade de S\u00e3o Paulo, para \nobten\u00e7\u00e3o do t\u00edtulo de Doutora em Odontologia \n(Periodontia). \n\n \n \nAprovado em:___/___/___ \n \n\nBanca Examinadora \n \n \n\nProf.(a). Dr.(a).:  _____________________________________________________________  \n\nInstitui\u00e7\u00e3o:  _________________________________________________________________  \n\nAssinatura:  _________________________________________________________________  \n\n \n\nProf.(a). Dr.(a).:  _____________________________________________________________  \n\nInstitui\u00e7\u00e3o:  _________________________________________________________________  \n\nAssinatura:  _________________________________________________________________  \n\n \n\nProf.(a). Dr.(a).:  _____________________________________________________________  \n\nInstitui\u00e7\u00e3o:  _________________________________________________________________  \n\nAssinatura:  _________________________________________________________________  \n\n \n\nProf.(a). Dr.(a).:  _____________________________________________________________  \n\nInstitui\u00e7\u00e3o:  _________________________________________________________________  \n\nAssinatura:  _________________________________________________________________  \n\n  \n\n\n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nPesquisa realizada nos Laborat\u00f3rios de Biologia \n\nMolecular, Histologia, LAB 3D BIO, e Biot\u00e9rio \n\nda Faculdade de Odontologia de Ribeir\u00e3o Preto \u2013 \n\nUSP, e no laborat\u00f3rio de Biomateriais da \n\nUniversidade de Nova York, com aux\u00edlio \n\nfinanceiro da Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa \n\ndo Estado de S\u00e3o Paulo (FAPESP) e do \n\nConselho Nacional de Desenvolvimento \n\nCient\u00edfico e Tecnol\u00f3gico (CNPQ). \n\n \n\n  \n\n\n\nDEDICAT\u00d3RIA \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDedico esse trabalho aos grandes amores \n\nda minha vida: S\u00edvia, Paulo, Adelina, \n\nPhilippe, Alann, Bernardo e Th\u00e9o. Sem \n\nvoc\u00eas, nada seria poss\u00edvel.  \n\n  \n\n\n\nAGRADECIMENTOS \n \n\nA materializa\u00e7\u00e3o desse sonho s\u00f3 foi poss\u00edvel porque Deus colocou no meu caminho \n\npessoas incr\u00edveis, que me encheram de amor e sem as quais eu nada seria. A voc\u00eas o meu \n\neterno agradecimento. \n\n \n\nAgrade\u00e7o a Deus por todas as oportunidades.  \n\nA Nossa Senhora de Nazar\u00e9, minha fonte inesgot\u00e1vel de f\u00e9. \n\nAos meus pais Paulo e S\u00edlvia, pelo sacrif\u00edcio que jamais poderei retribuir. Mesmo \n\nausentes fisicamente, estiveram do meu lado em cada momento dessa trajet\u00f3ria, acreditando \n\nem mim e me ajudando a alcan\u00e7ar todos os meus objetivos. Voc\u00eas s\u00e3o os grandes \n\nrespons\u00e1veis por mais essa conquista. \n\nAos meus irm\u00e3os Adelina e Philippe, que mesmo inconscientemente sempre me \n\nincentivaram. Pelo amor, amizade, e apoio depositados. Sem voc\u00eas, o sonho n\u00e3o seria \n\nposs\u00edvel.  \n\nAo meu grande amor Alann Thaffarell, meu parceiro da vida e porto seguro. \n\nObrigada por estar presente em todos os momentos dessa caminhada e ser a paz do meu \n\ncora\u00e7\u00e3o. Sua presen\u00e7a torna meus dias mais felizes e cheios de vida.  \n\nAo Bernardo, meu presente da vida, amor mais lindo do meu cora\u00e7\u00e3o. Ser sua \n\nmadrinha \u00e9 a maior alegria que eu poderia ter. Agrade\u00e7o aos amigos Juliana e Diogo pela \n\namizade verdadeira e por serem os grandes respons\u00e1veis por tamanha felicidade.  \n\nAos meus av\u00f3s, L\u00e9a e Herminio, Joana e Alberto, os melhores do mundo, fonte de \n\nmuita inspira\u00e7\u00e3o. \n\nUm agradecimento mais do que especial ao meu orientador e amigo, Prof. Dr. S\u00e9rgio \n\nLu\u00eds Scombatti de Souza. Voc\u00ea exerce como ningu\u00e9m a arte de ensinar. Suas palavras de \n\nest\u00edmulo, aten\u00e7\u00e3o e disponibilidade foram indispens\u00e1veis para a realiza\u00e7\u00e3o desse e muitos \n\noutros sonhos. N\u00e3o hesito em afirmar que voc\u00ea foi o maior incentivador e refer\u00eancia que tive \n\ndurante a vida acad\u00eamica. \u00c9 um orgulho enorme ter sido sua aluna. Serei eternamente grata. \n\nAo prof. Dr. Paulo Guilherme Coelho por todas as oportunidades oferecidas, por \n\nacreditar no meu potencial e pela excelente conviv\u00eancia no per\u00edodo em que estive em Nova \n\nYork. Agrade\u00e7o tamb\u00e9m ao Lukasz Witek pela amizade, paci\u00eancia e ensinamentos.  \n\n\n\nAos professores do programa de p\u00f3s gradua\u00e7\u00e3o em Periodontia da FORP \u2013 USP: Prof. \n\nDr. Arthur Bel\u00e9m Novaes J\u00fanior, pela oportunidade de participar do programa e pelos \n\nconhecimentos transmitidos; prof. Dr. M\u00e1rio Taba J\u00fanior pelo agrad\u00e1vel conv\u00edvio, pelos \n\nensinamentos e pelo exemplo de dedica\u00e7\u00e3o; Profa. Dra. Daniela Bazan Palioto, pela sua \n\naten\u00e7\u00e3o, dedica\u00e7\u00e3o, orienta\u00e7\u00e3o e incentivo e ao prof. Dr. Michel Reis Messora pelo \n\nincentivo, conviv\u00eancia e por tantos conhecimentos transmitidos.  \n\nAos amigos de turma: Nicolly Frota, Andr\u00e9 Moreira, Tulio Pignaton, Felipe \n\nSantos, Kelly Roccio, Umberto Ramos, Gustavo Vieira, Carolina Delmondes, Carolina \n\nMandeta, por todo companheirismo, cumplicidade e carinho compartilhados durante toda \n\nessa jornada. E em especial as minhas grandes amigas irm\u00e3s Cristine Borges e Mariana \n\nSales. Obrigada por serem t\u00e3o especiais, por tornarem os meus dias mais felizes e por \n\ncontribu\u00edrem de forma \u00edmpar para o meu crescimento pessoal e profissional. \n\nAos amores de Nova York e da vida: Edmara, Nath\u00e1lia, Ilana e Marina, por \n\ncompartilharem comigo a melhor experi\u00eancia desse mundo.  \n\nAos queridos Fabiola, Adriana, Milla, Roger e Sebasti\u00e3o, presen\u00e7as fundamentais \n\npara a realiza\u00e7\u00e3o desse trabalho. Obrigada pela amizade, paci\u00eancia, pelo excelente conv\u00edvio e \n\npelos diversos ensinamentos.  \n\nA SIN implantes pela doa\u00e7\u00e3o dos mat\u00e9rias necess\u00e1rios para a realiza\u00e7\u00e3o dessa \n\npesquisa. E em especial ao F\u00e1bio Bezerra e Bruna Ghiraldini.  \n\nAos funcion\u00e1rios do biot\u00e9rio: Aline, Massaro, Serginho, Rafael e Marmita, pessoas \n\nincr\u00edveis que tive o prazer de conviver. \n\nA minha amada professora Ana L\u00facia Pompeia Fraga de Almeida. Suas palavras de \n\nest\u00edmulo e sua m\u00e3o amiga me ajudaram a superar os obst\u00e1culos e a nunca desistir dos meus \n\nsonhos. Jamais esquecerei tudo que voc\u00ea fez por mim. \n\nAo professor M\u00e1rcio Matheus Beloti, pelas palavras de motiva\u00e7\u00e3o e incentivo e por \n\nter se tornado um grande amigo. \n\nAos eternos mestres: Ant\u00f4nio Athayde, Adriano Corr\u00eaa, S\u00edlvio Menezes, T\u00e2nia \n\nRodrigues, Ana L\u00facia Almeida, Jos\u00e9 Carlos Bastos, Luis Esper, Sueli Devides e Fl\u00e1vio \n\nAmado. \n\nA todos os funcion\u00e1rios da FORP, por todo carinho e boa vontade, especialmente \n\nTatiana, Dulce, Daniela, Carla Daniela, Suely, Dona Laura, Joana e Regiane. \n\n\n\nAo amigo Armando Lopes Pereira, um grande exemplo de profissional. Obrigada \n\npor tantas oportunidades e ensinamentos.  \n\nA t\u00e3o querida Adriana Silveira e Souza por tantos gestos de carinho a mim \n\ndedicados. \n\n\u00c0 Tia Bela, minha madrinha-m\u00e3e, meu amor incondicional. Obrigada pelo simples \n\nfato de ser voc\u00ea e de me amar como uma filha. \n\nA eles que foram a fam\u00edlia que eu pude escolher em Ribeir\u00e3o Preto: Adriana, \n\nAlexandre e Dilaina Santos. Obrigada pelo amor sincero e verdadeiro, pelo carinho e pela \n\namizade. \n\nAos amados Tio Rui e Tia Lene por se fazerem sempre presentes, me apoiando e me \n\nenchendo de amor. \n\nA Roberta Freitas e Anabela, sempre t\u00e3o presentes, meu eterno agradecimento por \n\ndividirem comigo as melhores risadas e principalmente o seu amor.  \n\nAo Marcus Viana, o irm\u00e3o que a vida me deu e que est\u00e1 comigo em absolutamente \n\ntodos os momentos. Sem d\u00favidas \u00e9s o meu anjo da guarda na terra.  \n\nA Renata Mendon\u00e7a, meu  porto seguro, pela torcida de sempre e amor \n\nincondicional. \n\nA Irema, que mesmo t\u00e3o longe sempre se fez presente, trazendo mais alegria para a \n\nminha vida. \n\nA minha fam\u00edlia maravilhosa e aos tantos amigos espalhados pelo mundo, agrade\u00e7o \n\npor toda cumplicidade e amor que me concederam nessa trajet\u00f3ria, me fazendo uma pessoa \n\nmais feliz. \n\nAgrade\u00e7o tamb\u00e9m, a Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo \n\n(FAPESP) e ao Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico \u2013 \n\n(CNPQ), pelo apoio financeiro essencial para a execu\u00e7\u00e3o deste trabalho. \n\nAo Centro Universit\u00e1rio do Par\u00e1. \n\nAo Hospital de Reabilita\u00e7\u00e3o de Anomalias Craniofaciais (Centrinho). \n\nAo laborat\u00f3rio de Biomateriais da Universidade de Nova York. \n\n\u00c0 Faculdade de Odontologia de Ribeir\u00e3o Preto. \n\n\n\nRESUMO \n\n \n\nOLIVEIRA, P. G. F. P. Avalia\u00e7\u00e3o de uma nova superf\u00edcie de implante recoberta por \n\nhidroxiapatita em escala nanom\u00e9trica. Estudo in vivo em ratos. Tese (Doutorado). \n\nFaculdade de Odontologia de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo, Ribeir\u00e3o Preto \n\n2018. 163p. \n\n \n\nA terapia com implantes t\u00eam sido uma alternativa previs\u00edvel para substituir aus\u00eancias \n\ndent\u00e1rias parciais ou totais. No entanto, influ\u00eancias sist\u00eamicas, tal como o diabetes mellitus \n\n(DM), podem influenciar negativamente nesse processo. Modifica\u00e7\u00f5es na microtopografia e \n\nsuperf\u00edcie dos implantes s\u00e3o estrat\u00e9gias usadas para promover uma melhor ancoragem \u00f3ssea. \n\nAssim, levando em considera\u00e7\u00e3o o desenvolvimento de novas superf\u00edcies de implantes \n\nvisando \u00e0 melhora qualitativa e quantitativa do fen\u00f4meno de osseointegra\u00e7\u00e3o, e por outro lado \n\na defici\u00eancia cicatricial dos portadores de DM, os quais podem ser utilizados como modelos \n\nde indiv\u00edduos com reparo \u00f3sseo deficiente, o objetivo desse projeto foi realizar um estudo in \n\nvivo, compreendendo ratos saud\u00e1veis e ratos diab\u00e9ticos, para avaliar a resposta biol\u00f3gica uma \n\nnova superf\u00edcie de implante, modificada pela adi\u00e7\u00e3o de nano-hidroxiapatita, por meio de \n\nan\u00e1lises microtomogr\u00e1fica: contato tridimensional osso implante (IS/TS, %), rela\u00e7\u00e3o entre \n\nvolume \u00f3sseo e superf\u00edcie \u00f3ssea (BV/TV, %), rela\u00e7\u00e3o entre superf\u00edcie \u00f3ssea e volume \u00f3sseo \n\n(BS/BV, mm), separa\u00e7\u00e3o trabecular (Tb.Sp, %) e porosidade total (Po.To, %); \n\nhistomorfom\u00e9trica: avalia\u00e7\u00e3o do contato osso-implante (BIC, %) e da densidade \u00f3ssea ao \n\nredor dos implantes (BAFO, %); nanomec\u00e2nica: m\u00f3dulo de elasticidade (ME) e dureza (D); \n\nde express\u00e3o g\u00eanica: fator de transcri\u00e7\u00e3o \u201crunt-related\u201d 2 (Runx2), fosfatase alcalina (Alp), \n\nosteocalcina (Oc), osteopontina (Opn), receptor ativador de fator nuclear kappa-B (Rank), \n\nreceptor ativador do fator nuclear kappa ligante (Rankl) e osteoprotegerina (Opg). Para isso, \n\nmini implantes (superf\u00edcie LISA, duplo ataque \u00e1cido (DAA) e com adi\u00e7\u00e3o de nano-\n\nhidroxiapatita (NANO)) foram instalados nas t\u00edbias de ratos saud\u00e1veis (n=36) e diab\u00e9ticos \n\n(n=36). Os animais foram eutanasiados aos 7 e 30 dias ap\u00f3s a instala\u00e7\u00e3o dos implantes. As \n\nt\u00edbias direitas foram removidas e fixadas para an\u00e1lise tri-dimensional, histol\u00f3gica e \n\nnanomec\u00e2nica e as esquerdas para avalia\u00e7\u00e3o da express\u00e3o g\u00eanica. Os dados foram avaliados \n\natrav\u00e9s da an\u00e1lise de vari\u00e2ncia + teste de Tukey e foram apresentados em fun\u00e7\u00e3o da m\u00e9dia e \n\nintervalo de confian\u00e7a de 95%. A % IS/TS mostrou que o revestimento com NANO HA \n\napresentou diferen\u00e7a estatisticamente significante quando comparado as superf\u00edcies LISA e \n\nDAA, independentemente do tempo e da condi\u00e7\u00e3o sist\u00eamica. BV/TV (%), BS/BV (mm) e \n\nPo.To (%) demonstraram valores mais elevados para o grupo NANO em todos os tempos \n\navaliados e independentemente da condi\u00e7\u00e3o sist\u00eamica quando comparado aos outros grupos \n\nexperimentais, com exce\u00e7\u00e3o do BS/BV (30 dias rato saud\u00e1vel e 7 e 30 dias rato diab\u00e9tico). J\u00e1 \n\nos resultados da Tb.Sp (%) revelaram diferen\u00e7as estat\u00edsticas favorecendo o grupo diab\u00e9tico \n\n\n\nNANO aos 7 e 30 dias. A partir da an\u00e1lise histomorfom\u00e9trica, a superf\u00edcie NANO apresentou \n\nmaiores % BIC e % BAFO quando comparados com LISA e DAA (dados avaliados em \n\nfun\u00e7\u00e3o da superf\u00edcie do implante). Al\u00e9m disso, a superf\u00edcie NANO apresentou maiores % BIC \n\ne % BAFO do que a LISA e DAA, com diferen\u00e7as estatisticamente significantes (avalia\u00e7\u00e3o \n\ndos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante). A superf\u00edcie NANO apresentou \n\nmaiores valores de ME e D quando comparado as superf\u00edcies LISA e DAA, com diferen\u00e7as \n\nestatisticamente significantes (avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \n\nimplante). Avaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), \n\na express\u00e3o relativa de Rank evidenciou que a superf\u00edcie NANO apresentou os melhores \n\nresultados aos 7 dias (rato diab\u00e9tico). Adicionalmente, os n\u00edveis de Runx2, Alp, Oc e Opn \n\nsugerem um aumento da prolifera\u00e7\u00e3o de osteoblastos, principalmente nos est\u00e1gios iniciais da \n\nosseointegra\u00e7\u00e3o. A partir dos resultados encontrados, podemos concluir que os implantes \n\nrecobertos com NANO-hidroxiapatita apresentaram resultados promissores em promover \n\nforma\u00e7\u00e3o de novo osso em um modelo de cicatriza\u00e7\u00e3o deficiente. \n\n \n\nPalavras-chave: Diabetes Mellitus, implantes dent\u00e1rios, express\u00e3o g\u00eanica, microtomografia \n\npor raio-X, histologia. \n\n  \n\n\n\nABSTRACT \n\n \n\nOLIVEIRA, P. G. F. P. Evaluation of a new hydroxiapatite covered nanometric implant \n\nsurface. An in vivo study in rats. Thesis (Doctor). School of Dentistry of Ribeir\u00e3o Preto, \n\nUniversity of S\u00e3o Paulo, Ribeir\u00e3o Preto, 2018. 163 p. \n\n \n\nImplant therapy has been a predictable alternative to replace partially or totally missing teeth. \n\nHowever, systemic disease such as diabetes mellitus (DM) may negatively influence the \n\nosseointegration. Changes in microtopography and implant surface are two strategies used to \n\npromote better bone anchorage. Thus, taking into account the development of new implant \n\nsurface to improve qualitative and quantitative osseointegration, and on the other hand the \n\nimpaired healing of DM, which can be used as models of subjects with impaired bone repair. \n\nThe aim of this in vivo study was to evaluate the biologic response of a new implant surface, \n\nmodified by the addition of nano-hydroxyapatite through three-dimensional (3D) evaluation \n\nusing micro-CT: percent intersection surface (IS/TS, %), percent bone volume (BV/TV, %), \n\nbone surface/volume ratio (BS/BV, mm), trabecular separation (Tb.Sp, %) and total porosity \n\n(To.Po, %); histological analysis: bone to implant contact (BIC, %) and bone area fraction \n\noccupancy (BAFO, %); nanomechanical properties: elastic modulus (EM) and hardness (H) \n\nand gene expression analysis: runt-related transcription factor 2 (Runx2), alkaline \n\nphosphatase (Alp), osteocalcin (Oc), osteopontin (Opn), receptor activator of nuclear factor-\n\nkappa B (Rank), receptor activator of nuclear factor-kappa B ligand (Rank-L) and \n\nosteoprotegerin (Opg). Mini implants (machined, double acid etched and with addition of \n\nnano-hydroxyapatite) were installed in tibias of healthy rats (n=36) and diabetic rats (n=36). \n\nThe animals were euthanized at 7 and 30 days. The right tibia were removed and fixed for \n\nmicro-CT, histological and nanomechanical analysis and the left for evaluation of gene \n\nexpression. Data were assessed through analysis of variance + Tukey test and are presented as \n\na function of mean and 95% confidence interval. The % IS/TS showed that NANO group \n\npresented statistically significant difference when compared to machined and DAE, regardless \n\nof time and systemic condition. BV/TV (%), BS/BV (mm) and To.Po (%) demonstrated \n\nhigher values for NANO group in all evaluated time point and irrespective of systemic \n\ncondition, but BS/BV 30 days (healthy rat) and 7 and 30 days (diabetic rat). The results of \n\nTb.Sp (%) revealed statistical differences for NANO diabetic group at 7 and 30 days. From \n\nthe histomorphometric analysis, NANO surface presented higher % BIC and % BAFO when \n\ncompared to machined and DAE (data evaluated as a function of implant surface). \n\nAdditionally, NANO surface presented higher % BIC and % BAFO than machined and DAE, \n\nwith statistically significant differences (data as a function of time and implant surface). \n\nNANO surface depicted higher EM and H values when compared to machined and DAE \n\nsurfaces, with statistically significant differences (data as a function of time and implant \n\n\n\nsurface). Evaluating all factors (time, systemic condition and surface treatment), the relative \n\nexpression of Rank showed that NANO surface presented the best results at 7 days (diabetic \n\nrats). Furthermore the levels of Runx2, Alp, Oc and Opn suggest an increase in osteoblasts \n\nproliferation, especially in early stages of osseointegration. Nano-hydroxyapatite coated \n\nimplants presented promising results and can be considered an important tool to compensate \n\nimpaired bone healing reported in diabetics. \n\n \n\nKeywords: Diabetes Mellitus, dental implants, gene expression, microtomography, histology. \n\n  \n\n\n\nLISTA DE FIGURAS  \n\n \n\nFigura 1. Verifica\u00e7\u00e3o do estado hiperglic\u00eamico ...................................................................... 32 \n\nFigura 2. Cirurgia para instala\u00e7\u00e3o dos implantes .................................................................... 33 \n\nFigura 3. Macroestrutura do implante  .................................................................................... 34 \n\nFigura 4. Remo\u00e7\u00e3o e preparo do material para posterior an\u00e1lise tridimensional por micro-\nCT, processamento histol\u00f3gico/an\u00e1lise histomorfom\u00e9trica e teste de nanoindenta\u00e7\u00e3o  ........... 36 \n\nFigura 5. Remo\u00e7\u00e3o e preparo do material para posterior avalia\u00e7\u00e3o da express\u00e3o g\u00eanica ....... 36 \n\nFigura 6. Desenho demonstrativo do local das medi\u00e7\u00f5es de BIC e BAFO  ............................ 38 \n\nFigura 7. Valores de glicemia (mg/dL) dos grupos saud\u00e1vel e diab\u00e9tico no momento da \ninstala\u00e7\u00e3o dos implantes e no dia da eutan\u00e1sia ......................................................................... 44 \n\nFigura 8. Reconstru\u00e7\u00e3o das imagens em 3D ........................................................................... 45 \n\nFigura 9. Gr\u00e1ficos representando % IS/TS ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ........................................ 47 \n\nFigura 10. Gr\u00e1fico representando a % IS/TS quando todos os dados se apresentam de \nforma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) .. 48 \n\nFigura 11. Gr\u00e1ficos representando % BV/TV ao redor do implante, organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ........................................ 49 \n\nFigura 12. Gr\u00e1fico representando a % BV/TV quando todos os dados se apresentam de \nforma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) .. 50 \n\nFigura 13. Gr\u00e1ficos representando BS/BV ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ........................................ 51 \n\nFigura 14. Gr\u00e1fico representando BS/BV quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 52 \n\nFigura 15. Gr\u00e1ficos representando Tb.Sp ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ........................................ 53 \n\nFigura 16. Gr\u00e1fico representando Tb.Sp quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 54 \n\nFigura 17. Gr\u00e1ficos representando % Po.To ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ........................................ 55 \n\nFigura 18. Gr\u00e1fico representando % Po.To quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 56 \n\nFigura 19. Imagens histol\u00f3gicas coradas com Stevenel\u2019s blue e Vermelho de Alizarina de \ntodos os grupos experimentais .................................................................................................. 57 \n\n\n\nFigura 20. Gr\u00e1ficos representando a % BIC organizados diferentemente em fun\u00e7\u00e3o dos \nfatores do estudo (m\u00e9dia e IC 95%) ......................................................................................... 59 \n\nFigura 21. Gr\u00e1fico representando a % BIC quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 60 \n\nFigura 22. Gr\u00e1ficos representando a %BAFO ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ........................................ 61 \n\nFigura 23. Gr\u00e1fico representando a % BAFO ao redor do implante quando todos os dados \nse apresentam de forma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) \n(m\u00e9dia e IC 95%) ...................................................................................................................... 62 \n\nFigura 24. Imagens representativas das \u00e1reas aonde foram realizados os ensaios de \nnanoindenta\u00e7\u00e3o de todos os grupos experimentais. .................................................................. 63 \n\nFigura 25. Gr\u00e1ficos representando o ME ao redor do implante organizados diferentemente \nem fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ................................................................. 65 \n\nFigura 26. Gr\u00e1fico representando o ME ao redor do implante quando todos os dados se \napresentam de forma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) \n(m\u00e9dia e IC 95%) ...................................................................................................................... 66 \n\nFigura 27. Gr\u00e1ficos representando D ao redor do implante organizados diferentemente em \nfun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ....................................................................... 67 \n\nFigura 28. Gr\u00e1fico representando a D ao redor do implante quando todos os dados se \napresentam de forma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) \n(m\u00e9dia e IC 95%) ...................................................................................................................... 68 \n\nFigura 29. Express\u00e3o relativa de Runx2 com dados organizados diferentemente em \nfun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%) ....................................................................... 69 \n\nFigura 30. Express\u00e3o relativa de Runx2 quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 70 \n\nFigura 31. Express\u00e3o relativa de Alp com dados organizados diferentemente em fun\u00e7\u00e3o \ndos fatores do estudo (m\u00e9dia e IC 95%) ................................................................................... 71 \n\nFigura 32. Express\u00e3o relativa de Alp quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 72 \n\nFigura 33. Express\u00e3o relativa de Oc organizados diferentemente em fun\u00e7\u00e3o dos fatores do \nestudo (m\u00e9dia e IC 95%) .......................................................................................................... 73 \n\nFigura 34. Express\u00e3o relativa de Oc quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 74 \n\nFigura 35. Express\u00e3o relativa de Opn com dados organizados diferentemente em fun\u00e7\u00e3o \ndos fatores do estudo (m\u00e9dia e IC 95%) ................................................................................... 75 \n\n\n\nFigura 36. Express\u00e3o relativa de Opn quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 76 \n\nFigura 37. Express\u00e3o relativa de Rank com dados organizados diferentemente em fun\u00e7\u00e3o \ndos fatores do estudo (m\u00e9dia e IC 95%) ................................................................................... 77 \n\nFigura 38. Express\u00e3o relativa de Rank quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 78 \n\nFigura 39. Express\u00e3o relativa de Rankl com dados organizados diferentemente em fun\u00e7\u00e3o \ndos fatores do estudo (m\u00e9dia e IC 95%) ................................................................................... 79 \n\nFigura 40. Express\u00e3o relativa de Rankl quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 80 \n\nFigura 41. Express\u00e3o relativa de Opg organizados diferentemente em fun\u00e7\u00e3o dos fatores \ndo estudo (m\u00e9dia e IC 95%) ..................................................................................................... 81 \n\nFigura 42. Express\u00e3o relativa de Opg quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%) ............ 82 \n\n  \n\n\n\nLISTA DE S\u00cdMBOLOS E SIGLAS \n\n \n\n? Graus \n\n?C Graus Celsius \n\n% Porcento \n\n> Maior \n\n&lt;Menor \n\n= Igual \n\n3D Tridimensional \n\nA \u00c1rea de contato \n\nAGE Produtos finais de glica\u00e7\u00e3o avan\u00e7ada \n\nAlp Fosfatase alcalina \n\nBAFO Densidade \u00f3ssea ao redor do implante \n\nBIC Contato osso implante \n\nBS/BV Rela\u00e7\u00e3o entre superf\u00edcie \u00f3ssea e volume \u00f3sseo \n\nBV/TV Rela\u00e7\u00e3o entre volume \u00f3sseo e superf\u00edcie \u00f3ssea \n\ncDNA \u00c1cido desoxirribonucleico complementar \n\nCEUA Comit\u00ea de \u00c9tica em Experimenta\u00e7\u00e3o Animal \n\ncm Centimetro \n\nCt Cicle threshold \n\nD Dureza \n\nDAA Duplo ataque \u00e1cido \n\nDM Diabetes Mellitus  \n\nDNA \u00c1cido desoxirribonucleico \n\nEi M\u00f3dulo el\u00e1stico para o penetrador \n\nFORP-USP Faculdade de Odontologia de Ribeir\u00e3o Preto da Universidade \nde S\u00e3o Paulo \n\ng Grama \n\nGapdh Gliceralde\u00eddo-3-fosfato desidrogenase \n\nGPa Gigapascal \n\n\n\nhc Profundidade de contato \n\nIC Intervalo de confian\u00e7a \n\nIS/TS Contato tridimensional osso implante \n\nKg Kilograma \n\nKV Kilovoltagem \n\nM Concentra\u00e7\u00e3o molar \n\nME M\u00f3dulo de elasticidade \n\nMicro-CT Microtomografia computadorizada  \n\nmL Mililitro \n\nmg Miligrama \n\nmg/dL Miligramas por decilitro \n\nmm Mil\u00edmetro \n\nmM Milimolar \n\n\u00b5A Microampere \n\n\u00b5g Micrograma \n\n\u00b5L Microlitro \n\n\u00b5m Micrometro \n\n\u00b5N Micronewton \n\nn \n\nNANO \n\nN\u00famero de animais \n\nNanom\u00e9trica  \n\nNANO HA Nano-hidroxiapatita  \n\nNm Nan\u00f4metros \n\nOc Osteocalcina \n\nOpn  Osteopontina \n\nOpg Osteoprotegerina \n\np Probabilidade de signific\u00e2ncia \n\nPCR Rea\u00e7\u00e3o em Cadeia de Polimerase \n\npH Potencial hidrogeni\u00f4nico \n\nP max For\u00e7a m\u00e1xima \n\n\n\nPo.To Porosidade total \n\nRAGE Receptor para produtos finais de glica\u00e7\u00e3o avan\u00e7ada \n\nRank Receptor ativador de fator nuclear kappa-B  \n\nRankl Receptor ativador do fator nuclear kappa ligante \n\nRIN \u00c1cido ribonucleico integrity number \n\nRNA \u00c1cido ribonucleico \n\nROI Regi\u00e3o de interesse \n\nRPM Rota\u00e7\u00e3o por minuto \n\nRunx2 Fator de transcri\u00e7\u00e3o \u201crunt-related\u201d 2 \n\nS Rigidez \n\nSD Saud\u00e1vel \n\nSeg Segundos \n\nSTZ Streptozotocina \n\nTb.Sp Separa\u00e7\u00e3o trabecular  \n\nUI Unidade internacional de medida \n\nvb Coeficiente de Poisson para o osso cortical \n\nvi Coeficiente de Poisson para penetrador \n\nVOI Volume de interesse \n\n \n\n \n\n \n \n \n \n \n \n\n\n\nSUM\u00c1RIO \n\n \n \n1 INTRODU\u00c7\u00c3O ................................................................................................................... 22 \n\n \n\n2 OBJETIVOS ........................................................................................................................ 29 \n\n \n\n3 MATERIAL E M\u00c9TODOS ................................................................................................ 31 \n\n3.1 Animais ............................................................................................................................... 31 \n\n3.2 Indu\u00e7\u00e3o do Diabetes Mellitus ............................................................................................. 31 \n\n3.3 Procedimentos Cir\u00fargicos .................................................................................................. 32 \n\n3.4 Grupos experimentais ......................................................................................................... 34 \n\n3.5 An\u00e1lise microtomogr\u00e1fica .................................................................................................. 37 \n\n3.6 Processamento e an\u00e1lise histol\u00f3gica ................................................................................... 37 \n\n3.7 Teste mec\u00e2nico de nanoindenta\u00e7\u00e3o .................................................................................... 38 \n\n3.8 Avalia\u00e7\u00e3o da express\u00e3o g\u00eanica ........................................................................................... 40 \n\n3.8.1 Extra\u00e7\u00e3o de RNA (\u00e1cido ribonucleico) total ................................................................... 40 \n\n3.8.2 S\u00edntese da fita de DNA (\u00e1cido desoxirribonucleico) complementar ............................... 41 \n\n3.8.3 Rea\u00e7\u00e3o de PCR em tempo real utilizando o sistema de sondas Taqman ........................ 41 \n\n3.9 An\u00e1lise Estat\u00edstica .............................................................................................................. 42 \n\n \n\n4 RESULTADOS .................................................................................................................... 44 \n\n4.1 Resultados Microtomogr\u00e1ficos ........................................................................................... 44 \n\n4.1.1 Contato tridimensional osso implante (IS/TS) ................................................................ 46 \n\n4.1.2 Densidade \u00f3ssea tridimensional (BV/TV) ....................................................................... 48 \n\n4.1.3 Rela\u00e7\u00e3o da superf\u00edcie \u00f3ssea pelo volume \u00f3sseo (BS/BV) ............................................... 50 \n\n4.1.4 Separa\u00e7\u00e3o Trabecular (Tb.Sp) ......................................................................................... 52 \n\n4.1.5 Porcentagem porosidade total (Po.To) ............................................................................ 54 \n\n4.2 Resultados Histomorfom\u00e9tricos: ........................................................................................ 56 \n\n4.2.1 Contato osso implante (BIC) ........................................................................................... 58 \n\n4.2.2 Densidade \u00f3ssea ao redor do implante (BAFO) .............................................................. 60 \n\n4.3 Resultados de nanoindenta\u00e7\u00e3o: ........................................................................................... 63 \n\n4.3.1 M\u00f3dulo de elasticidade (ME) .......................................................................................... 64 \n\n4.3.2 Dureza (D) ....................................................................................................................... 66 \n\n4.4 Resultados de express\u00e3o g\u00eanica:......................................................................................... 68 \n\n4.4.1 Fator de transcri\u00e7\u00e3o \u201crunt-related\u201d 2 (Runx2) ................................................................. 68 \n\n\n\n4.4.2 Fosfatase alcalina (Alp) ................................................................................................... 70 \n\n4.4.3 Osteocalcina (Oc) ............................................................................................................ 72 \n\n4.4.4 Osteopontina (Opn) ......................................................................................................... 74 \n\n4.4.5 Receptor ativador de fator nuclear kappa-B (Rank) ........................................................ 76 \n\n4.4.6 Receptor ativador do fator nuclear kappa ligante (Rankl) ............................................... 78 \n\n4.4.7 Osteoprotegerina (Opg) ................................................................................................... 80 \n\n \n\n5 DISCUSS\u00c3O ........................................................................................................................ 84 \n\n \n\n6 CONCLUS\u00c3O ...................................................................................................................... 90 \n\n \n\n7 REFER\u00caNCIAS .................................................................................................................. 92 \n\n \n\nANEXO .................................................................................................................................. 105 \n\n \n\nARTIGOS .............................................................................................................................. 106 \n\nArtigo 1 ................................................................................................................................... 107 \n\nArtigo 2 ................................................................................................................................... 135 \n\n \n\n \n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n1 Introdu\u00e7\u00e3o \n\n  \n\n\n\nIntrodu\u00e7\u00e3o  |  22 \n\n1 INTRODU\u00c7\u00c3O \n\n \n\nEm 1969, Branemark e colaboradores definiram a osseointegra\u00e7\u00e3o como o contato \n\ndireto entre o osso vivo e um implante em fun\u00e7\u00e3o, sem interposi\u00e7\u00e3o de qualquer outro tecido \n\n(Branemark et al. 1969). De acordo com Albrektson et al., em 1981, alguns requisitos s\u00e3o \n\ndecisivos para alcan\u00e7ar a osseointegra\u00e7\u00e3o, incluindo a biocompatibilidade do material, t\u00e9cnica \n\ncir\u00fargica, design do implante, condi\u00e7\u00f5es de carga ap\u00f3s a instala\u00e7\u00e3o, qualidade da superf\u00edcie e \n\na regi\u00e3o de instala\u00e7\u00e3o (Albrektsson et al. 1981). A terapia com implantes t\u00eam sido uma \n\nalternativa promissora para substituir aus\u00eancias dent\u00e1rias parciais ou totais (Adell et al. 1990; \n\nJemt and Lekholm 1993; Jemt et al. 1989). No entanto, fatores como o tabagismo \n\n(Chambrone et al. 2014; De la Rosa et al. 2013; Strietzel et al. 2007), rela\u00e7\u00e3o entre a \n\nrestaura\u00e7\u00e3o final e os dentes adjacentes (Lang et al. 2012), distribui\u00e7\u00e3o das cargas oclusais \n\n(Chambrone et al. 2010; Pjetursson et al. 2004), a sa\u00fade dos tecidos \u00f3sseo e mole ao redor dos \n\nimplantes (De la Rosa et al. 2013; Esposito et al. 2007; Pjetursson et al. 2004), e altera\u00e7\u00f5es \n\nsist\u00eamicas como o diabetes mellitus (DM) (Ajami et al. 2016; Giglio et al. 2000; He et al. \n\n2004; King et al. 2016) podem influenciar no sucesso do tratamento. \n\nO DM se apresenta como um dos maiores problemas de sa\u00fade do mundo (King et al. \n\n1998). \u00c9 definido como desordem metab\u00f3lica caracterizada pela hiperglicemia proveniente de \n\nanormalidades na secre\u00e7\u00e3o ou resposta das c\u00e9lulas \u00e0 insulina, que \u00e9 um horm\u00f4nio produzido \n\npelas c\u00e9lulas beta nas ilhotas pancre\u00e1ticas de Langerhans (Expert Committee on the and \n\nClassification of Diabetes 2000). Pode ser dividido em diabetes tipo 1 e tipo 2. O DM tipo 1 \u00e9 \n\numa doen\u00e7a auto-imune associada \u00e0 destrui\u00e7\u00e3o das c\u00e9lulas beta pancre\u00e1ticas e, portanto, \n\nrequer insulinoterapia, enquanto que o DM tipo 2 \u00e9 caracterizado por uma defici\u00eancia relativa \n\ne n\u00e3o absoluta de insulina e \u00e9 geralmente uma doen\u00e7a multifatorial (Retzepi and Donos 2010). \n\nAdicionalmente, o DM tem demonstrado aumentar significativamente os n\u00edveis de doen\u00e7a \n\nperiodontal e a perda dent\u00e1ria (Emrich et al. 1991; Oliver and Tervonen 1993; Safkan-Seppala \n\nand Ainamo 1992), e tem sido considerado como uma condi\u00e7\u00e3o de risco para o tratamento \n\ncom implantes pelo fato de estar associado com uma cicatriza\u00e7\u00e3o atrasada (Rothwell and \n\nRichard 1984), preval\u00eancia de doen\u00e7a micro vascular (Frantzis et al. 1971), e resposta \n\nprejudicada \u00e0 infec\u00e7\u00e3o (McMahon and Bistrian 1995). No entanto, o DM continua sendo uma \n\ncontra-indica\u00e7\u00e3o relativa para a terapia com implantes (Michaeli et al. 2009), ou seja, \n\npacientes diab\u00e9ticos bem controlados podem ser considerados apropriados para a terapia, \n\nenquanto que pacientes sem um bom controle glic\u00eamico podem ser privados dos benef\u00edcios \n\ndesse tratamento (Oates et al. 2013). A literatura revela que nesse cen\u00e1rio hiperglic\u00eamico, a \n\n\n\nIntrodu\u00e7\u00e3o  |  23 \n\nforma\u00e7\u00e3o \u00f3ssea ao redor dos implantes se apresenta de forma incompleta e atrasada, que o \n\ncontato osso-implante pode ser prejudicado e que o osso neoformado \u00e9 imaturo e pobremente \n\norganizado (Iyama et al. 1997; Johansson and Albrektsson 1987; Margonar et al. 2003; \n\nMcCracken et al. 2000; Nevins et al. 1998; Sennerby et al. 1992; Takeshita et al. 1997). \n\nAlguns estudos experimentais em animais demonstraram que o DM pode interferir \n\nnegativamente no processo de osseointegra\u00e7\u00e3o, diminuindo a forma\u00e7\u00e3o \u00f3ssea durante os \n\neventos de cicatriza\u00e7\u00e3o (Giglio et al. 2000; Johansson and Albrektsson 1987; Lu et al. 2003; \n\nMcCracken et al. 2000; Sennerby et al. 1992; Takeshita et al. 1997). A hiperglicemia \n\npersistente em indiv\u00edduos diab\u00e9ticos inibe a atividade osteobl\u00e1stica e altera a resposta do \n\nhorm\u00f4nio paratire\u00f3ideo que regula o metabolismo de c\u00e1lcio e fosfato (Santana et al. 2003), \n\ndiminui a forma\u00e7\u00e3o de col\u00e1geno durante a cicatriza\u00e7\u00e3o (Gooch et al. 2000), induz a apoptose \n\nem c\u00e9lulas de revestimento \u00f3sseo (He et al. 2004) e aumenta a atividade osteocl\u00e1stica devido \n\na uma resposta inflamat\u00f3ria persistente (Kayal et al. 2007). Al\u00e9m disso, tamb\u00e9m induz um \n\nefeito delet\u00e9rio na matriz \u00f3ssea e diminui o crescimento e o ac\u00famulo de matriz extracelular \n\n(Weiss et al. 1981).  \n\nAtualmente, o uso de implantes dent\u00e1rios tem sido considerado um procedimento \n\nseguro e altamente previs\u00edvel, com uma taxa de sobreviv\u00eancia de 94,6% e uma taxa de \n\nsucesso de 89,7% ap\u00f3s 10 anos (Moraschini et al. 2015). Apesar das altas taxas de sucesso \n\napresentadas, as caracter\u00edsticas dos implantes v\u00eam mudando ao longo dos anos, tendo como \n\nobjetivos a redu\u00e7\u00e3o no tempo de tratamento e a melhora no processo de osseointegra\u00e7\u00e3o em \n\nindiv\u00edduos que apresentam desordens metab\u00f3licas que podem prejudicar a cicatriza\u00e7\u00e3o \u00f3ssea \n\n(Schlegel et al. 2013). Dessa forma, uma variedade de m\u00e9todos tem sido utilizada na tentativa \n\nde melhorar a cicatriza\u00e7\u00e3o \u00f3ssea, incluindo mudan\u00e7as no design (Battula et al. 2015; Manna et \n\nal. 2018; Sennerby et al. 2015), adi\u00e7\u00e3o de compostos biol\u00f3gicos (Liu et al. 2004) e altera\u00e7\u00f5es \n\nna superf\u00edcie (Ajami et al. 2016; Berglundh et al. 2007; Boyan et al. 1996; Braceras et al. \n\n2009; Buser et al. 2004; Chehroudi et al. 1989; Coelho et al. 2014a; Jimbo et al. 2012a; \n\nKlokkevold et al. 1997; Liu et al. 2004; Meirelles et al. 2008; Novaes et al. 2010; Park et al. \n\n2005). A superf\u00edcie dos implantes \u00e9 um dos fatores de maior import\u00e2ncia, pois \u00e9 o primeiro \n\ncomponente a interagir com o hospedeiro. Modifica\u00e7\u00f5es na mesma v\u00eam sendo investigadas na \n\nbusca de uma melhor cicatriza\u00e7\u00e3o \u00f3ssea, objetivando melhorar a qualidade do novo osso \n\nformado (Berglundh et al. 2007; Buser et al. 2004; Coelho et al. 2012; Coelho et al. 2014a; Le \n\nGuehennec et al. 2007; Novaes et al. 2010; Wennerberg and Albrektsson 2011). \n\nAs primeiras rea\u00e7\u00f5es qu\u00edmicas entre a superf\u00edcie do implante e os tecidos org\u00e2nicos \n\ns\u00e3o reguladas pelos flu\u00eddos teciduais. Logo em seguida, \u00e9 formada na superf\u00edcie do implante \n\n\n\nIntrodu\u00e7\u00e3o  |  24 \n\numa camada de macromol\u00e9culas glicoproteicas e \u00e1gua, sendo esta determinante como parte \n\ndo substrato necess\u00e1rio para ades\u00e3o, prolifera\u00e7\u00e3o, diferencia\u00e7\u00e3o e s\u00edntese proteica de c\u00e9lulas \n\nosteobl\u00e1sticas. Em paralelo ao processo de repara\u00e7\u00e3o do tecido \u00f3sseo necr\u00f3tico remanescente \n\nno alv\u00e9olo cir\u00fargico preparado, uma s\u00e9rie de eventos bioqu\u00edmicos \u00e9 desencadeada, tais como \n\naltera\u00e7\u00f5es no pH tecidual, libera\u00e7\u00e3o de prote\u00ednas e enzimas reguladoras do processo de \n\ndivis\u00e3o e diferencia\u00e7\u00e3o celular, dentre elas os fatores de crescimento e citocinas. Logo em \n\nseguida, com a presen\u00e7a do tecido de granula\u00e7\u00e3o, inicia-se um processo de reparo tecidual por \n\nmeio do dep\u00f3sito de matriz col\u00e1gena n\u00e3o-calcificada e consequente forma\u00e7\u00e3o de matriz \n\nfibrosa. Com o aumento gradual da incorpora\u00e7\u00e3o de componentes inorg\u00e2nicos \u00e0 matriz, d\u00e1-se \n\nin\u00edcio ao modelamento e remodelamento dessa cobertura parcialmente mineralizada em torno \n\ndo implante (Albrektsson and Johansson 2001; Branemark et al. 1969; Davies 1998; Dinato \n\n2004). \n\nTanto a morfologia quanto a rugosidade superficial dos implantes exercem uma \n\nimportante influ\u00eancia na prolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o celular, na s\u00edntese da matriz \n\nextracelular, na produ\u00e7\u00e3o de fatores locais, e at\u00e9 mesmo no tipo celular (Anselme and \n\nBigerelle 2005; Elias and Meirelles 2010). Al\u00e9m disso, a forma da c\u00e9lula regula o seu \n\ncrescimento, a express\u00e3o de genes, a secre\u00e7\u00e3o de prote\u00ednas, a diferencia\u00e7\u00e3o e apoptose \n\n(Brunette et al. 2001). A ader\u00eancia dos osteoblastos \u00e0 superf\u00edcie dos implantes \u00e9 necess\u00e1ria \n\npara que a c\u00e9lula receba os sinais para induzir a prolifera\u00e7\u00e3o celular (Elias and Meirelles \n\n2010). A rugosidade, por sua vez, al\u00e9m de facilitar a reten\u00e7\u00e3o de c\u00e9lulas osteog\u00eanicas, permite \n\nque haja a migra\u00e7\u00e3o para a superf\u00edcie do implante atrav\u00e9s da osseocondu\u00e7\u00e3o (Braceras et al. \n\n2009), promovendo uma melhor ader\u00eancia do col\u00e1geno e aumentando a \u00e1rea da superf\u00edcie, \n\nresultando em mais s\u00edtios para a fixa\u00e7\u00e3o das c\u00e9lulas, maior crescimento tecidual e estabilidade \n\nmec\u00e2nica (Wennerberg and Albrektsson 2000; 2009; 2010). \n\nAs superf\u00edcies de implantes evolu\u00edram de lisas a moderadamente \u00e1speras, com \n\nalgumas altera\u00e7\u00f5es qu\u00edmicas (Albrektsson and Wennerberg 2004a; 2004b). Do ponto de vista \n\nda osseointegra\u00e7\u00e3o precoce, estudos com avalia\u00e7\u00f5es histomorfom\u00e9tricas e biomec\u00e2nicas t\u00eam \n\ndemonstrado uma maior osteocondutividade para as superf\u00edcies texturizadas, quando \n\ncomparado \u00e0s lisas (Albrektsson and Wennerberg 2004a; 2004b; Berglundh et al. 2007; Buser \n\net al. 2004; Coelho et al. 2011b; Coelho et al. 2014a). Klokkevold et al., em 1997, realizaram \n\num estudo comparativo da resist\u00eancia do torque de remo\u00e7\u00e3o de implantes de tit\u00e2nio com \n\nsuperf\u00edcie lisa e superf\u00edcie com duplo ataque \u00e1cido (DAA) e conclu\u00edram que o DAA tem a \n\npropriedade de aumentar significativamente a osseointegra\u00e7\u00e3o (Klokkevold et al. 1997). \n\nMarinho et al., em 2003, realizaram um estudo em coelhos e observaram um melhor contato \n\n\n\nIntrodu\u00e7\u00e3o  |  25 \n\nosso-implante quando na utiliza\u00e7\u00e3o de superf\u00edcies com jateamento e ataque \u00e1cido em \n\ncompara\u00e7\u00e3o \u00e0s superf\u00edcies lisas (Marinho et al. 2003). \n\nNanoestruturas aplicadas a biomateriais t\u00eam sido propostas para proporcionar um grau \n\nsuperior de osseointegra\u00e7\u00e3o (Coelho et al. 2014a; Ellingsen et al. 2004; Jimbo et al. 2012a). \n\nEstudos demonstram que a resposta biol\u00f3gica \u00e9 sens\u00edvel a diferentes nanoestruturas (Coelho \n\net al. 2011b; Coelho et al. 2014a; Jimbo et al. 2012a; Jimbo et al. 2012b). No ano de 2007, \n\nWebster e Ahn conclu\u00edram que nanoestruturas menores do que 100 nm s\u00e3o mais eficazes na \n\nintegra\u00e7\u00e3o celular (Webster and Ahn 2007). Meirelles et al., em 2008, realizaram um estudo \n\nem coelhos e observaram um  aumento precoce da forma\u00e7\u00e3o \u00f3ssea em implantes modificados \n\ncom nano-hidroxiapatita (NANO HA) (Meirelles et al. 2008). Os autores afirmaram que esses \n\nresultados podem ter resultado da poss\u00edvel bioatividade qu\u00edmica da hidroxiapatita ou da \n\ntopografia das nanoestruturas implementadas. Em outro estudo, abordando a express\u00e3o g\u00eanica \n\nem torno de implantes revestidos com NANO HA foi observado que houve uma melhora \n\nsignificativa na express\u00e3o de genes osteog\u00eanicos, sugerindo que a NANO HA est\u00e1 ativamente \n\nenvolvida na forma\u00e7\u00e3o \u00f3ssea (Coelho et al. 2014a; Jimbo et al. 2012a; Jimbo et al. 2011; \n\nMeirelles et al. 2008; Webster and Ahn 2007).  \n\nA forma\u00e7\u00e3o de um contato direto entre o osso e o implante (BIC) \u00e9 um par\u00e2metro \n\nimportante que influencia no sucesso global e na sobrevida da terapia com implantes \n\ndent\u00e1rios (Javed et al. 2011; Pinholt 2003; Schulz et al. 2014). A fixa\u00e7\u00e3o osteobl\u00e1stica e a \n\ns\u00edntese de col\u00e1geno s\u00e3o significativamente maiores em torno de implantes de superf\u00edcie \n\n\u00e1spera, em contraste com implantes com superf\u00edcies lisas (Jiang et al. 2015; Marin-Pareja et \n\nal. 2014). Jimbo et al., em 2012, avaliaram 20 implantes de tit\u00e2nio, metade preparados com \n\nsuperf\u00edcie de nanopart\u00edculas de hidroxiapatita est\u00e1vel e metade jateada, tratados com \u00e1cido e \n\nposteriormente, tratados termicamente, os quais foram inseridos em f\u00eamures de coelhos \n\n(Jimbo et al. 2012a). Ap\u00f3s 3 semanas de cicatriza\u00e7\u00e3o, as amostras foram preparadas para \n\nan\u00e1lise histomorfom\u00e9trica. As propriedades nanomec\u00e2nicas do osso circundante foram \n\navaliadas atrav\u00e9s do teste de nanoindenta\u00e7\u00e3o. Enquanto ambos os implantes revelaram BIC \n\nsemelhante, a nanoindenta\u00e7\u00e3o demonstrou que a qualidade do tecido foi significativamente \n\naumentada em torno dos implantes revestidos com NANO HA. Dessa forma, pode-se sugerir \n\nque atrav\u00e9s da nanoindenta\u00e7\u00e3o \u00e9 poss\u00edvel avaliar puramente as propriedades mec\u00e2nicas do \n\nosso em escala reduzida, sem a influ\u00eancia de outros fatores (Coelho et al. 2014a).  \n\nMartinez et al., 2018 realizaram um estudo in vitro para avaliar a influ\u00eancia de \n\nnanocristais de hidroxiapatita agregados em superf\u00edcies NANO sobre o comportamento de \n\nc\u00e9lulas osteobl\u00e1sticas em compara\u00e7\u00e3o a uma superf\u00edcie convencional com DAA. Para isso, \n\n\n\nIntrodu\u00e7\u00e3o  |  26 \n\ndiscos de tit\u00e2nio comercialmente puros foram selecionados e a prolifera\u00e7\u00e3o e viabilidade \n\ncelular foram avaliadas nos tempos de 24, 48 e 72 horas. A express\u00e3o do col\u00e1geno tipo I e \n\nosteopontina tamb\u00e9m foram analisados. Os resultados mostraram que as c\u00e9lulas apresentaram \n\nmaior espalhamento morfol\u00f3gico na superf\u00edcie NANO quando comparada com a superf\u00edcie \n\nconvencional de DAA em todos os tempos avaliados. Um aumento da prolifera\u00e7\u00e3o e \n\nviabilidade celular foram detectados na superf\u00edcie NANO, especialmente ap\u00f3s 72 horas. A \n\nexpress\u00e3o de osteopontina foi maior ap\u00f3s 24 horas na superf\u00edcie de NANO quando comparada  \n\nDAA. Para o col\u00e1geno tipo I, foi observada uma maior express\u00e3o na superf\u00edcie NANO \n\ntamb\u00e9m no tempo de 72 horas (p&lt;0,05). Esse estudo mostrou que a superf\u00edcie NANO \n\nfavoreceu os eventos iniciais da osseointegra\u00e7\u00e3o (Martinez et al. 2018). \n\nAjami et al., 2014 realizaram dois experimentos paralelos, um modelo de osteotomia e \n\num modelo de c\u00e2mara de crescimento \u00f3sseo (Ajami et al. 2014). O modelo de osteotomia \n\nrastreou a cicatriza\u00e7\u00e3o do osso temporal nos f\u00eamures de ratos euglic\u00eamicos e hiperglic\u00eamicos \n\nutilizando an\u00e1lise de micro-tomografia computadorizada (micro-CT) e histologia. O modelo \n\nde c\u00e2mara \u00f3ssea em crescimento utilizou superf\u00edcies de implantes de complexidade micro ou \n\nnanotopogr\u00e1fica e mediu o BIC em ambos os grupos metab\u00f3licos. An\u00e1lises quantitativas de \n\nmicro-CT sobre volume \u00f3sseo, n\u00famero de trab\u00e9culas e densidade de conectividade trabecular \n\nforneceram evid\u00eancias claras de que tanto a forma\u00e7\u00e3o \u00f3ssea trabecular reparativa quanto a \n\nremodela\u00e7\u00e3o estavam atrasadas na hiperglicemia, e o volume \u00f3sseo reparativo mudou com o \n\ntempo entre os grupos metab\u00f3licos. Um aumento da probabilidade de osteocondu\u00e7\u00e3o foi visto \n\nno grupo NANO quando comparado \u00e0 superf\u00edcie MICRO, independente do grupo metab\u00f3lico. \n\nAs superf\u00edcies NANO na hiperglicemia superaram superf\u00edcies MICRO em animais \n\neuglic\u00eamicos. Dessa forma, os atutores conclu\u00edram que a integra\u00e7\u00e3o comprometida do \n\nimplante na hiperglicemia \u00e9 anulada pela adi\u00e7\u00e3o de caracter\u00edsticas nanotopogr\u00e1ficas a uma \n\nsuperf\u00edcie subjacente de implantes microtopograficamente complexa (Ajami et al. 2014). \n\nOutros estudos conclu\u00edram que o osso rec\u00e9m-formado ao redor dos implantes se apresenta de \n\nforma imatura e menos organizada em ratos diab\u00e9ticos n\u00e3o controlados quando comparados a \n\ncontroles n\u00e3o diab\u00e9ticos, sugerindo diferen\u00e7as qualitativas no osso neoformado (Giglio et al. \n\n2000; McCracken et al. 2000; Nevins et al. 1998; Takeshita et al. 1997).  \n\nA rugosidade da superf\u00edcie em nanoescala pode ser um fator decisivo para a \n\nosteog\u00eanese devido ao tamanho das prote\u00ednas e dos receptores da membrana celular \n\ncorresponderem \u00e0 topografia da superf\u00edcie nessa escala de comprimento. Gittens et al., em \n\n2011, relataram que modifica\u00e7\u00f5es em n\u00edvel nanom\u00e9trico aumentaram consideravelmente a \n\ndiferencia\u00e7\u00e3o pr\u00e9-osteobl\u00e1stica atrav\u00e9s de n\u00edveis significativamente mais altos de express\u00e3o \n\n\n\nIntrodu\u00e7\u00e3o  |  27 \n\nde osteocalcina e osteoprotegerina in vitro (Gittens et al. 2011). Meirelles et al., em 2007 \n\nrealizaram um estudo em animais com implantes contendo nanoestruturas e implantes \n\ncontroles sem mudan\u00e7as na superf\u00edcie, e revelaram que implantes com nano estruturas \n\napresentaram maior BIC quando comparado com o controle (Meirelles et al. 2007). Essas \n\ninforma\u00e7\u00f5es sugerem que c\u00e9lulas, particularmente osteoblastos, respondem a altera\u00e7\u00f5es \n\ntopogr\u00e1ficas em escala nanom\u00e9trica. Adicionalmente, a forma\u00e7\u00e3o reduzida de oste\u00f3ide, a \n\nmineraliza\u00e7\u00e3o oste\u00f3ide retardada e a redu\u00e7\u00e3o do volume e matura\u00e7\u00e3o \u00f3ssea global na presen\u00e7a \n\nde hiperglicemia foram relatados por Goodman e Hori, 1984 (Goodman and Hori 1984). \n\nAs t\u00e9cnicas mais comumente usadas para avaliar a osseointegra\u00e7\u00e3o em modelos in \n\nvivo s\u00e3o radiografias, testes mec\u00e2nicos, histol\u00f3gicos e/ou histomorfom\u00e9tricos (Johansson et al. \n\n2012). Mais recentemente, o micro-CT passou a ser utilizado para avalia\u00e7\u00e3o da morfologia e \n\nmicro-estrutura \u00f3sseas, usando dados de proje\u00e7\u00f5es de raios-X em v\u00e1rios \u00e2ngulos para \n\nreconstruir uma representa\u00e7\u00e3o em 3D (tridimensional) do modelo que caracteriza a \n\ndistribui\u00e7\u00e3o da densidade do material, permitindo assim o estudo de estruturas de alguns \n\nmicr\u00f4metros, tais como trab\u00e9culas \u00f3sseas (Gonzalez-Garcia and Monje 2013; Martin-Badosa \n\net al. 2003). \u00c9 amplamente usada para analisar a estrutura interna do tecido \u00f3sseo devido \u00e0s \n\nsuas vantagens de rapidez, reprodutibilidade e n\u00e3o-destrutividade (Feldkamp et al. 1989). \n\nPodem ser avaliados por meio da resposta \u00f3ssea analisada por micro-CT diversos par\u00e2metros \n\nexperimentais, tais como comprimento, di\u00e2metro, formato, superf\u00edcie e material do implante, \n\na condensa\u00e7\u00e3o \u00f3ssea, o tempo de implanta\u00e7\u00e3o, o s\u00edtio de implanta\u00e7\u00e3o, a aplica\u00e7\u00e3o ou n\u00e3o de \n\ncarga funcional sobre os implantes analisados e o per\u00edodo de cicatriza\u00e7\u00e3o antes da aplica\u00e7\u00e3o \n\nda carga funcional (Gonzalez-Garcia and Monje 2013; Park et al. 2008). \n\nAssim, levando em considera\u00e7\u00e3o o desenvolvimento de novas superf\u00edcies de implantes \n\ncom processos visando \u00e0 melhora qualitativa e quantitativa do fen\u00f4meno de osseointegra\u00e7\u00e3o, \n\ne por outro lado a defici\u00eancia cicatricial dos portadores de DM, os quais podem ser utilizados \n\ncomo modelos de indiv\u00edduos com reparo \u00f3sseo deficiente, seria interessante avaliar, em um \n\nestudo in vivo, em ratos saud\u00e1veis e diab\u00e9ticos (como um modelo de reparo \u00f3sseo deficiente) \n\na resposta biol\u00f3gica a uma nova superf\u00edcie de implante modificada pela adi\u00e7\u00e3o de NANO HA. \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n2 Objetivos \n\n  \n\n\n\nObjetivos  |  29 \n\n2 OBJETIVOS \n\n \n\nAvaliar in vivo, utilizando ratos diab\u00e9ticos (como um modelo de repara\u00e7\u00e3o \u00f3ssea \n\ndeficiente) e ratos saud\u00e1veis (controle com repara\u00e7\u00e3o \u00f3ssea normal) uma nova superf\u00edcie de \n\nimplantes com nanopart\u00edculas de hidroxiapatita (NANO HA), por meio de: \n\n \n\n- An\u00e1lise microtomogr\u00e1fica (micro-CT): avalia\u00e7\u00e3o, no osso interno \u00e0s roscas dos implantes, \n\ndos seguintes par\u00e2metros tomogr\u00e1ficos: contato tridimensional osso implante (IS/TS, %), \n\nrela\u00e7\u00e3o entre volume \u00f3sseo e superf\u00edcie \u00f3ssea (BV/TV, %), rela\u00e7\u00e3o entre superf\u00edcie \u00f3ssea e \n\nvolume \u00f3sseo (BS/BV, mm), separa\u00e7\u00e3o trabecular (Tb.Sp, %) e porosidade total (Po.To, %);  \n\n \n\n- An\u00e1lise histomorfom\u00e9trica: avalia\u00e7\u00e3o do contato osso-implante (BIC, %) e da densidade \n\n\u00f3ssea ao redor dos implantes (BAFO, %); \n\n \n\n- An\u00e1lise nanomec\u00e2nica: m\u00f3dulo de elasticidade (ME) e dureza (D); \n\n \n\n- Avalia\u00e7\u00e3o da express\u00e3o g\u00eanica dos seguintes genes marcadores do metabolismo \u00f3sseo: fator \n\nde transcri\u00e7\u00e3o \u201crunt-related\u201d 2 (Runx2), fosfatase alcalina (Alp), osteocalcina (Oc), \n\nosteopontina (Opn), receptor ativador de fator nuclear kappa-B (Rank), receptor ativador do \n\nfator nuclear kappa ligante (Rankl) e osteoprotegerina (Opg).  \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3 Material e M\u00e9todos \n\n  \n\n\n\nMaterial e M\u00e9todos  |  31 \n\n3 MATERIAL E M\u00c9TODOS \n\n \n\n3.1 Animais \n\n \n\nForam selecionados 72 ratos adultos machos do tipo Wistar (Rattus norvegicus \n\nalbinus) com peso entre 200 a 250 g, provenientes do biot\u00e9rio central da Faculdade de \n\nOdontologia de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo (FORP-USP). Os animais foram \n\nmantidos com livre acesso \u00e0 \u00e1gua e dieta padr\u00e3o, e mantidos em gaiolas pl\u00e1sticas apropriadas \n\nem ambiente com ciclo de 12 horas de luz e temperatura entre 22 e 24\u00baC. Antes dos \n\nprocedimentos cir\u00fargicos, todos os animais permaneceram no biot\u00e9rio por um per\u00edodo de 7 \n\ndias para aclimata\u00e7\u00e3o. Os animais foram distribu\u00eddos, aleatoriamente, nos grupos diabetes \n\nmellitus (DM) e saud\u00e1vel (SD). O protocolo do estudo foi previamente aprovado pelo Comit\u00ea \n\nde \u00c9tica em Experimenta\u00e7\u00e3o Animal (CEUA) da FORP-USP (protocolo n\u00famero: \n\n2014.1.1083.58.4) (Anexo 1).  \n\n \n\n3.2 Indu\u00e7\u00e3o do Diabetes Mellitus \n\n \n\nO DM foi induzido em 36 animais, escolhidos de acordo com uma tabela num\u00e9rica \n\naleat\u00f3ria gerada pelo site Randomization.com (http: //www.randomization.com). Cada um dos \n\nanimais recebeu um dos seguintes protocolos: administra\u00e7\u00e3o de estreptozotocina ou \n\nadministra\u00e7\u00e3o do tamp\u00e3o citrato. Os mesmos permaneceram em jejum de 12 horas antes do \n\nin\u00edcio da indu\u00e7\u00e3o. A indu\u00e7\u00e3o foi realizada atrav\u00e9s da administra\u00e7\u00e3o de estreptozotocina (STZ) \n\n(Sigma Chemical Co, Saint Louis, Missouri, EUA), um agente diabetog\u00eanico. A STZ foi \n\nadministrada em uma \u00fanica aplica\u00e7\u00e3o, via intraperitoneal na dosagem de 60 mg/Kg de peso \n\ndo animal, dissolvido em 0,2 mL de tamp\u00e3o citrato 0,01 M, pH 4,45. O grupo saud\u00e1vel \n\nrecebeu apenas o ve\u00edculo, via intraperitoneal, a um volume de 1 ml/kg (n = 36).  \n\nAp\u00f3s 7 dias, foi verificado o n\u00edvel de glicose circulante para confirma\u00e7\u00e3o do estado \n\nhiperglic\u00eamico, utilizando o Accu-Chek (Active monitoring system, Roche Diagnostics, \n\nRotkreuz, Zug, Sui\u00e7a), segundo as instru\u00e7\u00f5es do fabricante (Figura 1A, 1B e 1C). Esse \n\ncontrole glic\u00eamico, tanto no grupo DM quanto no grupo SD foi realizado no dia da instala\u00e7\u00e3o \n\ndos implantes e no dia da eutan\u00e1sia atrav\u00e9s de uma pun\u00e7\u00e3o superficial na cauda distal. Apenas \n\nanimais com glicemia acima de 300 mg/dL foram considerados diab\u00e9ticos e inclu\u00eddos no \n\nestudo (Margonar et al. 2003). O n\u00edvel de glicose sangu\u00ednea considerado normal para a \n\nesp\u00e9cie varia entre 50 a 135 mg/dL (Harkness and Wagner 1993).  \n\n\n\nMaterial e M\u00e9todos  |  32 \n\n \n\nFigura 1. Verifica\u00e7\u00e3o do estado hiperglic\u00eamico. A) Posicionamento inicial. B) Coleta do \nsangue na tira de papel. C) Verifica\u00e7\u00e3o realizada em um animal do grupo diabetes mellitus. \n\n \n\n3.3 Procedimentos Cir\u00fargicos \n\n \n\nOs animais foram primeiramente pesados para o correto c\u00e1lculo anest\u00e9sico. A \n\nanestesia geral foi obtida pela administra\u00e7\u00e3o de uma inje\u00e7\u00e3o de 100-130 \u00b5L/100g de peso \n\nanimal em uma combina\u00e7\u00e3o 4:3 de ketamina (74,1 mg/g de cloridrato de ketamina a 10%; \n\nAgener, Uni\u00e3o Qu\u00edmica Farmac\u00eautica Nacional S/A, Embu-Gua\u00e7u, S\u00e3o Paulo, Brasil) e \n\nxilazina (11,2 mg/kg dopaser; Calier Laboratories S/A, Barcelona, Espanha). Logo em \n\nseguida foi realizado a tricotomia da regi\u00e3o a ser operada e a antissepsia com solu\u00e7\u00e3o de iodo \n\na 10% (Rioquimica Ind. Farmac\u00eautica, S\u00e3o Paulo, Brasil). \n\nSubsequentemente, com o auxilio de um cabo de bisturi n\u00b0 3, montado com l\u00e2mina de \n\nbisturi n\u00ba 15C (Swann-Morton, Sheffield, Inglaterra), foi realizada uma incis\u00e3o nas t\u00edbias \n\ndireita e esquerda dos animais, medindo aproximadamente 15 mm, paralela ao longo do eixo \n\ndas t\u00edbias (Figura 2A). O local de elei\u00e7\u00e3o para a incis\u00e3o foi estabelecido pela por\u00e7\u00e3o mais \n\nvolumosa do tecido \u00f3sseo, atrav\u00e9s da palpa\u00e7\u00e3o. O tecido muscular foi seccionado at\u00e9 a \n\nexposi\u00e7\u00e3o do peri\u00f3steo. O descolamento foi realizado utilizando descoladores de Freer e de \n\nMolt e com o aux\u00edlio de uma pin\u00e7a de Adson com dente. Esses mesmos instrumentos, \n\njuntamente com uma pin\u00e7a anat\u00f4mica, auxiliaram no afastamento do retalho e estabiliza\u00e7\u00e3o \n\nda t\u00edbia (Figura 2B). Para melhora da hemostasia no campo operat\u00f3rio foi utilizada gaze \n\nest\u00e9ril. \n\nA cirurgia para a instala\u00e7\u00e3o dos implantes (um em cada t\u00edbia) foi realizada por meio \n\numa perfura\u00e7\u00e3o com uma broca piloto com 1.0 mm de di\u00e2metro e 15 mm de comprimento \n\n(S.I.N. \u2013 Sistema de Implante, S\u00e3o Paulo, Brasil) sob constante irriga\u00e7\u00e3o com solu\u00e7\u00e3o salina \n\n(0,9%), utilizando um motor de implante (Dentscler, Ribeir\u00e3o Preto, S\u00e3o Paulo, Brasil) numa \n\n\n\nMaterial e M\u00e9todos  |  33 \n\nrota\u00e7\u00e3o de 1000 rpm (Figura 2C e 2D), conforme recomendado pelo fabricante (S.I.N. \u2013 \n\nSistema de Implante, S\u00e3o Paulo, Brasil). Todos os mini-implantes foram especialmente \n\npreparados pela empresa S.I.N (Sistema de Implante, S\u00e3o Paulo, Brasil) para essa pesquisa, e \n\ntinham macroestrutura igual, com formato de parafuso e as seguintes dimens\u00f5es: 2,7 mm de \n\ncomprimento e 1,4 mm de di\u00e2metro (Figura 3). \n\nOs implantes foram instalados, aleatoriamente, com o auxilio de uma chave de m\u00e3o \n\n(S.I.N. \u2013 Sistema de Implante, S\u00e3o Paulo, Brasil) de forma que as roscas ficassem \n\ncompletamente introduzidas no interior do osso cortical (Figura 2E). O ato cir\u00fargico foi \n\nfinalizado por meio de pontos simples, utilizando fios de sutura absorv\u00edveis (Vicryl Ethicon \n\n5.0, Johnson Prod., S\u00e3o Jos\u00e9 dos Campos, S\u00e3o Paulo, Brasil) (Figura 2F). \n\n \n\n \n\nFigura 2. Cirurgia para instala\u00e7\u00e3o dos implantes. A) Incis\u00e3o medindo aproximadamente 2 cm, \nparalela ao longo do eixo das t\u00edbias. B) Aspecto encontrado ap\u00f3s abertura do retalho. C e D) \nCirurgia para a instala\u00e7\u00e3o dos implantes sob constante irriga\u00e7\u00e3o com soro fisiol\u00f3gico. E) \nImplante instalado com as roscas completamente introduzidas no interior do osso cortical. F) \nS\u00edntese. \n\n\n\nMaterial e M\u00e9todos  |  34 \n\n \n\nFigura 3. Macroestrutura do implante (2,7 mm de comprimento e 1,4 mm de di\u00e2metro). \n\n \n\nAp\u00f3s a cirurgia, os animais receberam uma dose \u00fanica de antibi\u00f3tico via intramuscular \n\nde Penicilina G-benzatina (24.000 UI/kg) na dose de 0,01 ml para cada 100g do peso \n\ncorp\u00f3reo do rato (Pentabi\u00f3tico Veterin\u00e1rio Pequeno Porte, Fort Dodge\u00ae Sa\u00fade Animal Ltda., \n\nCampinas, S\u00e3o Paulo, Brasil) e um anti-inflamat\u00f3rio na concentra\u00e7\u00e3o de 0,3 mg/ml \u2013 dose \n\n0,05mg/kg - Inje\u00e7\u00e3o subcut\u00e2nea, 12/12 horas (Buprenorfina, Plurivet Richter Pharma AG, \n\nAustria, Inglaterra). Nenhuma restri\u00e7\u00e3o de movimenta\u00e7\u00e3o ou alimenta\u00e7\u00e3o foi feita ap\u00f3s a \n\ncirurgia, e os mesmos foram mantidos em caixas pl\u00e1sticas apropriadas durante todo o per\u00edodo \n\nexperimental. Todos os animais se recuperaram bem ap\u00f3s os procedimentos e n\u00e3o \n\nnecessitaram de doses adicionais de medicamentos.  \n\n \n\n3.4 Grupos experimentais \n\n \n\nOs 72 animais foram divididos aleatoriamente em 6 grupos experimentais, cada qual \n\ncontendo 12 ratos: \n\n- GRUPO 1 (n=12) \u2013 Rato saud\u00e1vel (SD) \u2013 superf\u00edcie LISA. Foram instalados nas \n\nt\u00edbias de ratos saud\u00e1veis, mini implantes de superf\u00edcie lisa (sem nenhum outro tratamento de \n\nsuperf\u00edcie a n\u00e3o ser os sulcos normais de usinagem); \n\n\n\nMaterial e M\u00e9todos  |  35 \n\n- GRUPO 2 (n=12) \u2013 Rato saud\u00e1vel (SD) \u2013 superf\u00edcie tratada com duplo ataque \u00e1cido \n\n(DAA). Foram instalados nas t\u00edbias de ratos saud\u00e1veis, mini implantes com superf\u00edcie tratada \n\ncom duplo ataque \u00e1cido; \n\n- GRUPO 3 (n=12) \u2013 Rato saud\u00e1vel (SD) \u2013 superf\u00edcie tratada com adi\u00e7\u00e3o de nano-\n\nhidroxiapatita (NANO). Foram instalados nas t\u00edbias de ratos saud\u00e1veis, mini implantes com \n\nsuperf\u00edcie tratada com adi\u00e7\u00e3o de nano-hidroxiapatita; \n\n- GRUPO 4 (n=12) \u2013 Rato Diab\u00e9tico (DM) \u2013 superf\u00edcie LISA. Foram instalados nas \n\nt\u00edbias de ratos diab\u00e9ticos, mini implantes de superf\u00edcie lisa; \n\n- GRUPO 5 (n=12) \u2013 Rato Diab\u00e9tico (DM) \u2013 superf\u00edcie com duplo ataque \u00e1cido \n\n(DAA). Foram instalados nas t\u00edbias de ratos diab\u00e9ticos, mini implantes com superf\u00edcie tratada \n\ncom duplo ataque \u00e1cido; \n\n- GRUPO 6 (n=12) \u2013 Rato Diab\u00e9tico (DM) \u2013 superf\u00edcie tratada com adi\u00e7\u00e3o de nano-\n\nhidroxiapatita (NANO). Foram instalados nas t\u00edbias de ratos diab\u00e9ticos, mini implantes com \n\nsuperf\u00edcie tratada com adi\u00e7\u00e3o de nano-hidroxiapatita. \n\nOs animais foram eutanasiados com aprofundamento anest\u00e9sico de 150 mg/kg de \n\ntiopentato de s\u00f3dio 2.5% (Thiopentax, Crist\u00e1lia, S\u00e3o Paulo, Brasil), via intraperitoneal, nos \n\nper\u00edodos de 7 e 30 dias  ap\u00f3s a instala\u00e7\u00e3o dos implantes (36 animais para cada tempo, 6 de \n\ncada um dos grupos experimentais). \n\nAs t\u00edbias esquerdas foram removidas e fixadas em 10% de formol tamponado para \n\nposterior an\u00e1lise tridimensional por micro-CT, processamento histol\u00f3gico/an\u00e1lise \n\nhistomorfom\u00e9trica e teste de nanoindenta\u00e7\u00e3o  (Figura 4A e 4B). As t\u00edbias direitas foram \n\nremovidas com o auxilio de uma trefina de 3 mm de di\u00e2metro (Alpha instrumentos, Ribeir\u00e3o \n\nPreto, S\u00e3o Paulo, Brasil) (Figura 5A e 5B), lavadas com solu\u00e7\u00e3o salina tamponada com \n\nfosfato (PBS, Gibco, Invitrogen, Carlsbad, EUA) (Figura 5C), armazenadas em nitrog\u00eanio \n\nl\u00edquido e em seguida no freezer -80\u00baC para posterior avalia\u00e7\u00e3o da express\u00e3o g\u00eanica.  \n\n  \n\n\n\nMaterial e M\u00e9todos  |  36 \n\n \n\n \n\nFigura 4. Remo\u00e7\u00e3o e preparo do material para posterior an\u00e1lise tridimensional por micro-CT, \nprocessamento histol\u00f3gico/an\u00e1lise histomorfom\u00e9trica e teste de nanoindenta\u00e7\u00e3o. A) Aspecto \ninicial. B) T\u00edbia esquerda removida para an\u00e1lise tridimensional por micro-CT, processamento \nhistol\u00f3gico/an\u00e1lise histomorfom\u00e9trica e teste de nanoindenta\u00e7\u00e3o.  \n\n \n\n \n\n \n\n \n\nFigura 5. Remo\u00e7\u00e3o e preparo do material para posterior avalia\u00e7\u00e3o da express\u00e3o g\u00eanica. A) \nAspecto inicial. B) Remo\u00e7\u00e3o do implante e tecido \u00f3sseo adjacente com o auxilio de uma \ntrefina de 3 mm de di\u00e2metro. C) Lavagem da amostra com solu\u00e7\u00e3o de PBS. \n\n  \n\n\n\nMaterial e M\u00e9todos  |  37 \n\n3.5 An\u00e1lise microtomogr\u00e1fica \n\n \n\nAp\u00f3s 48 horas de fixa\u00e7\u00e3o em formol tamponado a 10%, as amostras foram escaneadas \n\nutilizando o Microtom\u00f3grafo SkyScan 1172-160 micro-CT de alta resolu\u00e7\u00e3o (Bruker, \n\nKontich, Antwerp, B\u00e9lgica) para a obten\u00e7\u00e3o das proje\u00e7\u00f5es tomogr\u00e1ficas bidimensionais e a \n\nreconstru\u00e7\u00e3o tridimensional. Todas os escaneamentos foram obtidas em 100 kV e 100 \u00b5A, \n\nusando um filtro de alum\u00ednio-cobre para otimizar o contraste, e definido em 5,87 mm de \n\ntamanho de pixel, rota\u00e7\u00e3o de 360\u00b0, um passo de rota\u00e7\u00e3o de 0,40. As proje\u00e7\u00f5es tomogr\u00e1ficas \n\nbidimensionais e a reconstru\u00e7\u00e3o tridimensional foram realizadas utilizando o software \n\nNRecon (NRecon v.1.6.10.4, Bruker, Kontich, Antwerp, B\u00e9lgica) e os implantes foram \n\nposicionados no seu longo eixo utilizando o software DataViewer (v.1.5.0, Bruker, Kontich, \n\nAntwerp, B\u00e9lgica), onde \u00e9 poss\u00edvel a movimenta\u00e7\u00e3o e visualiza\u00e7\u00e3o dos tr\u00eas eixos (coronal, \n\naxial e sagital). Foi selecionado o eixo de interesse (sagital) para a visualiza\u00e7\u00e3o completa dos \n\nimplantes.  \n\nSequentemente, as reconstru\u00e7\u00f5es foram submetidas a an\u00e1lise morfom\u00e9trica utilizando \n\no software CT Analyser (CTAn., v.1.15.4.0, Bruker, Kontich, Antwerp, B\u00e9lgica) para a \n\nobten\u00e7\u00e3o dos seguintes par\u00e2metros estruturais no osso interno \u00e0s roscas dos implantes: \n\ncontato tridimensional osso implante (IS/TS, %), rela\u00e7\u00e3o entre volume \u00f3sseo e superf\u00edcie \n\n\u00f3ssea (BV/TV, %), rela\u00e7\u00e3o entre superf\u00edcie \u00f3ssea e volume \u00f3sseo (BS/BV, mm), separa\u00e7\u00e3o \n\ntrabecular (Tb.Sp, %) e porosidade total (Po.To, %). \n\nNo CTAN utilizamos uma ferramenta de an\u00e1lise avan\u00e7ada (custom processing), onde \n\ncriamos uma lista de tarefas para an\u00e1lise dos par\u00e2metros adotados. As medi\u00e7\u00f5es foram feitas a \n\npartir de 1 mm da por\u00e7\u00e3o mais coronal do implante, atingindo todo o seu comprimento. Esse \n\nprocesso envolveu a determina\u00e7\u00e3o regi\u00e3o de interesse (ROI). A soma coletiva de todos os \n\nROIs sobre um conjunto cont\u00edguo de fatias da imagem transversal foi usada para determinar o \n\nvolume de interesse (VOI), representando o volume 3D selecionado. A binariza\u00e7\u00e3o foi \n\nrealizada usando a escala de cinza definida por uma densidade de 35-150 para osso, e 150-255 \n\npara implante. Todas as an\u00e1lises de micro-CT foram realizadas por um \u00fanico examinador, \n\ncego para os grupos experimentais.  \n\n \n\n3.6 Processamento e an\u00e1lise histol\u00f3gica \n\n \n\nAp\u00f3s a realiza\u00e7\u00e3o da microtomografia, os esp\u00e9cimes foram transferidos para uma \n\nsolu\u00e7\u00e3o de 70% \u00e1lcool por 72 horas e, ent\u00e3o, desidratados de forma ascendente, at\u00e9 atingir a \n\n\n\nMaterial e M\u00e9todos  |  38 \n\nconcentra\u00e7\u00e3o de 100%. Ap\u00f3s a desidrata\u00e7\u00e3o, as t\u00edbias foram inclu\u00eddas em resina Hard Grade \n\nLR White (London Resin Company, Londres, Londres, Reino Unido) e cortadas usando \n\nExakt Cutting System (Exakt, Norderstedt, Hamburgo, Alemanha). Os cortes longitudinais \n\nobtidos foram polidos e montados em l\u00e2minas de acr\u00edlico, utilizando o Exakt Grinding \n\nSystem (Exakt). As sec\u00e7\u00f5es de 40 \u00b5m de espessura foram reduzidas para uma espessura de 20 \n\n\u00b5m e coradas com Stevenel\u2019s blue e Vermelho de Alizarina. Em seguida, foram digitalizadas \n\natrav\u00e9s de um sistema autom\u00e1tico de digitaliza\u00e7\u00e3o de dispositivos e software de computador \n\nespecializado (Aperio Technologies, Vista, Calif\u00f3rnia, EUA).  \n\nPara avalia\u00e7\u00e3o histomorfom\u00e9trica, um software de an\u00e1lise de imagens (ImageJ, NIH, \n\nBethesda, Maryland, EUA) foi utilizado para quantificar e avaliar os par\u00e2metros de \n\nosseointegra\u00e7\u00e3o em torno da superf\u00edcie peri-implantar. A porcentagem de contato osso-\n\nimplante (% BIC) quantifica o grau de osseointegra\u00e7\u00e3o derivada da estabilidade prim\u00e1ria, \n\nmedindo a porcentagem de osso em contato com o per\u00edmetro da superf\u00edcie do implante \n\n(Figura 6A). J\u00e1 a densidade \u00f3ssea ao redor dos implantes % BAFO avalia o grau de \n\nosseointegra\u00e7\u00e3o derivada da estabilidade secund\u00e1ria, medindo a porcentagem de osso (osso \n\nneoformado, osso nativo rec\u00e9m-formado e n\u00e3o vital devido \u00e0 instrumenta\u00e7\u00e3o) dentro das \n\nroscas do implante (Figura 6B) (Coelho et al. 2012; Gil et al. 2017; Jinno et al. 2017). Todas \n\nas avalia\u00e7\u00f5es foram realizadas por um \u00fanico examinador, cego para os grupos experimentais.  \n\n \n\n \n\nFigura 6.  Esquema ilustrativo dos locais das medi\u00e7\u00f5es de BIC (A) e BAFO (B). \n\n \n\n3.7 Teste mec\u00e2nico de nanoindenta\u00e7\u00e3o \n\n \n\nO teste de nanoindenta\u00e7\u00e3o foi realizado conforme previamente descrito por Coelho et \n\nal., 2014 (Coelho et al. 2014a). Os blocos de resina foram processados da mesma maneira que \n\n\n\nMaterial e M\u00e9todos  |  39 \n\nos cortes histol\u00f3gicos, sem colora\u00e7\u00e3o, polidos com suspens\u00f5es de diamante de 9 a 1 \u00b5m de \n\ntamanho de part\u00edcula (Buehler, Lake Bluff, Illinois, EUA) e hidratados por 24 horas. O \n\nm\u00f3dulo de elasticidade e a dureza do osso neoformado foram avaliados no nanoindentador \n\n(Hysitron TI 950, Minneapolis, Minnesota, EUA) (n = 30 por amostra) equipado com uma \n\nponta em forma de pir\u00e2mide de tr\u00eas lados com diamante Berkovich (Baldassarri et al. 2012). \n\nUm perfil de carga foi desenvolvido com uma carga de pico de 300 \u00b5N a uma taxa de 60 \n\n\u00b5N/seg, seguido por um tempo de espera de 10 segundos e um tempo de descarga de 2 \n\nsegundos. O per\u00edodo de carga prolongado permitiu que o osso relaxasse para uma resposta \n\nmais linear, de modo que nenhum efeito de flu\u00eancia tecidual ocorreu na por\u00e7\u00e3o de descarga \n\ndo perfil (ISO 14577-4). Ao fim de cada indenta\u00e7\u00e3o uma curva de deslocamento de carga foi \n\nobtida (Doerner and Nix 1986). \n\nPara cada amostra, o teste mec\u00e2nico foi realizado dentro da regi\u00e3o de rosca, localizada \n\nentre a primeira e a segunda rosca. Se n\u00e3o houvesse osso cortical nessa regi\u00e3o, o esp\u00e9cime foi \n\ndescartado. O tecido \u00f3sseo nessas regi\u00f5es foi detectado inicialmente por meio de imagem \n\natrav\u00e9s de um microsc\u00f3pio de luz (Hysitron) (Doerner and Nix 1986). \n\nA partir de cada curva de deslocamento de carga gerada, o m\u00f3dulo de elasticidade \n\n(ME, em GPa) e a dureza (D, em GPa) do tecido \u00f3sseo cortical foram calculados por meio do \n\nsoftware Hysitron TriboScan usando as seguintes f\u00f3rmulas, respectivamente: \n\n \n\nE?\t = ??2?A(h?) \u00d7 \tS; \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tH =\t\nPmax\t\nA(h?)  \n\n \n\nOnde S \u00e9 a rigidez, hc \u00e9 a profundidade de contato, Pmax \u00e9 a for\u00e7a m\u00e1xima aplicada \n\n(300 \u00b5N) e A (hc) \u00e9 a \u00e1rea de contato computada do software TriboScan utilizando a fun\u00e7\u00e3o \n\nde \u00e1rea com rela\u00e7\u00e3o \u00e0 profundidade de contato. Atrav\u00e9s do m\u00f3dulo reduzido Er, o m\u00f3dulo de \n\nelasticidade correspondente Eb (GPa) pode ser calculado usando a seguinte equa\u00e7\u00e3o: \n\n \n\n1\nE? =\n\n1 ?\tv??\nE? +\n\n1 ?\tv??\nE?  \n\n \n\nOnde vb (0,3) \u00e9 o coeficiente de Poisson para o osso cortical, Ei (1140 GPa) \u00e9 o \n\nm\u00f3dulo el\u00e1stico do penetrador, e vi (0,07) \u00e9 o coeficiente de Poisson para o penetrador \n\n(Hoffler et al. 2005; Hoffler et al. 2000). Essa metodologia mostrou-se bem sucedida na \n\n\n\nMaterial e M\u00e9todos  |  40 \n\ndetermina\u00e7\u00e3o das propriedades mec\u00e2nicas do osso atrav\u00e9s da nanoindenta\u00e7\u00e3o (Anchieta et al. \n\n2014; Baldassarri et al. 2012; Jimbo et al. 2013; Jimbo et al. 2012a; Lee et al. 2013). \n\n \n\n3.8 Avalia\u00e7\u00e3o da express\u00e3o g\u00eanica  \n\n \n\n3.8.1 Extra\u00e7\u00e3o de RNA (\u00e1cido ribonucleico) total \n\n \n\nAs amostras (2 t\u00edbias do mesmo grupo) foram colocadas em um cadinho de porcelana \n\npreviamente queimado a 200\u00ba por 6 horas. Em seguida, foi acrescentado nitrog\u00eanio l\u00edquido e \n\ncom auxilio de um pistilo foi realizado o maceramento das amostras, com movimento e for\u00e7a \n\nmec\u00e2nica, at\u00e9 que todo tecido \u00f3sseo se destacasse do implante e obtivesse o aspecto \n\n\"esfarelado\". Sequentemente, foi adicionado 1 ml do reagente Trizol (Gibco, Invitrogen, \n\nCarlsbad, EUA). As amostras foram mantidas em temperatura ambiente durante 15 minutos e \n\narmazenadas no freezer -20\u00baC at\u00e9 serem processadas. Ao final, foi poss\u00edvel obter quantidade \n\nde RNA total para realiza\u00e7\u00e3o dos experimentos envolvendo express\u00e3o g\u00eanica. \n\nNo momento da extra\u00e7\u00e3o do RNA, para cada 1 mL do reagente Trizol (Gibco, \n\nInvitrogen, Carlsbad, EUA) foram adicionados 250 \u00b5L de clorof\u00f3rmio (Merck, Darmstadt, \n\nAlemanha). Os tubos foram vigorosamente agitados por 30 segundos e mantidos no gelo \n\ndurante 5 minutos. A seguir, as amostras foram centrifugadas a 4\u00b0C e 12000 g, por 15 \n\nminutos, e a fase aquosa (superior) coletada em novos tubos de 2 mL (Eppendorf AG, \n\nHamburg, Alemanha). Em seguida, foram adicionados 250 \u00b5L de etanol 96% (Merck, \n\nDarmstadt, Alemanha) \u00e0s amostras e as mesmas centrifugadas em colunas de s\u00edlica gel \n\npresentes no kit SV Total RNA Isolation System (Promega, Madison, EUA). O restante do \n\nprocesso de extra\u00e7\u00e3o de RNA total foi realizado de acordo com instru\u00e7\u00f5es do fabricante. \n\nA concentra\u00e7\u00e3o e pureza do RNA total foram avaliadas por espectrofotometria em \n\naparelho NanoVue (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). A \n\nleitura foi realizada nos comprimentos de onda de 260 nm e as raz\u00f5es 260:280 nm e 260:230 \n\nnm para a obten\u00e7\u00e3o da concentra\u00e7\u00e3o de RNA/\u00b5L e verifica\u00e7\u00e3o de contamina\u00e7\u00e3o por prote\u00ednas \n\ne fenol, respectivamente. Apenas as amostras que apresentaram a propor\u00e7\u00e3o 260:280 e \n\n260:230 maior que 1.8 foram consideradas para os ensaios de PCR (Rea\u00e7\u00e3o em Cadeia de \n\nPolimerase) em tempo real. Em seguida, a integridade do RNA total foi analisada utilizando o \n\nequipamento 2100 Bioanalyzer (Agilent Technologies, Stockport, Manchester, United \n\nKingdom). Brevemente, as amostras do RNA total foram aquecidas a 70\u00baC por 2 minutos e \n\n\n\nMaterial e M\u00e9todos  |  41 \n\nmantidas no gelo at\u00e9 o momento da aplica\u00e7\u00e3o no gel. A matriz do gel aplicada nos capilares \n\ndo chip cont\u00e9m uma mistura de fluor\u00f3foros e marcadores de peso molecular. A liga\u00e7\u00e3o dos \n\nfluor\u00f3foros ao marcador de tamanho e ao RNA resulta na emiss\u00e3o de fluoresc\u00eancia, que \u00e9 \n\nquantificada, permitindo a separa\u00e7\u00e3o do RNA riboss\u00f4mico 18S e 28S e a verifica\u00e7\u00e3o da \n\nintegridade do RNA total a partir da atribui\u00e7\u00e3o de um n\u00famero de integridade do RNA (RNA \n\nIntegrity Number - RIN) que varia de 1 a 10. As amostras que apresentaram RIN maior ou \n\nigual a 7 foram consideradas para an\u00e1lise.  \n\n \n\n3.8.2 S\u00edntese da fita de DNA (\u00e1cido desoxirribonucleico) complementar \n\n \n\nO DNA complementar (cDNA) foi sintetizado a partir de 1 \u00b5g de RNA total por \n\nrea\u00e7\u00e3o de transcri\u00e7\u00e3o reversa utilizando-se o kit High-capacity cDNA Reverse Transcription \n\nKits (Applied Biosystems, Foster City, EUA), de acordo com as instru\u00e7\u00f5es do fabricante. \n\nBrevemente, em um tubo de 200 \u00b5L (Axygen Scientific Inc., Union City, EUA) foram \n\nadicionados: 1 \u00b5g de RNA total dilu\u00eddo em um volume final de 10 \u00b5L de \u00e1gua previamente \n\ntratada com DEPC (Sigma Aldrich, St. Louis, EUA), 2 \u00b5L de (10X) RT buffer, 0,8 \u00b5L de \n\n(25X) dNTP mix (100 mM), 2 \u00b5L (10X) RT Random Primers, 1 \u00b5L de MultiScribeTM \n\nReverse Transcriptase, 1 \u00b5L de RNase Inhibitor e 3,2 \u00b5L de \u00e1gua DEPC, para um volume \n\nfinal de 20 \u00b5L/rea\u00e7\u00e3o. Em seguida, as amostras foram incubadas em termociclador Master \n\nCycler Gradiente (Eppendorf AG) sob as seguintes condi\u00e7\u00f5es: 25\u00baC por 10 minutos, 37\u00baC por \n\n120 minutos, 85\u00baC por 5 minutos, seguido pelo resfriamento a 4\u00baC. Ao final da rea\u00e7\u00e3o de \n\ntranscri\u00e7\u00e3o reversa as amostras de DNAc foram estocadas em freezer -20\u00b0C. \n\n \n\n3.8.3 Rea\u00e7\u00e3o de PCR em tempo real utilizando o sistema de sondas Taqman \n\n \n\nPara realiza\u00e7\u00e3o da t\u00e9cnica de PCR em tempo real foi utilizado o sistema de sondas \n\nTaqman em um aparelho StepOnePlus (Life Technologies). Para cada rea\u00e7\u00e3o foram \n\nadicionados: 5 \u00b5L de Taqman\u00ae Gene Expression Master Mix (2X)2, 0,5 \u00b5L de (20X) \n\nTaqman\u00ae Gene Expression Master Mix e 4,5 \u00b5L de cDNA (11,25 ng), para um volume final \n\nde 10 \u00b5L/rea\u00e7\u00e3o. As rea\u00e7\u00f5es de amplifica\u00e7\u00e3o consistem em 2 minutos a 50\u00baC, 10 minutos a \n\n95\u00baC, e quarenta ciclos de 15 segundos a 95\u00baC e, 1 minuto a 60\u00baC.  \n\nOs resultados foram analisados com base no valor de Ct (cicle threshold), sendo este o \n\nponto correspondente ao n\u00famero de ciclos em que a amplifica\u00e7\u00e3o das amostras atinge um \n\nlimiar (determinado entre o n\u00edvel de fluoresc\u00eancia dos controles negativos e a fase de \n\n\n\nMaterial e M\u00e9todos  |  42 \n\namplifica\u00e7\u00e3o exponencial das amostras) permitindo a an\u00e1lise quantitativa da express\u00e3o do \n\ngene avaliado. O gene de refer\u00eancia Gapdh foi utilizados para a normaliza\u00e7\u00e3o dos n\u00edveis de \n\nexpress\u00e3o do gene alvo e o grupo saud\u00e1vel 7 dias (superf\u00edcie LISA) foi considerado calibrador \n\ndas amostras. Uma amostra negativa (\u00e1gua) foi submetida \u00e0 rea\u00e7\u00e3o com cada sonda Taqman \n\nutilizada. A quantifica\u00e7\u00e3o dos dados de express\u00e3o g\u00eanica foi realizada utilizado o m\u00e9todo de \n\n2- ??CT (Livak and Schmittgen 2001). \n\n \n\n3.9 An\u00e1lise Estat\u00edstica \n\n \n\nTodas as vari\u00e1veis foram apresentadas em fun\u00e7\u00e3o dos valores m\u00e9dios com o intervalo \n\nde confian\u00e7a correspondente a 95% (m\u00e9dia \u00b1 95% IC). An\u00e1lises preliminares mostraram \n\nvari\u00e2ncias indistingu\u00edveis (teste de Levene, todas p> 0,25). Adicionalmente, os dados foram \n\ncoletados e alinhados ao longo de um modelo linear misto com fatores fixos de tempo (7 e 30 \n\ndias), condi\u00e7\u00e3o sist\u00eamica (saud\u00e1vel e diab\u00e9tico) e modifica\u00e7\u00f5es de superf\u00edcie (lisa, duplo \n\nataque \u00e1cido e nano-hidroxiapatita). Teste de Tukey foi utilizado para compara\u00e7\u00f5es m\u00faltiplas. \n\nA an\u00e1lise foi realizada usando SPSS (IBM SPSS 23, IBM Corp., Armonk, Nova York, EUA). \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4 Resultados \n\n  \n\n\n\nResultados  |  44 \n\n4 RESULTADOS  \n\n \n\nN\u00e3o houve complica\u00e7\u00f5es relacionadas ao procedimento cir\u00fargico, todos os animais \n\nrecuperaram a consci\u00eancia at\u00e9 30 minutos ap\u00f3s a cirurgia e o per\u00edodo p\u00f3s-operat\u00f3rio \n\ntranscorreu sem intercorr\u00eancias. Adicionalmente, n\u00e3o foram detectados eventos adversos, \n\ncomo a exposi\u00e7\u00e3o do implante, e foi observado um aspecto clinicamente saud\u00e1vel na \u00e1rea \n\noperada ao longo de todo o per\u00edodo experimental.  \n\nA figura 7 demonstra os valores de glicemia (mg/dL) (m\u00e9dia e desvio padr\u00e3o) dos \n\ngrupos saud\u00e1vel e diab\u00e9tico no momento da instala\u00e7\u00e3o dos implantes e no dia da eutan\u00e1sia. \n\nOs valores encontrados para o grupo saud\u00e1vel (cirurgia: 89,55 \u00b1 8,88 e eutan\u00e1sia: 92,19 \u00b1 \n\n9,67) e diab\u00e9tico (cirurgia: 499,88 \u00b1 62,27 e eutan\u00e1sia: 544,63 \u00b1 57,07) confirmam o \n\nestabelecimento do modelo proposto.  \n\n \n\n \n\nFigura 7. Valores de glicemia (mg/dL) (m\u00e9dia e desvio padr\u00e3o) os grupos saud\u00e1vel e diab\u00e9tico \nno momento da instala\u00e7\u00e3o dos implantes e no dia da eutan\u00e1sia \n\n \n\n4.1 Resultados Microtomogr\u00e1ficos \n\n \n\nUma avalia\u00e7\u00e3o qualitativa das imagens reconstru\u00eddas em 3D de todos os grupos \n\nexperimentais \u00e9 evidenciada na Figura 8 (A-L). Todas as imagens confirmam o reparo \u00f3sseo \n\nbem sucedido, independentemente do tempo, tipo de implante e condi\u00e7\u00e3o sist\u00eamica. Uma \n\ndiferen\u00e7a expressiva foi observada entre 7 e 30 dias. Com rela\u00e7\u00e3o ao tratamento de superf\u00edcie, \n\no grupo NANO evidenciou um contato \u00f3sseo mais \u00edntimo ao implante quando comparado \u00e0s \n\n89,55 92,19\n\n499,88\n544,63\n\n0\n\n100\n\n200\n\n300\n\n400\n\n500\n\n600\n\nCirurgia Eutan\u00e1sia Cirurgia Eutan\u00e1sia\n\nSaud\u00e1vel Diab\u00e9tico\n\nm\ng\n\n/\nd\n\nL\n\nGlicemia \n\n\n\nResultados  |  45 \n\nsuperf\u00edcies LISA e DAA. Al\u00e9m disso, aos 30 dias, implantes com revestimento NANO \n\nrepresentaram locais de remodela\u00e7\u00e3o aumentados e forma\u00e7\u00e3o de novo osso em compara\u00e7\u00e3o ao \n\nper\u00edodo experimental de 7 dias. \n\n \n\n \n\nFigura 8. (A-L) Reconstru\u00e7\u00e3o das imagens em 3D. Implante com superf\u00edcie LISA (A, D, G e \nJ), DAA (B, E, H, K) e NANO (C, F, I, L) instalados em t\u00edbias de ratos saud\u00e1veis (A, B, C) e \ndiab\u00e9ticos (D, E, F) nos tempos de 7 (A-F) e 30 (G-L) dias.  \n\n  \n\n\n\nResultados  |  46 \n\n4.1.1 Contato tridimensional osso implante (IS/TS) \n\n \n\nA porcentagem do contato tridimensional osso implante (% IS/TS) em fun\u00e7\u00e3o do \n\ntempo demonstrou diferen\u00e7a estatisticamente significantes entre 7 (24,74 \u00b1 1,11) e 30 (40,47 \n\n\u00b1 1,11) dias (p<0.001) (Figura 9 A). O grupo saud\u00e1vel (35,23 \u00b1 1,11) apresentou maior % \n\nIS/TS quando comparado ao diab\u00e9tico (29,98 \u00b1 1,11) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o \n\nsist\u00eamica) (p<0.001) (Figura 9 B). Ao considerar a superf\u00edcie do implante, o grupo NANO \n\n(38,52 \u00b1 1,36) exibiu maior % IS/TS em rela\u00e7\u00e3o aos grupos LISA (26,60 \u00b1 1,36) e DAA \n\n(32,69 \u00b1 1,36) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.001) (Figura 9 C). \n\nComparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias (44,01 \u00b1 1,57) apresentou \n\ndiferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos experimentais (saud\u00e1vel 7 \n\ndias = 26,44 \u00b1 1,57, diab\u00e9tico 7 dias = 23,05 \u00b1 1,57, diab\u00e9tico 30 dias = 36,92 \u00b1 1,57) \n\n(p<0.004) (Figura 9 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \n\nimplante, evidenciou uma superioridade do grupo NANO 30 dias (46,14 \u00b1 1,92) em rela\u00e7\u00e3o \n\naos demais (LISA 7 dias = 18,70 \u00b1 1,92, DAA 7 dias = 24,63 \u00b1 1,92, NANO 7 dias 30,91 \u00b1 \n\n1,92, LISA 30 dias = 34,50 \u00b1 1,92, DAA 30 dias = 40,75 \u00b1 1,92) (p<0.001) (Figura 9 E). \n\nQuando a % IS/TS foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o grupo \n\nNANO saud\u00e1vel (40,82 \u00b1 1,92) apresentou diferen\u00e7a estatisticamente significante (p=0.001) \n\n(Figura 9 F). Avaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de \n\nsuperf\u00edcie), os resultados evidenciaram que a superf\u00edcie NANO apresentou os melhores \n\nresultados aos 7 dias (saud\u00e1vel = 32,34 \u00b1 2,72 e diab\u00e9tico = 29,47 \u00b1 2,72) e aos 30 dias \n\n(saud\u00e1vel = 49,30 \u00b1 2,72) (p<0.046) (Figura 10). \n\n  \n\n\n\nResultados  |  47 \n\n \n\n \n\n \n\n \n\n \nFigura 9. A-F. Gr\u00e1ficos representando % IS/TS ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do \ntempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). \nEm fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \nimplante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam \nque n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n\n\nResultados  |  48 \n\n \nFigura 10. Gr\u00e1fico representando a % IS/TS quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n \n\n4.1.2 Densidade \u00f3ssea tridimensional (BV/TV)  \n\n \n\nA porcentagem da densidade \u00f3ssea tridimensional (% BV/TV) em fun\u00e7\u00e3o do tempo \n\ndemonstrou diferen\u00e7a estatisticamente significantes entre 7 (16,16 \u00b1 0,58) e 30 (21,12 \u00b1 0,58) \n\ndias (p<0.001) (Figura 11 A). O grupo saud\u00e1vel (19,22 \u00b1 0,58) apresentou maior % BV/TV \n\nquando comparado ao diab\u00e9tico (18,07 \u00b1 0,58) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) \n\n(p=0.007) (Figura 11 B). Ao considerar a superf\u00edcie do implante, o grupo NANO (20,97 \u00b1 \n\n0,71) exibiu maior % BV/TV em rela\u00e7\u00e3o aos grupos LISA (16,60 \u00b1 0,71) e DAA (18,36 \u00b1 \n\n0,71) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.001) (Figura 11 C). Comparando \n\ntempo e condi\u00e7\u00e3o sist\u00eamica, os grupos 30 dias (saud\u00e1vel = 21,82 \u00b1 0,82 e diab\u00e9tico = 20,42 \u00b1 \n\n0,82) apresentaram diferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o ao grupo de 7 dias \n\n(saud\u00e1vel = 16,62 \u00b1 0,82 e diab\u00e9tico = 15,71 \u00b1 0,82) (p<0.001) (Figura 11 D). A avalia\u00e7\u00e3o \n\ndos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante, evidenciou uma superioridade do \n\ngrupo NANO aos 30 dias (23,58 \u00b1 1,01) em rela\u00e7\u00e3o aos demais (LISA 7 dias = 13,98 \u00b1 1,01, \n\nDAA 7 dias = 16,15 \u00b1 1,01, NANO 7 dias = 18,36 \u00b1 1,01, LISA 30 dias = 19,22 \u00b1 1,01, DAA \n\n30 dias = 20,56 \u00b1 1,01) (p<0.001) (Figura 11 E). Quando a % BV/TV foi avaliada em fun\u00e7\u00e3o \n\nda condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, os grupos NANO saud\u00e1vel (20,85 \u00b1 1,01) e diab\u00e9tico \n\n(21,08 \u00b1 1,01) apresentaram diferen\u00e7as estatisticamente significantes (p=0.027) (Figura 11 F). \n\nAvaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os \n\n\n\nResultados  |  49 \n\nresultados evidenciaram que a superf\u00edcie NANO apresentou os melhores resultados aos 7 dias \n\n(saud\u00e1vel = 18,51 \u00b1 1,43 e diab\u00e9tico = 18,20 \u00b1 1,43) e aos 30 dias (saud\u00e1vel = 23,20 \u00b1 1,43 e \n\ndiab\u00e9tico = 23,95 \u00b1 1,43) (p<0.001) (Figura 12). \n\n \n\n \n\nFigura 11. A-F. Gr\u00e1ficos representando % BV/TV ao redor do implante, organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do \ntempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). \nEm fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \nimplante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam \nque n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  50 \n\n \n\nFigura 12. Gr\u00e1fico representando a % BV/TV quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significativa entre os grupos. \n\n \n\n4.1.3 Rela\u00e7\u00e3o da superf\u00edcie \u00f3ssea pelo volume \u00f3sseo (BS/BV)  \n\n \n\nA rela\u00e7\u00e3o da superf\u00edcie \u00f3ssea pelo volume \u00f3sseo (BS/BV) em fun\u00e7\u00e3o do tempo \n\ndemonstrou diferen\u00e7a estatisticamente significante entre 7 (96,28 \u00b1 1,65) e 30 (81,77 \u00b1 1,65) \n\ndias (p<0.001) (Figura 13 A). N\u00e3o houve diferen\u00e7a entre o grupo saud\u00e1vel (88,55 \u00b1 1,65) e \n\ndiab\u00e9tico (89,51 \u00b1 1,65) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) (p=0.414) (Figura 13 B). \n\nAo considerar a superf\u00edcie do implante, o grupo NANO (95,28 \u00b1 2,02) exibiu maior BS/BV \n\nem rela\u00e7\u00e3o aos grupos LISA (85,25 \u00b1 2,02) e DAA (86,55 \u00b1 2,02) (dados em fun\u00e7\u00e3o da \n\nsuperf\u00edcie do implante) (p<0.001) (Figura 13 C). Comparando tempo e condi\u00e7\u00e3o sist\u00eamica, os \n\ngrupos de 7 dias (saud\u00e1vel = 95,99 \u00b1 2,33 e diab\u00e9tico = 96,58 \u00b1 2,33) apresentaram diferen\u00e7as \n\nestat\u00edsticas significantes em rela\u00e7\u00e3o aos grupos de 30 dias (saud\u00e1vel = 81,11 \u00b1 2,33 e \n\ndiab\u00e9tico = 82,43 \u00b1 2,33) (p<0.001) (Figura 13 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do \n\ntempo e da superf\u00edcie do implante evidenciou uma superioridade do grupo NANO 7 dias \n\n(105,34 \u00b1 2,86) em rela\u00e7\u00e3o aos demais (LISA 7 dias = 90,99 \u00b1 2,86, DAA 7 dias = 92,52 \u00b1 \n\n2,86, LISA 30 dias = 79,31 \u00b1 2,86, DAA 30 dias = 80,57 \u00b1 2,86, NANO 30 dias = 85,23 \u00b1 \n\n2,86) (p<0.025) (Figura 13 E). Quando a BS/BV foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o \n\nsist\u00eamica e da superf\u00edcie, o grupo NANO saud\u00e1vel (98,17 \u00b1 2,86) apresentou diferen\u00e7a \n\nestatisticamente significante (p=0.006) (Figura 13 F). Avaliando todos os fatores (tempo, \n\ncondi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os resultados evidenciaram que a superf\u00edcie \n\n\n\nResultados  |  51 \n\nNANO saud\u00e1vel apresentou os melhores resultados aos 7 dias (109,87 \u00b1 4,04) (p=0.003) \n\n(Figura 14). \n\n \n\n \n\nFigura 13. A-F. Gr\u00e1ficos representando BS/BV ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do \ntempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). \nEm fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \nimplante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam \nque n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  52 \n\n \n\nFigura 14. Gr\u00e1fico representando BS/BV quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significativa entre os grupos. \n\n \n\n4.1.4 Separa\u00e7\u00e3o Trabecular (Tb.Sp)  \n\n \n\nA separa\u00e7\u00e3o trabecular (Tb.Sp) em fun\u00e7\u00e3o do tempo n\u00e3o demonstrou diferen\u00e7a \n\nestatisticamente significantes entre 7 (0,44 \u00b1 0,04) e 30 (0,43 \u00b1 0,04) dias (p=0.844) (Figura \n\n15 A). N\u00e3o houve diferen\u00e7a entre o grupo saud\u00e1vel (0,41 \u00b1 0,04) e diab\u00e9tico (0,46 \u00b1 0,04) \n\n(dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) (p=0.116) (Figura 15 B). Ao considerar a superf\u00edcie \n\ndo implante, o grupo NANO (0,50 \u00b1 0,05) exibiu maior Tb.Sp em rela\u00e7\u00e3o aos grupos LISA \n\n(0,39 \u00b1 0,05) e DAA (0,42 \u00b1 0,05) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p=0.013) \n\n(Figura 15 C). N\u00e3o houve diferen\u00e7as estatisticamente significantes ao comparar tempo e \n\ncondi\u00e7\u00e3o sist\u00eamica (p>0.208) (Figura 15 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da \n\nsuperf\u00edcie do implante demonstrou para o grupo NANO 7 dias (0,49 \u00b1 0,07) valores \n\nequivalentes aos grupos DAA e NANO 30 dias (p>0.715) (Figura 15 E). Ao avaliar Tb.Sp em \n\nfun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o grupo diab\u00e9tico NANO (0,55 \u00b1 0,11) \n\napresentou diferen\u00e7as significantes em rela\u00e7\u00e3o aos outros grupos (p<0.046) (Figura 15F). \n\nAvaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os \n\nresultados evidenciaram que a superf\u00edcie NANO apresentou os melhores resultados aos 7 dias \n\n(diab\u00e9tico = 0,54 \u00b1 0,11) e aos 30 dias (diab\u00e9tico = 0,57 \u00b1 0,11) (p<0.029) (Figura 16). \n\n  \n\n\n\nResultados  |  53 \n\n \n\n \n\n \n\n \n\nFigura 15. A-F. Gr\u00e1ficos representando Tb.Sp ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do \ntempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). \nEm fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \nimplante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam \nque n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  54 \n\n \n\nFigura 16. Gr\u00e1fico representando Tb.Sp quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.1.5 Porcentagem porosidade total (Po.To)  \n\n \n\nA porcentagem de porosidade total (% Po.To) em fun\u00e7\u00e3o do tempo demonstrou \n\ndiferen\u00e7a estatisticamente significante entre 7 (83,29 \u00b1 0,58) e 30 (80,15 \u00b1 0,58) dias \n\n(p<0.001) (Figura 17 A). O grupo saud\u00e1vel (80,76 \u00b1 0,58) apresentou maior % Po.To quando \n\ncomparado ao diab\u00e9tico (82,69 \u00b1 0,58) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) (p<0.001) \n\n(Figura 17 B). Ao considerar a superf\u00edcie do implante, o grupo NANO (84,39 \u00b1 0,71) exibiu \n\nmaior % Po.To em rela\u00e7\u00e3o aos grupos LISA (80,22 \u00b1 0,71) e DAA (80,57 \u00b1 0,71) (dados em \n\nfun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.001)  (Figura 17 C). N\u00e3o houve diferen\u00e7as estat\u00edsticas \n\nao comparar tempo e condi\u00e7\u00e3o sist\u00eamica (p=0.643) (Figura 17 D). A avalia\u00e7\u00e3o dos dados em \n\nfun\u00e7\u00e3o do tempo e da superf\u00edcie do implante evidenciou uma superioridade do grupo NANO \n\n7 dias (87,04 \u00b1 1,01) em rela\u00e7\u00e3o aos demais (LISA 7 dias = 81,38 \u00b1 1,01, DAA 7 dias = 81,46 \n\n\u00b1 1,01, LISA 30 dias = 79,05 \u00b1 1,01, DAA 30 dias = 79,68 \u00b1 1,01, NANO 30 dias = 81,73 \u00b1 \n\n1,01) (p<0.016) (Figura 17 E). Quando % Po.To foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o \n\nsist\u00eamica e da superf\u00edcie, o grupo NANO diab\u00e9tico (85,53 \u00b1 1,01) apresentou diferen\u00e7a \n\nestatisticamente significante (p<0.001) (Figura 17 F). Avaliando todos os fatores (tempo, \n\ncondi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os resultados evidenciaram que a superf\u00edcie \n\n\n\nResultados  |  55 \n\nNANO apresentou os melhores resultados aos 7 dias (saud\u00e1vel = 86,90 \u00b1 1,43 e diab\u00e9tico = \n\n87,19 \u00b1 1,43) e aos 30 dias (diab\u00e9tico = 83,87 \u00b1 1,43) (p<0.022) (Figura 18). \n\n \n\n \n\nFigura 17. A-F. Gr\u00e1ficos representando % Po.To ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do \ntempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). \nEm fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \nimplante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam \nque n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  56 \n\n \n\nFigura 18. Gr\u00e1fico representando % Po.To quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.2 Resultados Histomorfom\u00e9tricos:  \n\n \n\nUma avalia\u00e7\u00e3o qualitativa das micrografias histol\u00f3gicas de todos os grupos \u00e9 \n\nevidenciada na Figura 19 (A-L). Todas as imagens confirmam uma osseointegra\u00e7\u00e3o bem \n\nsucedida, independentemente do tempo, tipo de implante e condi\u00e7\u00e3o sist\u00eamica. No geral, foi \n\nevidente a diferen\u00e7a observada entre 7 e 30 dias. Com rela\u00e7\u00e3o ao tratamento de superf\u00edcie, o \n\ngrupo NANO apresentou um contato \u00f3sseo mais \u00edntimo ao implante quando comparado a \n\nsuperf\u00edcie LISA e DAA. Al\u00e9m disso, aos 30 dias, micrografias de implantes de revestimento \n\nNANO representaram locais de remodela\u00e7\u00e3o aumentados e forma\u00e7\u00e3o de novo osso em \n\ncompara\u00e7\u00e3o com imagens de 7 dias. \n\n  \n\n\n\nResultados  |  57 \n\n \n\n \n\nFigura 19. A-L. Imagens histol\u00f3gicas coradas com Stevenel\u2019s blue e Vermelho de Alizarina \nde todos os grupos experimentais. Grupo saud\u00e1vel (A, B, C, G, H e I) e diab\u00e9tico (D, E, F, J, \nK e L) dos implantes com superf\u00edcie LISA (A, D, G e J), DAA (B, E, H e K) e NANO (C, F, I \ne L).  \n\n \n\n\n\nResultados  |  58 \n\n4.2.1 Contato osso implante (BIC) \n\n \n\nCorrelacionando a an\u00e1lise histol\u00f3gica, as medidas histomorfom\u00e9tricas da porcentagem \n\nde contato osso-implante (% BIC) em fun\u00e7\u00e3o do tempo demonstraram diferen\u00e7a \n\nestatisticamente significante entre 7 (25,32 \u00b1 2,61) e 30 (59,69 \u00b1 2,61) dias (p<0.001) (Figura \n\n20 A). N\u00e3o foram encontradas diferen\u00e7as significativas ao comparar o grupo saud\u00e1vel (43,03 \n\n\u00b1 2,61) e diab\u00e9tico (41,96 \u00b1 2,61) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) (p=0.632) (Figura \n\n20 B). Ao considerar a superf\u00edcie do implante, o grupo NANO (57,39 \u00b1 3,20) exibiu maior % \n\nBIC em rela\u00e7\u00e3o aos grupos LISA (32,35 \u00b1 3,20) e DAA (37,74 \u00b1 3,20) (dados em fun\u00e7\u00e3o da \n\nsuperf\u00edcie do implante) (p<0.001) (Figura 20 C). Ao comparar tempo e condi\u00e7\u00e3o sist\u00eamica, os \n\ngrupos 30 dias (saud\u00e1vel = 59,37 \u00b1 4,27, diab\u00e9tico = 59,66 \u00b1 4,27) apresentaram diferen\u00e7as \n\nsignificantes em rela\u00e7\u00e3o aos grupos 7 dias (saud\u00e1vel 7 dias = 28 \u00b1 4,27, diab\u00e9tico 7 dias = \n\n25,65 \u00b1 4,27) (p<0.001) (Figura 20 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da \n\nsuperf\u00edcie do implante evidenciou a superioridade do grupo NANO 30 dias (74,13 \u00b1 4,53) em \n\nrela\u00e7\u00e3o aos demais (LISA 7 dias = 13,62 \u00b1 4,53, DAA 7 dias = 21,62 \u00b1 4,53, NANO 7 dias = \n\n40,65 \u00b1 4,53, LISA 30 dias = 51,07 \u00b1 4,53, DAA 30 dias = 53,87 \u00b1 4,53) (p<0.001) (Figura \n\n20 E). Quando a % BIC foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o grupo \n\nNANO diab\u00e9tico (62,58 \u00b1 4,53) apresentou diferen\u00e7a estat\u00edstica significante (p<0.001) \n\n(Figura 20 F). Avaliando todos os fatores: tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de \n\nsuperf\u00edcie, os resultados evidenciaram que a superf\u00edcie NANO apresentou os melhores \n\nresultados nos grupos diab\u00e9ticos 7 dias (35,94 \u00b1 6,40) e 30 dias (79,80 \u00b1 6,40) (p<0.001) \n\n(Figura 21). \n\n \n\n  \n\n\n\nResultados  |  59 \n\n \n\n \n\n \n\nFigura 20. A-F. Gr\u00e1ficos representando a % BIC organizados diferentemente em fun\u00e7\u00e3o dos \nfatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o \nsist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o \nsist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o \nsist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a estatisticamente \nsignificante entre os grupos. \n\n \n\n\n\nResultados  |  60 \n\n \n\nFigura 21. Gr\u00e1fico representando a % BIC quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.2.2 Densidade \u00f3ssea ao redor do implante (BAFO) \n\n \n\nA porcentagem da densidade \u00f3ssea ao redor do implante (% BAFO) em fun\u00e7\u00e3o do \n\ntempo demonstrou diferen\u00e7a estatisticamente significantes entre 7 (31,46 \u00b1 2,99) e 30 (52,87 \n\n\u00b1 2,99) dias (p<0.001) (Figura 22 A). O grupo saud\u00e1vel (44,31 \u00b1 2,99) apresentou maior % \n\nBAFO quando comparado ao diab\u00e9tico (40,02 \u00b1 2,99) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o \n\nsist\u00eamica) (p=0.048) (Figura 22 B). Ao considerar a superf\u00edcie do implante, o grupo NANO \n\n(47,64 \u00b1 3,66) exibiu maior % BAFO em rela\u00e7\u00e3o aos grupos LISA (38,80 \u00b1 3,66) e DAA \n\n(40,05 \u00b1 3,66) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p=0.002) (Figura 22 C). \n\nComparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias ( 59,16 \u00b1 4,23 ) \n\napresentou diferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos experimentais \n\n(saud\u00e1vel 7 dias = 29,45 \u00b1 4,23, diab\u00e9tico 7 dias = 33,47 \u00b1 4,23, diab\u00e9tico 30 dias = 46,58 \u00b1 \n\n4,23) (p<0.001) (Figura 22 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \n\nimplante, evidenciou uma superioridade do grupo NANO 30 dias (56,95 \u00b1 5,18) dias em \n\nrela\u00e7\u00e3o aos demais (LISA 7 dias = 26,83 \u00b1 5,18, DAA 7 dias = 29,22 \u00b1 5,18, NANO 7 dias \n\n38,34 \u00b1 5,18, LISA 30 dias = 50,77 \u00b1 5,18, DAA 30 dias = 50,88 \u00b1 5,18) (p<0.001) (Figura \n\n22 E). N\u00e3o foram encontradas diferen\u00e7as estatisticamente significants quando a % BAFO foi \n\navaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (p=0.616) (Figura 22 F). Avaliando \n\n\n\nResultados  |  61 \n\ntodos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os resultados \n\nevidenciaram que a superf\u00edcie NANO apresentou os melhores resultados aos 7 dias (saud\u00e1vel \n\n= 38,28 \u00b1 7,33 e diab\u00e9tico = 38,39 \u00b1 7,33) (p<0.009) (Figura 23). \n\n \n\n \n\nFigura 22. A-F. Gr\u00e1ficos representando a %BAFO ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do \ntempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). \nEm fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \nimplante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam \nque n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n  \n\n\n\nResultados  |  62 \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 23. Gr\u00e1fico representando a % BAFO ao redor do implante quando todos os dados se \napresentam de forma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia \ne IC 95%). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n  \n\n\n\nResultados  |  63 \n\n4.3 Resultados de nanoindenta\u00e7\u00e3o: \n\n \n\nImagens representativas das \u00e1reas aonde foram realizados os ensaios de \n\nnanoindenta\u00e7\u00e3o est\u00e3o evidenciados na figura 24. Para cada implante, o teste mec\u00e2nico foi \n\nrealizado dentro da regi\u00e3o de rosca, localizada entre a primeira e a segunda rosca, num total \n\nde 30 indenta\u00e7\u00f5es por amostra.  \n\n \n\n \n\nFigura 24. A-L. Imagens representativas das \u00e1reas aonde foram realizados os ensaios de \nnanoindenta\u00e7\u00e3o de todos os grupos experimentais (A-L). Grupo saud\u00e1vel (A, B, C, G, H e I) e \ndiab\u00e9tico (D, E, F, J, K e L) dos implantes com superf\u00edcie LISA (A, D, G e J), DAA (B, E, H \ne K) e NANO (C, F, I e L).  \n\n \n\n  \n\n\n\nResultados  |  64 \n\n4.3.1 M\u00f3dulo de elasticidade (ME) \n\n \n\nO m\u00f3dulo elasticidade (ME) em fun\u00e7\u00e3o do tempo demonstrou diferen\u00e7a \n\nestatisticamente significante entre 7 (8,94 \u00b1 1,36) e 30 (14,14 \u00b1 1,22) dias (p<0.001) \n\n(Figura 25 A). N\u00e3o foram encontradas diferen\u00e7as significantes ao comparar o grupo \n\nsaud\u00e1vel (11,07 \u00b1 1,35) e diab\u00e9tico (12,01 \u00b1 1,24) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o \n\nsist\u00eamica) (p=0.308) (Figura 25 B). Ao considerar a superf\u00edcie do implante, o grupo \n\nNANO (14,89 \u00b1 1,59) exibiu maior ME em rela\u00e7\u00e3o aos grupos LISA (7,28 \u00b1 1,51) e DAA \n\n(12,45 \u00b1 1,65) (dados em fun\u00e7\u00e3o de superf\u00edcie do implante) (p<0.037) (Figura 25 C). \n\nComparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias (15,06 \u00b11,87) \n\napresentou diferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos \n\nexperimentais (saud\u00e1vel 7 dias = 7,08 \u00b1 1,95, diab\u00e9tico 7 dias = 10,79 \u00b1 1,90, diab\u00e9tico 30 \n\ndias = 13,22 \u00b1 1,60) (p<0.001) (Figura 25 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo \n\ne da superf\u00edcie do implante evidenciou a superioridade do grupo NANO em 30 dias (16,70 \n\n\u00b1 1,97) em rela\u00e7\u00e3o aos demais (LISA 30 dias = 12,52 \u00b1 2,23, DAA 30 dias = 13,20 \u00b1 \n\n2,16) (p<0.027) (Figura 25 E). Quando o ME foi avaliado em fun\u00e7\u00e3o da condi\u00e7\u00e3o \n\nsist\u00eamica e da superf\u00edcie, o grupo diab\u00e9tico NANO (15,71 \u00b1 2,16) apresentou diferen\u00e7a \n\nestat\u00edstica significante (p<0.001) (Figura 25 F). Avaliando todos os fatores: tempo, \n\ncondi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie, os resultados evidenciaram que os \n\nimplantes com tratamento de superf\u00edcie apresentaram ME superior \u00e0 superf\u00edcie LISA \n\n(p<0.031) (Figura 26). \n\n  \n\n\n\nResultados  |  65 \n\n \n\n \n\n \n\n \n\nFigura 25. A-F. Gr\u00e1ficos representando o ME ao redor do implante organizados \ndiferentemente em fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do \ntempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). \nEm fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do \nimplante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam \nque n\u00e3o h\u00e1 diferen\u00e7a estatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  66 \n\n \n\nFigura 26. Gr\u00e1fico representando o ME ao redor do implante quando todos os dados se \napresentam de forma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia \ne IC 95%). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.3.2 Dureza (D) \n\n \n\nA dureza (D) em fun\u00e7\u00e3o do tempo demonstrou diferen\u00e7a estatisticamente significante \n\nentre 7 (0,31 \u00b1 0,06) e 30 (0,64 \u00b1 0,05) dias (p<0.001) (Figura 27 A). O grupo saud\u00e1vel (0,53 \n\n\u00b1 0,06) apresentou maior D quando comparado ao diab\u00e9tico (0,42 \u00b1 0,05) (dados em fun\u00e7\u00e3o \n\nda condi\u00e7\u00e3o sist\u00eamica) (p=0.015) (Figura 27 B). Ao considerar a superf\u00edcie do implante, o \n\ngrupo NANO (0,66 \u00b1 0,07) exibiu maior D em rela\u00e7\u00e3o aos grupos LISA (0,34 \u00b1 0,07) e DAA \n\n(0,43 \u00b1 0,07) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.037) (Figura 27 C). \n\nComparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias (0,81 \u00b1 0,08) apresentou \n\ndiferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos experimentais (saud\u00e1vel 7 \n\ndias = 0,25 \u00b1 0,09, diab\u00e9tico 7 dias = 0,38 \u00b1 0,09, diab\u00e9tico 30 dias = 0,46 \u00b1 0,08) (p<0.001) \n\n(Figura 27 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante \n\nevidenciou a superioridade do grupo NANO em 30 dias (0,9 \u00b1 0,09)  em rela\u00e7\u00e3o aos demais \n\n(LISA 30 dias = 0,55 \u00b1 0,10, DAA 30 dias = 0,47 \u00b1 0,10) (p<0.027) (Figura 27 E). Quando o \n\nD foi avaliado em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o grupo saud\u00e1vel NANO \n\n(0,79 \u00b1 0,11) apresentou diferen\u00e7a estat\u00edstica significante (p<0.002) (Figura 27 F). Avaliando \n\ntodos os fatores: tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie, os resultados \n\nevidenciaram que os implantes com tratamento de superf\u00edcie apresentaram D superior \u00e0 \n\n\n\nResultados  |  67 \n\nsuperf\u00edcie LISA (p<0.025), e que o grupo NANO saud\u00e1vel 30 dias (1,25 \u00b1 0,14) apresentou \n\nos maiores valores para D (Figura 28).  \n\n \n\n \n\nFigura 27. A-F. Gr\u00e1ficos representando D ao redor do implante organizados diferentemente \nem fun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em \nfun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do \ntempo e da condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em \nfun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 \ndiferen\u00e7a estatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  68 \n\n \n\nFigura 28. Gr\u00e1fico representando a D ao redor do implante quando todos os dados se \napresentam de forma colapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia \ne IC 95%). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.4 Resultados de express\u00e3o g\u00eanica:  \n\n \n\n4.4.1 Fator de transcri\u00e7\u00e3o \u201crunt-related\u201d 2 (Runx2) \n\n \n\nA express\u00e3o relativa do Fator de transcri\u00e7\u00e3o \u201crunt-related\u201d 2 (Runx2) em fun\u00e7\u00e3o do \n\ntempo demonstrou diferen\u00e7a estatisticamente significante entre 7 (1,00 \u00b1 0,05) e 30 (1,88 \u00b1 \n\n0,05) dias (p<0.001) (Figura 29 A). O grupo saud\u00e1vel (1,90 \u00b1 0,05) apresentou maior \n\nexpress\u00e3o relativa de Runx2 quando comparado ao diab\u00e9tico (0,98 \u00b1 0,05) (dados em fun\u00e7\u00e3o \n\nda condi\u00e7\u00e3o sist\u00eamica) (p<0.001) (Figura 29 B). Ao considerar a superf\u00edcie do implante, o \n\ngrupo NANO (2,23 \u00b1 0,06) exibiu maior express\u00e3o relativa de Runx2 em rela\u00e7\u00e3o aos grupos \n\nLISA (0,58 \u00b1 0,06) e DAA (1,52 \u00b1 0,06) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) \n\n(p<0.001) (Figura 29 C). Comparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias \n\n(2,77 \u00b1 0,07) apresentou diferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos \n\nexperimentais (saud\u00e1vel 7 dias = 1,04 \u00b1 0,07, diab\u00e9tico 7 dias = 0,96 \u00b1 0,07, diab\u00e9tico 30 dias \n\n= 1,00 \u00b1 0,07) (p<0.001) (Figura 29 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da \n\nsuperf\u00edcie do implante, evidenciou uma superioridade do grupo NANO 30 dias (2,97 \u00b1 0,09) \n\ndias em rela\u00e7\u00e3o aos demais (LISA 7 dias = 0,62 \u00b1 0,09, DAA 7 dias = 0,89 \u00b1 0,09, NANO 7 \n\ndias = 1,49 \u00b1 0,09, LISA 30 dias = 0,53 \u00b1 0,09, DAA 30 dias = 2,14 \u00b1 0,09) (p<0.001) \n\n\n\nResultados  |  69 \n\n(Figura 29 E). Quando a express\u00e3o relativa de Runx2 foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o \n\nsist\u00eamica e da superf\u00edcie, o grupo NANO saud\u00e1vel (2,90 \u00b1 0,09) apresentou diferen\u00e7a \n\nestatisticamente significante em rela\u00e7\u00e3o aos outros grupos experimentais (p<0.001) (Figura 29 \n\nF). Avaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os \n\nresultados evidenciaram que a superf\u00edcie NANO apresentou os melhores resultados aos 7 dias \n\n(diab\u00e9tico = 1,78 \u00b1 0,13) e aos 30 dias (saud\u00e1vel = 4,59 \u00b1 0,13) (p<0.035) (Figura 30). \n\n \n\n \n\nFigura 29. A-F. Express\u00e3o relativa de Runx2 com dados organizados diferentemente em \nfun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o \nda condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e \nda condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o \nda condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a \nestatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  70 \n\n \n\nFigura 30. Express\u00e3o relativa de Runx2 quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.4.2 Fosfatase alcalina (Alp)  \n\n \n\nA express\u00e3o relativa de Fosfatase alcalina (Alp) em fun\u00e7\u00e3o do tempo n\u00e3o demonstrou \n\ndiferen\u00e7a estatisticamente significante entre 7 (1,09 \u00b1 0,04) e 30 (1,05 \u00b1 0,04) dias (p=0.152) \n\n(Figura 31 A). O grupo saud\u00e1vel (1,48 \u00b1 0,04) apresentou maior express\u00e3o relativa de Alp \n\nquando comparado ao diab\u00e9tico (0,66 \u00b1 0,04) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) \n\n(p<0.001) (Figura 31 B). Ao considerar a superf\u00edcie do implante, o grupo NANO (1,70 \u00b1 \n\n0,05) exibiu maior express\u00e3o relativa de Alp em rela\u00e7\u00e3o aos grupos LISA (0,48 \u00b1 0,05) e \n\nDAA (1,03 \u00b1 0,05) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.001) (Figura 31 C). \n\nComparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias (1,81 \u00b1 0,06) apresentou \n\ndiferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos experimentais (saud\u00e1vel 7 \n\ndias = 1,15 \u00b1 0,06, diab\u00e9tico 7 dias = 1,03 \u00b1 0,06, diab\u00e9tico 30 dias = 0,28 \u00b1 0,06) (p<0.001) \n\n(Figura 31 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante, \n\nevidenciou uma superioridade do grupo NANO aos 7 dias (1,94 \u00b1 0,07) em rela\u00e7\u00e3o aos \n\ndemais (LISA 7 dias = 0,50 \u00b1 0,07, DAA 7 dias = 0,84 \u00b1 0,07, LISA 30 dias = 0,46 \u00b1 0,07, \n\nDAA 30 dias = 1,23 \u00b1 0,07, NANO 30 dias = 1,45 \u00b1 0,07) (p<0.001) (Figura 31 E). Quando a \n\nexpress\u00e3o relativa de Alp foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o \n\ngrupo NANO saud\u00e1vel (1,88 \u00b1 0,07) apresentou diferen\u00e7a estatisticamente significante \n\n\n\nResultados  |  71 \n\n(p<0.001) (Figura 31 F). Avaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento \n\nde superf\u00edcie), os resultados evidenciaram que a superf\u00edcie NANO apresentou os melhores \n\nresultados aos 7 dias (diab\u00e9tico = 2,57 \u00b1 0,10) e aos 30 dias (saud\u00e1vel = 2,44 \u00b1 0,10) \n\n(p<0.001) (Figura 32). \n\n \n\n \n\nFigura 31. A-F. Express\u00e3o relativa de Alp com dados organizados diferentemente em fun\u00e7\u00e3o \ndos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o da \ncondi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e da \ncondi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o da \ncondi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a \nestatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  72 \n\n \n\nFigura 32. Express\u00e3o relativa de Alp quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.4.3 Osteocalcina (Oc)  \n\n \n\nA express\u00e3o relativa de Osteocalcina (Oc) em fun\u00e7\u00e3o do tempo demonstrou diferen\u00e7a \n\nestatisticamente significante entre 7 (1,59 \u00b1 0,10) e 30 (2,47 \u00b1 0,10) dias (p<0.001) (Figura 33 \n\nA). O grupo saud\u00e1vel (3,34 \u00b1 0,10) apresentou maior express\u00e3o relativa de Oc quando \n\ncomparado ao diab\u00e9tico (0,82 \u00b1 0,10) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) (p<0.001) \n\n(Figura 33 B). Ao considerar a superf\u00edcie do implante, os grupos DAA (2,49 \u00b1 0,13) e NANO \n\n(2,37 \u00b1 0,13) exibiram maior express\u00e3o relativa de Oc em rela\u00e7\u00e3o ao grupo LISA (1,25 \u00b1 \n\n0,13) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.001) (Figura 33 C). Comparando \n\ntempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias (4,49 \u00b1 0,15) apresentou diferen\u00e7as \n\nestat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos experimentais (saud\u00e1vel 7 dias = 2,02 \n\n\u00b1 0,15, diab\u00e9tico 7 dias = 1,18 \u00b1 0,15, diab\u00e9tico 30 dias = 0,46 \u00b1 0,15) (p<0.001) (Figura 33 \n\nD). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante, evidenciou uma \n\nsuperioridade do grupo DAA 30 dias (3,55 \u00b1 0,18) em rela\u00e7\u00e3o aos demais (LISA 7 dias = \n\n0,50 \u00b1 0,18, DAA 7 dias = 1,44 \u00b1 0,18, NANO 7 dias = 2,83 \u00b1 0,18, LISA 30 dias = 2,01 \u00b1 \n\n0,18, NANO 30 dias = 1,86 \u00b1 0,18) (p<0.001) (Figura 33 E). Quando a express\u00e3o relativa de \n\nOc foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o grupo DAA saud\u00e1vel (4,56 \n\n\u00b1 0,18) apresentou diferen\u00e7a estatisticamente significante (p<0.001) (Figura 33 F). Avaliando \n\n\n\nResultados  |  73 \n\ntodos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os resultados \n\nevidenciaram que a superf\u00edcie NANO apresentou os melhores resultados aos 7 dias (diab\u00e9tico \n\n= 3,38 \u00b1 0,26) (p<0.001) (Figura 34). \n\n \n\n \n\nFigura 33. A-F. Express\u00e3o relativa de Oc organizados diferentemente em fun\u00e7\u00e3o dos fatores \ndo estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o \nsist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o \nsist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o \nsist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a estatisticamente \nsignificante entre os grupos. \n\n \n\n\n\nResultados  |  74 \n\n \n\nFigura 34. Express\u00e3o relativa de Oc quando todos os dados se apresentam de forma colapsada \n(tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras id\u00eanticas \nindicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.4.4 Osteopontina (Opn)  \n\n \n\nA express\u00e3o relativa de Osteopontina (Opn) em fun\u00e7\u00e3o do tempo n\u00e3o demonstrou \n\ndiferen\u00e7a estatisticamente significante entre 7 (0,78 \u00b1 0,01) e 30 (0,81 \u00b1 0,01) dias (p<0.003) \n\n(Figura 35 A). O grupo saud\u00e1vel (1,18 \u00b1 0,01) apresentou maior express\u00e3o relativa de Opn \n\nquando comparado ao diab\u00e9tico (0,41 \u00b1 0,01) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) \n\n(p<0.001) (Figura 35 B). Ao considerar a superf\u00edcie do implante, o grupo NANO (1,13 \u00b1 \n\n0,02) exibiu maior express\u00e3o relativa de Opn em rela\u00e7\u00e3o aos grupos LISA (0,49 \u00b1 0,02) e \n\nDAA (0,77 \u00b1 0,02) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.001) (Figura 35 C). \n\nComparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias (1,45 \u00b1 0,02) apresentou \n\ndiferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos experimentais (saud\u00e1vel 7 \n\ndias \u2013 0,91 \u00b1 0,02, diab\u00e9tico 7 dias \u2013 0,64 \u00b1 0,02, diab\u00e9tico 30 dias \u2013 0,18 \u00b1 0,02) (p<0.001) \n\n(Figura 35 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante, \n\nevidenciou uma superioridade do grupo NANO aos 7 dias (1,24 \u00b1 0,02) em rela\u00e7\u00e3o aos \n\ndemais (LISA 7 dias = 0,50 \u00b1 0,02, DAA 7 dias = 0,59 \u00b1 0,02, LISA 30 dias = 0,48 \u00b1 0,02, \n\nDAA 30 dias = 0,96 \u00b1 0,02 e NANO 30 dias = 1,01 \u00b1 0,02) (p<0.013) (Figura 35 E). Quando \n\na express\u00e3o relativa de Opn foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o \n\ngrupo NANO saud\u00e1vel (1,38 \u00b1 0,02) apresentou diferen\u00e7a estatisticamente significante \n\n\n\nResultados  |  75 \n\n(p<0.001) (Figura 35 F). Avaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento \n\nde superf\u00edcie), os resultados evidenciaram que a superf\u00edcie NANO apresentou os melhores \n\nresultados aos 7 dias (diab\u00e9tico = 1,55 \u00b1 0,04) e aos 30 dias (saud\u00e1vel = 1,81 \u00b1 0,04) \n\n(p<0.001) (Figura 36). \n\n \n\n \n\nFigura 35. A-F. Express\u00e3o relativa de Opn com dados organizados diferentemente em fun\u00e7\u00e3o \ndos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o da \ncondi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e da \ncondi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o da \ncondi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a \nestatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  76 \n\n \n\nFigura 36. Express\u00e3o relativa de Opn quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.4.5 Receptor ativador de fator nuclear kappa-B (Rank) \n\n \n\nA express\u00e3o relativa de Receptor ativador do fator nuclear kappa-B (Rank) em fun\u00e7\u00e3o \n\ndo tempo n\u00e3o demonstrou diferen\u00e7a estatisticamente significantes entre 7 (0,86 \u00b1 0,02) e 30 \n\n(0,84 \u00b1 0,02) dias (p=0.169) (Figura 37 A). O grupo saud\u00e1vel (1,18 \u00b1 0,02) apresentou maior \n\nexpress\u00e3o relativa de Rank quando comparado ao diab\u00e9tico (0,52 \u00b1 0,02) (dados em fun\u00e7\u00e3o da \n\ncondi\u00e7\u00e3o sist\u00eamica) (p<0.001) (Figura 37 B). Ao considerar a superf\u00edcie do implante, os \n\ngrupos DAA (1,02 \u00b1 0,03) e NANO (1,02 \u00b1 0,03) exibiram maior express\u00e3o relativa de Rank \n\nem rela\u00e7\u00e3o ao grupo LISA (0,51 \u00b1 0,03) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) \n\n(p<0.001) (Figura 37 C). Comparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo saud\u00e1vel 30 dias \n\n(1,38 \u00b1 0,03) apresentou diferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos \n\nexperimentais (saud\u00e1vel 7 dias = 0,98 \u00b1 0,03, diab\u00e9tico 7 dias = 0,75 \u00b1 0,03, diab\u00e9tico 30 dias \n\n= 0,30 \u00b1 0,03) (p<0.001)  (Figura 37 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da \n\nsuperf\u00edcie do implante, evidenciou uma superioridade dos grupo NANO 7 dias (1,45 \u00b1 0,04) e \n\nDAA 30 dias (1,39 \u00b1 0,04) em rela\u00e7\u00e3o aos demais (LISA 7 dias = 0,50 \u00b1 0,04, DAA 7 dias = \n\n0,65 \u00b1 0,04, LISA 30 dias = 0,53 \u00b1 0,04, NANO 30 dias = 0,06 \u00b1 0,04) (p<0.001)  (Figura 37 \n\nE). Quando a express\u00e3o relativa de Rank foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da \n\nsuperf\u00edcie, o grupo DAA saud\u00e1vel (1,59 \u00b1 0,04) apresentou diferen\u00e7a estatisticamente \n\n\n\nResultados  |  77 \n\nsignificante (p<0.001) (Figura 37 F). Avaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e \n\ntratamento de superf\u00edcie), os resultados evidenciaram que a superf\u00edcie NANO apresentou os \n\nmelhores resultados aos 7 dias (diab\u00e9tico = 1,84 \u00b1 0,06) (p<0.001) (Figura 38). \n\n \n\n \n\nFigura 37. A-F. Express\u00e3o relativa de Rank com dados organizados diferentemente em fun\u00e7\u00e3o \ndos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o da \ncondi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e da \ncondi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o da \ncondi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a \nestatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  78 \n\n \n\nFigura 38. Express\u00e3o relativa de Rank quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.4.6 Receptor ativador do fator nuclear kappa ligante (Rankl)  \n\n \n\nA express\u00e3o relativa do Receptor ativador do fator nuclear kappa ligante (Rankl) em \n\nfun\u00e7\u00e3o do tempo demonstrou diferen\u00e7a estatisticamente significantes entre 7 (0,66 \u00b1 0,05) e \n\n30 (0,80 \u00b1 0,05) dias (p<0.001) (Figura 39 A). O grupo saud\u00e1vel (1,06 \u00b1 0,05) apresentou \n\nmaior express\u00e3o relativa de Rankl quando comparado ao diab\u00e9tico (0,39 \u00b1 0,05) (dados em \n\nfun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) (p<0.001) (Figura 39 B). Ao considerar a superf\u00edcie do \n\nimplante, o grupo DAA (0,98 \u00b1 0,06) exibiu maior express\u00e3o relativa de Rankl em rela\u00e7\u00e3o aos \n\ngrupos LISA (0,48 \u00b1 0,06) e NANO (0,72 \u00b1 0,06) (dados em fun\u00e7\u00e3o da superf\u00edcie do \n\nimplante) (p<0.001) (Figura 39 C). Comparando tempo e condi\u00e7\u00e3o sist\u00eamica, o grupo \n\nsaud\u00e1vel 30 dias (1,24 \u00b1 0,08) apresentou diferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos \n\ndemais grupos experimentais (saud\u00e1vel 7 dias = 0,89 \u00b1 0,08, diab\u00e9tico 7 dias = 0,42 \u00b1 0,08, \n\ndiab\u00e9tico 30 dias = 0,37 \u00b1 0,08) (p<0.001) (Figura 39 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o \n\ndo tempo e da superf\u00edcie do implante, evidenciou uma superioridade do grupo DAA 30 dias \n\n(1,40 \u00b1 0,09) em rela\u00e7\u00e3o aos demais (LISA 7 dias = 0,50 \u00b1 0,09, DAA 7 dias = 0,57 \u00b1 0,09, \n\nNANO 7 dias = 0,90 \u00b1 0,09, LISA 30 dias = 0,47 \u00b1 0,09, NANO 30 dias = 0,54 \u00b1 0,09) \n\n(p<0.001) (Figura 39 E). Quando a express\u00e3o relativa de Rankl foi avaliada em fun\u00e7\u00e3o da \n\ncondi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o grupo DAA saud\u00e1vel (1,50 \u00b1 0,09) apresentou diferen\u00e7a \n\n\n\nResultados  |  79 \n\nestatisticamente significativa (p<0.013) (Figura 39 F). Avaliando todos os fatores (tempo, \n\ncondi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie), os resultados evidenciaram que o grupo \n\ndiab\u00e9tico NANO 7 dias (1,11 \u00b1 0,13) se equivaleu ao grupo saud\u00e1vel DAA 7 dias (0,97 \u00b1 \n\n0,13) (Figura 40). \n\n \n\n \n\nFigura 39. A-F. Express\u00e3o relativa de Rankl com dados organizados diferentemente em \nfun\u00e7\u00e3o dos fatores do estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o \nda condi\u00e7\u00e3o sist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e \nda condi\u00e7\u00e3o sist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o \nda condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a \nestatisticamente significante entre os grupos. \n\n \n\n\n\nResultados  |  80 \n\n \n\nFigura 40. Express\u00e3o relativa de Rankl quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significante entre os grupos. \n\n \n\n4.4.7 Osteoprotegerina (Opg) \n\n \n\nA express\u00e3o relativa de Osteoprotegerina (Opg) em fun\u00e7\u00e3o do tempo demonstrou \n\ndiferen\u00e7a estatisticamente significantes entre 7 (0,67 \u00b1 0,05) e 30 (0,87 \u00b1 0,05) dias (p<0.011) \n\n(Figura 41 A). O grupo saud\u00e1vel (0,92 \u00b1 0,05) apresentou maior express\u00e3o relativa de Opg \n\nquando comparado ao diab\u00e9tico (0,63 \u00b1 0,05) (dados em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica) \n\n(p<0.011) (Figura 41 B). Ao considerar a superf\u00edcie do implante, o grupo DAA (1,00 \u00b1 0,07) \n\nexibiu maior express\u00e3o relativa de Opg em rela\u00e7\u00e3o aos grupos LISA (0,51 \u00b1 0,07) e NANO \n\n(0,81 \u00b1 0,07) (dados em fun\u00e7\u00e3o da superf\u00edcie do implante) (p<0.011) (Figura 41 C). \n\nComparando tempo e condi\u00e7\u00e3o sist\u00eamica, os grupos saud\u00e1vel 7 (0,89 \u00b1 0,08) e 30 dias (0,94 \u00b1 \n\n0,08) apresentaram diferen\u00e7as estat\u00edsticas significantes em rela\u00e7\u00e3o aos demais grupos \n\nexperimentais (diab\u00e9tico 7 dias = 0,45 \u00b1 0,08, diab\u00e9tico 30 dias = 0,81 \u00b1 0,08) (p<0.027) \n\n(Figura 41 D). A avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante, \n\nevidenciou uma superioridade do grupo DAA 30 dias (1,28 \u00b1 0,10) em rela\u00e7\u00e3o aos demais \n\n(LISA 7 dias = 0,50 \u00b1 0,10, DAA 7 dias = 0,72 \u00b1 0,10, NANO 7 dias = 0,79 \u00b1 0,10, LISA 30 \n\ndias = 0,51 \u00b1 0,10, NANO 30 dias = 0,84 \u00b1 0,10) (p<0.011) (Figura 41 E). Quando a \n\nexpress\u00e3o relativa de Opg foi avaliada em fun\u00e7\u00e3o da condi\u00e7\u00e3o sist\u00eamica e da superf\u00edcie, o \n\ngrupo DAA saud\u00e1vel (1,28 \u00b1 0,10) apresentou diferen\u00e7as estatisticamente significantes \n\n\n\nResultados  |  81 \n\n(p<0.011) (Figura 41 F). Avaliando todos os fatores (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento \n\nde superf\u00edcie), os resultados os resultados evidenciaram que o grupo diab\u00e9tico NANO 7 dias \n\n(0,99 \u00b1 0,14) se equivaleu ao grupo saud\u00e1vel DAA 7 dias (1,08 \u00b1 0,14) (Figura 42). \n\n \n\n \n\nFigura 41. A-F. Express\u00e3o relativa de Opg organizados diferentemente em fun\u00e7\u00e3o dos fatores \ndo estudo (m\u00e9dia e IC 95%). Dados em fun\u00e7\u00e3o do tempo (A). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o \nsist\u00eamica (B). Em fun\u00e7\u00e3o da superf\u00edcie do implante (C). Em fun\u00e7\u00e3o do tempo e da condi\u00e7\u00e3o \nsist\u00eamica (D). Em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante (E). Em fun\u00e7\u00e3o da condi\u00e7\u00e3o \nsist\u00eamica e da superf\u00edcie (F). Letras id\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a estatisticamente \nsignificante entre os grupos. \n\n \n\n\n\nResultados  |  82 \n\n \n\nFigura 42. Express\u00e3o relativa de Opg quando todos os dados se apresentam de forma \ncolapsada (tempo, condi\u00e7\u00e3o sist\u00eamica e tratamento de superf\u00edcie) (m\u00e9dia e IC 95%). Letras \nid\u00eanticas indicam que n\u00e3o h\u00e1 diferen\u00e7a significantes entre os grupos. \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n5 Discuss\u00e3o \n\n  \n\n\n\nDiscuss\u00e3o  |  84 \n\n5 DISCUSS\u00c3O  \n\n \n\nNas \u00faltimas duas d\u00e9cadas, uma aten\u00e7\u00e3o significativa foi destinada \u00e0 melhoria da \n\nbiocompatibilidade entre o hospedeiro e o implante e as respostas biomec\u00e2nicas por meio do \n\ndesign do implante. Dentre as altera\u00e7\u00f5es de design, o par\u00e2metro mais avaliado s\u00e3o as \n\nmodifica\u00e7\u00f5es na superf\u00edcie, pois \u00e9 a primeira parte do implante a interagir com os biofluidos \n\ndo hospedeiro, tendo o potencial de alterar significativamente a intera\u00e7\u00e3o entre osso e \n\nimplante (Albrektsson and Wennerberg 2004a; 2004b; Berglundh et al. 2007; Buser et al. \n\n2004; Coelho et al. 2009; Mendes et al. 2007). Mudan\u00e7as na topografia da superf\u00edcie podem \n\nafetar as intera\u00e7\u00f5es c\u00e9lula-matriz-substrato por meio de: a) adsor\u00e7\u00e3o de prote\u00ednas alteradas, \n\nforma\u00e7\u00e3o de co\u00e1gulos de fibrina e express\u00e3o da integrina, b) a pr\u00f3pria topografia e/ou c) \n\nmudan\u00e7as na molhabilidade/energia da superf\u00edcie (Boyan et al. 2003; de Oliveira and Nanci \n\n2004). De fato, tais aspectos t\u00eam sido implicados como principais mecanismos para o controle \n\nda ades\u00e3o celular seletiva, sinaliza\u00e7\u00e3o, diferencia\u00e7\u00e3o e eventual forma\u00e7\u00e3o de tecido em \n\nsuperf\u00edcies de biomateriais (Boyan et al. 2003; de Oliveira and Nanci 2004). \n\nO presente estudo avaliou, utilizando ratos diab\u00e9ticos (como um modelo de repara\u00e7\u00e3o \n\n\u00f3ssea deficiente) e ratos saud\u00e1veis (controle com repara\u00e7\u00e3o \u00f3ssea normal) uma nova \n\nsuperf\u00edcie de implantes recoberta com nanopart\u00edculas de hidroxiapatita (NANO HA), por \n\nmeio de: an\u00e1liseS microtomogr\u00e1fica (micro-CT), histomorfom\u00e9trica, nanomec\u00e2nica e da \n\navalia\u00e7\u00e3o da express\u00e3o g\u00eanica de genes marcadores do metabolismo \u00f3sseo.  \n\nA literatura \u00e9 bem estabelecida no que diz respeito aos malef\u00edcios causados por \n\ncondi\u00e7\u00f5es de sa\u00fade metabolicamente comprometidas, como o diabetes mellitus (DM), durante \n\nos eventos b\u00e1sicos da osseointegra\u00e7\u00e3o: hemostasia, inflama\u00e7\u00e3o, prolifera\u00e7\u00e3o e remodelamento \n\n(Giglio et al. 2000; King et al. 2016; Miyata et al. 1997; Nevins et al. 1998). Esses estudos \n\nmostraram que o diabetes leva a um menor contato osso-implante e menor densidade \u00f3ssea \n\n(Johansson and Albrektsson 1987; Sennerby et al. 1992). No presente estudo, os valores de \n\nglicemia dos grupos saud\u00e1vel (cirurgia: 89,55 \u00b1 8,88 e eutan\u00e1sia: 92,19 \u00b1 9,67) e diab\u00e9tico \n\n(cirurgia: 499,88 \u00b1 62,27 e eutan\u00e1sia: 544,63 \u00b1 57,07) est\u00e3o de acordo com os achados da \n\nliteratura (Margonar et al. 2003). Margonar et al., 2003 utilizaram o mesmo par\u00e2metro para \n\ndefinir o modelo diab\u00e9tico (n\u00edveis de glicose plasm\u00e1tica igual ou acima de 300 mg/dL) e \n\nsugeriram que n\u00edveis glic\u00eamicos mais elevados poderiam levar a altera\u00e7\u00f5es mais severas na \n\nosseointegra\u00e7\u00e3o. O osso rec\u00e9m-formado ao redor dos implantes foi relatado imaturo e menos \n\norganizado em ratos diab\u00e9ticos descontrolados do que em controles n\u00e3o diab\u00e9ticos, sugerindo \n\ndiferen\u00e7as qualitativas no osso neoformado (Nevins et al. 1998). \n\n\n\nDiscuss\u00e3o  |  85 \n\nCom o objetivo de melhorar a taxa e a extens\u00e3o da osseointegra\u00e7\u00e3o em cen\u00e1rios \n\ndesafiadores, tal como DM, foram sugeridas mudan\u00e7as na superf\u00edcie dos implantes (Burgos et \n\nal. 2008; Cochran et al. 1998). No entanto, estudos comparando seus benef\u00edcios potenciais \n\nainda n\u00e3o s\u00e3o claros quando usados em um modelo de DM (Jiang et al. 2017). No presente \n\nestudo, o remodelamento \u00f3sseo pareceu estar em um est\u00e1gio mais avan\u00e7ado em torno de \n\nimplantes com superf\u00edcies tratadas e em menor grau na superf\u00edcie lisa. Esses resultados \n\nsugerem que a remodela\u00e7\u00e3o \u00f3ssea pode se dar de forma mais precoce em torno de superf\u00edcies \n\nmodificadas. \n\nA estrutura\u00e7\u00e3o de topografia de superf\u00edcie em n\u00edvel de micro e nanoescala foi \n\ndesenvolvida com o objetivo de promover a forma\u00e7\u00e3o \u00f3ssea adjacente ou em contato com as \n\nsuperf\u00edcies dos implantes. Al\u00e9m disso, superf\u00edcies de tit\u00e2nio comercialmente puro micro e \n\nnanoestruturadas podem promover uma melhor ades\u00e3o, fun\u00e7\u00e3o e forma\u00e7\u00e3o de n\u00f3dulos \u00f3sseos \n\nde osteoblastos, al\u00e9m de favorecer um maior contato osso-implante (Boyan et al. 2003; de \n\nOliveira and Nanci 2004; Huang et al. 2005). \n\nZuo et al., 2013 tamb\u00e9m revelaram que mudan\u00e7as na topografia da superf\u00edcie, \n\nparticularmente a nanotopografia, desempenharam um papel importante na ades\u00e3o e \n\nprolifera\u00e7\u00e3o celular (Zuo et al. 2013). Estudos anteriores descreveram que superf\u00edcies de \n\nbiomateriais com rugosidade em microescala podem diminuir a prolifera\u00e7\u00e3o de osteoblastos, \n\nmas a topografia em nanoescala tende a ajudar nos processos de prolifera\u00e7\u00e3o (Gittens et al. \n\n2013; Kubo et al. 2009; Zhuang et al. 2014). No presente estudo, em um modelo de rato \n\ndiab\u00e9tico, a superf\u00edcie de implante revestida com nano-hidroxiapatita foi superior \u00e0s \n\nsuperf\u00edcies DAA e LISA, sugerindo que a adi\u00e7\u00e3o de part\u00edculas de nano-hidroxiapatita \n\ninfluenciou significativamente no processo de osseointegra\u00e7\u00e3o. \n\nA avalia\u00e7\u00e3o em 3D com a utiliza\u00e7\u00e3o do micro-CT tem recebido consider\u00e1vel aten\u00e7\u00e3o \n\nnos \u00faltimos anos pois facilita a observa\u00e7\u00e3o e a quantifica\u00e7\u00e3o da forma\u00e7\u00e3o \u00f3ssea ao redor de \n\nimplantes ou substitutos \u00f3sseos em um plano tridimensional (Sarve et al. 2011). T\u00e9cnicas de \n\naquisi\u00e7\u00e3o de imagem 3D de alta resolu\u00e7\u00e3o, como micro-CT, medem diretamente a \n\nmicroarquitetura \u00f3ssea. No presente estudo, a % IS/TS mostrou que o revestimento com \n\nNANO HA apresentou diferen\u00e7a estatisticamente significante quando comparado \u00e0s \n\nsuperf\u00edcies LISA e DAA, independentemente do tempo e da condi\u00e7\u00e3o sist\u00eamica. Essa \n\nevid\u00eancia pode sugerir que a nova superf\u00edcie de implante pode compensar as limita\u00e7\u00f5es de um \n\nmodelo de reparo \u00f3sseo deficiente. Esses resultados est\u00e3o de acordo com outros estudos que \n\ndemonstraram que modifica\u00e7\u00f5es na superf\u00edcie em escala nanom\u00e9trica foram capazes de inibir \n\no efeito de altas concentra\u00e7\u00f5es de glicose (Ajami et al. 2016; Ajami et al. 2014). Al\u00e9m disso, \n\n\n\nDiscuss\u00e3o  |  86 \n\nsuperficies micro/nanoestruturadas possuem biocompatibilidade favor\u00e1vel na melhoria da \n\nprolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o de osteoblastos na presen\u00e7a da hiperglic\u00eamia (Jiang et al. 2017). \n\nA an\u00e1lise micro-CT de BV/TV (%), BS/BV (mm) e Po.To (%) demonstraram valores \n\nmais elevados, padr\u00f5es \u00f3sseos mais organizados e maiores densidades volum\u00e9tricas para o \n\ngrupo NANO em todos os tempos avaliados e independentemente da condi\u00e7\u00e3o sist\u00eamica \n\nquando comparado aos outros grupos experimentais, com exce\u00e7\u00e3o do BS/BV (30 dias rato \n\nsaud\u00e1vel e 7 e 30 dias rato diab\u00e9tico), sugerindo uma resposta \u00f3ssea mais favor\u00e1vel nestes \n\ngrupos. J\u00e1 os resultados da Tb.Sp (%) revelaram diferen\u00e7as estat\u00edsticas favorecendo o grupo \n\ndiab\u00e9tico NANO aos 7 e 30 dias. Os resultados do presente estudo concordam com Ajami et \n\nal., 2014 que pesquisaram a osseointegra\u00e7\u00e3o em ratos euglic\u00eamicos e hiperglic\u00eamicos \n\nutilizando an\u00e1lise de micro-CT e histologia e conclu\u00edram que a integra\u00e7\u00e3o comprometida do \n\nimplante na hiperglicemia \u00e9 anulada pela adi\u00e7\u00e3o de caracter\u00edsticas nanotopogr\u00e1ficas a uma \n\nsuperf\u00edcie subjacente de implantes microtopograficamente complexa (Ajami et al. 2014). \n\nA quantidade de osso que envolve a superf\u00edcie dos implantes diferiu nos diferentes \n\ntratamentos superficiais, condi\u00e7\u00e3o sist\u00eamica e tempo. Verificou-se que a forma\u00e7\u00e3o de osso na \n\ninterface osso-implante foi superior em grupos NANO, independentemente da condi\u00e7\u00e3o \n\nsist\u00eamica e tempo. As imagens reconstru\u00eddas em 3D demonstram o estado da forma\u00e7\u00e3o \u00f3ssea \n\ntrabecular na superf\u00edcie do implante, fornecendo informa\u00e7\u00f5es adicionais de perspectivas \n\nqualitativas e quantitativas. \n\nO desenvolvimento de uma topografia de superf\u00edcie em microescala, como implantes \n\ncom duplo \u00e1cido-\u00e1cido (DAA), aumentaram a forma\u00e7\u00e3o \u00f3ssea junto \u00e0 superf\u00edcie do implante \n\nquando comparada \u00e0s superf\u00edcies sem tratamento (LISA) (Coelho et al. 2011a; Coelho et al. \n\n2015; Khang et al. 2001). Al\u00e9m disso, o surgimento de superf\u00edcies \n\nquimicamente/topograficamente complexas, como implantes revestidos com nano-\n\nhidroxiapatita (NANO), proporcionaram um arranjo mais adequado que mimetiza melhor a \n\norganiza\u00e7\u00e3o natural do tecido \u00f3sseo e facilita a intera\u00e7\u00e3o com biomol\u00e9culas dos tecidos e \n\ncomunica\u00e7\u00e3o c\u00e9lula-c\u00e9lula durante o processo de cicatriza\u00e7\u00e3o (Hayashi et al. 2012; Tomsia et \n\nal. 2013; Webster and Ahn 2007). A partir da an\u00e1lise histomorfom\u00e9trica, a superf\u00edcie NANO \n\napresentou maiores % BIC e % BAFO quando comparada com LISA e DAA (dados avaliados \n\nem fun\u00e7\u00e3o da superf\u00edcie do implante). Al\u00e9m disso, por um mecanismo de cicatriza\u00e7\u00e3o \n\nespec\u00edfico do implante, aos 30 dias a superf\u00edcie NANO apresentou maiores % BIC e % BAFO \n\ndo que as superf\u00edcies LISA e DAA, com diferen\u00e7as estatisticamente significantes (avalia\u00e7\u00e3o \n\ndos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante). Os achados da literatura apoiam \n\nesta evid\u00eancia por meio de estudos anteriores em animais que demonstraram superf\u00edcies \n\n\n\nDiscuss\u00e3o  |  87 \n\ncomplexas NANO superando superf\u00edcies de microtopografia em indiv\u00edduos metabolicamente \n\ncomprometidos (Ajami et al. 2016; Ajami et al. 2014; Schlegel et al. 2013).  \n\nOs resultados apresentados por superf\u00edcies de implantes complexas em cen\u00e1rios \n\ndesafiadores, como ossos de baixa densidade, motivaram o seu uso em casos de \n\ncomprometimento sist\u00eamico que afetam o metabolismo \u00f3sseo e a osseointegra\u00e7\u00e3o (Coelho et \n\nal. 2014b). A nanoindenta\u00e7\u00e3o do osso ao redor dos implantes tem o potencial de elucidar os \n\naspectos qualitativos da osseointegra\u00e7\u00e3o (Jimbo et al. 2012a). No presente estudo, os dados \n\navaliados em fun\u00e7\u00e3o do tempo mostraram a superioridade de ME e D no tempo experimental \n\nde 30 dias em compara\u00e7\u00e3o a 7 dias. Quando os dados foram avaliados em fun\u00e7\u00e3o da \n\nsuperf\u00edcie do implante, o grupo NANO apresentou maior ME e D que DAA e LISA. Al\u00e9m \n\ndisso, aos 30 dias, a superf\u00edcie NANO apresentou maiores valores de ME e D quando \n\ncomparada \u00e0s superf\u00edcies LISA e DAA, com diferen\u00e7as estatisticamente significantes \n\n(avalia\u00e7\u00e3o dos dados em fun\u00e7\u00e3o do tempo e da superf\u00edcie do implante). Achados da literatura \n\ncomparando o uso de superf\u00edcies NANO e DAA confirmaram a superioridade do primeiro em \n\nrela\u00e7\u00e3o aos par\u00e2metros histol\u00f3gicos (Coelho et al. 2011b; Coelho et al. 2014b). \n\nA express\u00e3o g\u00eanica de Runx2, Alp, Oc e Opn, genes marcadores do metabolismo \n\n\u00f3sseo, foi utilizada para avaliar o desenvolvimento do fen\u00f3tipo osteobl\u00e1stico. Como \n\namplamente relatado, Runx2 \u00e9 o principal fator de transcri\u00e7\u00e3o que inicia a forma\u00e7\u00e3o \u00f3ssea \n\n(Lian et al. 2006) e a diferencia\u00e7\u00e3o de osteoblastos (Komori and Kishimoto 1998). Sabe-se \n\ntamb\u00e9m que a Alp \u00e9 um fator regulador da mineraliza\u00e7\u00e3o da matriz e \u00e9 expresso nos est\u00e1gios \n\niniciais da osteog\u00eanese (Hoemann et al. 2009). Oc \u00e9 um gene espec\u00edfico de osteoblastos que \n\nregula a mineraliza\u00e7\u00e3o \u00f3ssea (Ducy et al. 1996). Opn \u00e9 geralmente considerada como uma \n\nprote\u00edna da matriz extracelular multifuncional envolvida na ades\u00e3o e migra\u00e7\u00e3o celular e na \n\nregula\u00e7\u00e3o da deposi\u00e7\u00e3o mineral (Denhardt et al. 2001; Giachelli and Steitz 2000). O sistema \n\nOpg/ Rankl/Rank desempenha um papel central na regula\u00e7\u00e3o par\u00e1crina e na fun\u00e7\u00e3o dos \n\nosteoclastos (Blair et al. 2006). A Opg liga-se ao Rankl, ambos secretados pelos osteoblastos, \n\ne previne a liga\u00e7\u00e3o do Rankl ao Rank, que est\u00e1 presente na membrana dos osteoclastos, \n\ninibindo a reabsor\u00e7\u00e3o \u00f3ssea (Khosla 2001). \n\nNo presente estudo, observou-se uma redu\u00e7\u00e3o na express\u00e3o de Opg no tempo de 7 dias \n\ndo grupo NANO saud\u00e1vel. Este resultado sugere que as c\u00e9lulas osteobl\u00e1sticas do revestimento \n\nNANO-HA podem aumentar a atividade osteocl\u00e1stica. Entretanto, isso n\u00e3o deve ser \n\ninterpretado como um poss\u00edvel aumento na reabsor\u00e7\u00e3o \u00f3ssea, uma vez que v\u00e1rias citocinas \n\nliberadas pelas c\u00e9lulas osteobl\u00e1sticas exercem fun\u00e7\u00f5es regulat\u00f3rias sobre os osteoclastos \n\n(Petri et al. 2010). Provavelmente, a atividade de reabsor\u00e7\u00e3o dos osteoclastos foi suprimida \n\n\n\nDiscuss\u00e3o  |  88 \n\npor altas concentra\u00e7\u00f5es de Opg, em n\u00edvel molecular, e a Opg por sua vez, diminuiu a \n\nexpress\u00e3o de genes osteocl\u00e1ticos relacionados \u00e0 reabsor\u00e7\u00e3o \u00f3ssea. Esse resultado est\u00e1 de \n\nacordo com o estudo realizado por Fu et al., 2013 (Fu et al. 2013).  \n\nExistem evid\u00eancias que sugerem que altos n\u00edveis de glicose no sangue podem levar \u00e0 \n\nforma\u00e7\u00e3o de produtos finais de glica\u00e7\u00e3o avan\u00e7ada (AGEs) irrevers\u00edveis que podem se ligar ao \n\nreceptor para produtos finais de glica\u00e7\u00e3o avan\u00e7ada (RAGE) e podem se acumular nos \n\nfibroblastos (Lalla et al. 2000). Quando isso ocorre, pode haver uma maior destrui\u00e7\u00e3o do \n\ntecido conjuntivo e do osso, devido \u00e0 diminui\u00e7\u00e3o da s\u00edntese de col\u00e1geno e aumento dos \n\nmediadores inflamat\u00f3rios (Lalla et al. 2000). He et al., 2004 sugeriram que o diabetes pode \n\nexibir mais reabsor\u00e7\u00e3o \u00f3ssea devido \u00e0 apoptose prolongada dos osteoblastos e \u00e0 diminui\u00e7\u00e3o \n\nna forma\u00e7\u00e3o \u00f3ssea (He et al. 2004). No presente estudo, alguns resultados indicaram que a \n\nsuperf\u00edcie NANO-HA pode ser menos afetada pelos efeitos adversos resultantes da \n\nhiperglicemia: os n\u00edveis de Runx2 (diab\u00e9tico NANO 7 dias: 1,78), Alp (diab\u00e9tico NANO 7 \n\ndias: 2,57), Oc (diab\u00e9tico NANO 7 dias: 3,38) Opn (diab\u00e9tico NANO 7 dias: 1,55) sugerem \n\num aumento da prolifera\u00e7\u00e3o de osteoblastos, principalmente nos est\u00e1gios iniciais da \n\nosseointegra\u00e7\u00e3o. Al\u00e9m disso, a cascata de mineraliza\u00e7\u00e3o altamente ativa do osso interfacial \n\nem torno dos implantes revestidos com NANO HA pode ser explicada a partir de uma \n\nperspectiva gen\u00e9tica. Tem sido relatado que a express\u00e3o de Alp no osso ao redor de implantes \n\nrevestidos com NANO HA foi significativamente maior do que nos controles sem tratamento \n\n(Jimbo et al. 2011). Uma vez que uma alta atividade de Alp aumenta a express\u00e3o da \n\nosteopontina, que \u00e9 conhecida por ser um fator coesivo para a mineraliza\u00e7\u00e3o, podemos sugerir \n\nque o revestimento de NANO HA foi parcialmente respons\u00e1vel pelo aumento das \n\npropriedades \u00f3sseas.  \n\nA import\u00e2ncia da topografia e da qu\u00edmica da superf\u00edcie do implante t\u00eam sido \n\namplamente discutidas (Albrektsson and Wennerberg 2004a; Berglundh et al. 2007; Boyan et \n\nal. 2003; Coelho et al. 2014a; Jiang et al. 2017; Martinez et al. 2018). O presente estudo \n\ndemonstrou, em modelo in vivo, por meio de par\u00e2metros microtomogr\u00e1ficos, histol\u00f3gicos, de \n\nnanoindenta\u00e7\u00e3o e de express\u00e3o g\u00eanica, que o revestimento com NANO HA promoveu um \n\naumento significativo da regula\u00e7\u00e3o do processo de mineraliza\u00e7\u00e3o, independentemente da \n\ncondi\u00e7\u00e3o sist\u00eamica e do tempo, sugerindo que modifica\u00e7\u00f5es de superf\u00edcie bioativas em \n\nnanoescala podem agir como uma compensa\u00e7\u00e3o para a influ\u00eancia negativa do DM na \n\nosseointegra\u00e7\u00e3o. \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n6 Conclus\u00e3o \n\n  \n\n\n\nConclus\u00e3o  |  90 \n\n6 CONCLUS\u00c3O \n\n \n\nA partir dos resultados encontrados no presente estudo, pudemos concluir que: \n\n \n\na) os implantes recobertos com NANO-hidroxiapatita apresentaram resultados \n\nmicrotomogr\u00e1ficos, histol\u00f3gicos, de nanodureza e de express\u00e3o g\u00eanica \n\nsuperiores em promover forma\u00e7\u00e3o de novo osso em um modelo de \n\ncicatriza\u00e7\u00e3o deficiente; \n\nb) a superf\u00edcie de NANO-hidroxiapatita apresentou potencial para compensar \n\na cicatriza\u00e7\u00e3o \u00f3ssea prejudicada que ocorre em indiv\u00edduos diab\u00e9ticos. Os \n\npresentes resultados sugerem que esta superf\u00edcie seja testada em estudos \n\ncl\u00ednicos controlados em humanos em modelos \u00f3sseos desafiadores, \n\navaliando se os achados em animais resultar\u00e3o em diferen\u00e7as cl\u00ednicas em \n\ntermos de sucesso e/ou sobreviv\u00eancia de implantes. \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n7 Refer\u00eancias \n\n  \n\n\n\nRefer\u00eancias  |  92 \n\n7 REFER\u00caNCIAS  \n\n \n\nAdell R, Eriksson B, Lekholm U, Branemark PI, Jemt T. 1990. Long-term follow-up study of \nosseointegrated implants in the treatment of totally edentulous jaws. Int J Oral \nMaxillofac Implants. 5(4):347-359. \n\nAjami E, Bell S, Liddell RS, Davies JE. 2016. Early bone anchorage to micro- and nano-\ntopographically complex implant surfaces in hyperglycemia. Acta Biomater. 39:169-179. \n\nAjami E, Mahno E, Mendes VC, Bell S, Moineddin R, Davies JE. 2014. Bone healing and the \neffect of implant surface topography on osteoconduction in hyperglycemia. Acta \nBiomater. 10(1):394-405. \n\nAlbrektsson T, Branemark PI, Hansson HA, Lindstrom J. 1981. Osseointegrated titanium \nimplants. Requirements for ensuring a long-lasting, direct bone-to-implant anchorage \nin man. Acta Orthop Scand. 52(2):155-170. \n\nAlbrektsson T, Johansson C. 2001. Osteoinduction, osteoconduction and osseointegration. \nEur Spine J. 10 Suppl 2:S96-101. \n\nAlbrektsson T, Wennerberg A. 2004a. Oral implant surfaces: Part 1--review focusing on \ntopographic and chemical properties of different surfaces and in vivo responses to \nthem. Int J Prosthodont. 17(5):536-543. \n\nAlbrektsson T, Wennerberg A. 2004b. Oral implant surfaces: Part 2--review focusing on \nclinical knowledge of different surfaces. Int J Prosthodont. 17(5):544-564. \n\nAnchieta RB, Baldassarri M, Guastaldi F, Tovar N, Janal MN, Gottlow J, Dard M, Jimbo R, \nCoelho PG. 2014. Mechanical property assessment of bone healing around a titanium-\nzirconium alloy dental implant. Clin Implant Dent Relat Res. 16(6):913-919. \n\nAnselme K, Bigerelle M. 2005. Topography effects of pure titanium substrates on human \nosteoblast long-term adhesion. Acta Biomater. 1(2):211-222. \n\nBaldassarri M, Bonfante E, Suzuki M, Marin C, Granato R, Tovar N, Coelho PG. 2012. \nMechanical properties of human bone surrounding plateau root form implants \nretrieved after 0.3-24 years of function. J Biomed Mater Res B Appl Biomater. \n100(7):2015-2021. \n\nBattula S, Lee JW, Wen HB, Papanicolaou S, Collins M, Romanos GE. 2015. Evaluation of \ndifferent implant designs in a ligature-induced peri-implantitis model: A canine study. \nInt J Oral Maxillofac Implants. 30(3):534-545. \n\n\n\nRefer\u00eancias  |  93 \n\nBerglundh T, Abrahamsson I, Albouy JP, Lindhe J. 2007. Bone healing at implants with a \nfluoride-modified surface: An experimental study in dogs. Clin Oral Implants Res. \n18(2):147-152. \n\nBlair JM, Zhou H, Seibel MJ, Dunstan CR. 2006. Mechanisms of disease: Roles of opg, rankl \nand rank in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol. 3(1):41-\n49. \n\nBoyan BD, Hummert TW, Dean DD, Schwartz Z. 1996. Role of material surfaces in \nregulating bone and cartilage cell response. Biomaterials. 17(2):137-146. \n\nBoyan BD, Lossdorfer S, Wang L, Zhao G, Lohmann CH, Cochran DL, Schwartz Z. 2003. \nOsteoblasts generate an osteogenic microenvironment when grown on surfaces with \nrough microtopographies. Eur Cell Mater. 6:22-27. \n\nBraceras I, De Maeztu MA, Alava JI, Gay-Escoda C. 2009. In vivo low-density bone \napposition on different implant surface materials. Int J Oral Maxillofac Surg. \n38(3):274-278. \n\nBranemark PI, Adell R, Breine U, Hansson BO, Lindstrom J, Ohlsson A. 1969. Intra-osseous \nanchorage of dental prostheses. I. Experimental studies. Scand J Plast Reconstr Surg. \n3(2):81-100. \n\nBrunette D, Tengvall P, Textor M, Thomsen P. 2001. Titanium in medicine. Berlin. \n\nBurgos PM, Rasmusson L, Meirelles L, Sennerby L. 2008. Early bone tissue responses to \nturned and oxidized implants in the rabbit tibia. Clin Implant Dent Relat Res. \n10(3):181-190. \n\nBuser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, Hoffmann B, Lussi \nA, Steinemann SG. 2004. Enhanced bone apposition to a chemically modified sla \ntitanium surface. J Dent Res. 83(7):529-533. \n\nChambrone L, Chambrone LA, Lima LA. 2010. Effects of occlusal overload on peri-implant \ntissue health: A systematic review of animal-model studies. J Periodontol. \n81(10):1367-1378. \n\nChambrone L, Preshaw PM, Ferreira JD, Rodrigues JA, Cassoni A, Shibli JA. 2014. Effects \nof tobacco smoking on the survival rate of dental implants placed in areas of maxillary \nsinus floor augmentation: A systematic review. Clin Oral Implants Res. 25(4):408-\n416. \n\n\n\nRefer\u00eancias  |  94 \n\nChehroudi B, Gould TR, Brunette DM. 1989. Effects of a grooved titanium-coated implant \nsurface on epithelial cell behavior in vitro and in vivo. J Biomed Mater Res. \n23(9):1067-1085. \n\nCochran DL, Schenk RK, Lussi A, Higginbottom FL, Buser D. 1998. Bone response to \nunloaded and loaded titanium implants with a sandblasted and acid-etched surface: A \nhistometric study in the canine mandible. J Biomed Mater Res. 40(1):1-11. \n\nCoelho PG, Bonfante EA, Pessoa RS, Marin C, Granato R, Giro G, Witek L, Suzuki M. \n2011a. Characterization of five different implant surfaces and their effect on \nosseointegration: A study in dogs. J Periodontol. 82(5):742-750. \n\nCoelho PG, Freire JN, Granato R, Marin C, Bonfante EA, Gil JN, Chuang SK, Suzuki M. \n2011b. Bone mineral apposition rates at early implantation times around differently \nprepared titanium surfaces: A study in beagle dogs. Int J Oral Maxillofac Implants. \n26(1):63-69. \n\nCoelho PG, Granjeiro JM, Romanos GE, Suzuki M, Silva NR, Cardaropoli G, Thompson VP, \nLemons JE. 2009. Basic research methods and current trends of dental implant \nsurfaces. J Biomed Mater Res B Appl Biomater. 88(2):579-596. \n\nCoelho PG, Jimbo R, Tovar N, Bonfante EA. 2015. Osseointegration: Hierarchical designing \nencompassing the macrometer, micrometer, and nanometer length scales. Dent Mater. \n31(1):37-52. \n\nCoelho PG, Marin C, Granato R, Giro G, Suzuki M, Bonfante EA. 2012. Biomechanical and \nhistologic evaluation of non-washed resorbable blasting media and alumina-\nblasted/acid-etched surfaces. Clin Oral Implants Res. 23(1):132-135. \n\nCoelho PG, Takayama T, Yoo D, Jimbo R, Karunagaran S, Tovar N, Janal MN, Yamano S. \n2014a. Nanometer-scale features on micrometer-scale surface texturing: A bone \nhistological, gene expression, and nanomechanical study. Bone. 65:25-32. \n\nCoelho PG, Teixeira HS, Marin C, Witek L, Tovar N, Janal MN, Jimbo R. 2014b. The in vivo \neffect of p-15 coating on early osseointegration. J Biomed Mater Res B Appl \nBiomater. 102(3):430-440. \n\nDavies JE. 1998. Mechanisms of endosseous integration. Int J Prosthodont. 11(5):391-401. \n\nDe la Rosa M, Rodriguez A, Sierra K, Mendoza G, Chambrone L. 2013. Predictors of peri-\nimplant bone loss during long-term maintenance of patients treated with 10-mm \nimplants and single crown restorations. Int J Oral Maxillofac Implants. 28(3):798-802. \n\n\n\nRefer\u00eancias  |  95 \n\nde Oliveira PT, Nanci A. 2004. Nanotexturing of titanium-based surfaces upregulates \nexpression of bone sialoprotein and osteopontin by cultured osteogenic cells. \nBiomaterials. 25(3):403-413. \n\nDenhardt DT, Giachelli CM, Rittling SR. 2001. Role of osteopontin in cellular signaling and \ntoxicant injury. Annu Rev Pharmacol Toxicol. 41:723-749. \n\nDinato JC. 2004. Implantes osseointegrados: Cirurgia e pr\u00f3tese. S\u00e3o Paulo. \n\nDoerner M, Nix W. 1986. A method for interpreting the data from depth- sensing indentation \ninstruments. . J Mater Res 1:601 - 609. \n\nDucy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, \nGundberg C et al. 1996. Increased bone formation in osteocalcin-deficient mice. \nNature. 382(6590):448-452. \n\nElias CN, Meirelles L. 2010. Improving osseointegration of dental implants. Expert Rev Med \nDevices. 7(2):241-256. \n\nEllingsen JE, Johansson CB, Wennerberg A, Holmen A. 2004. Improved retention and bone-\ntolmplant contact with fluoride-modified titanium implants. Int J Oral Maxillofac \nImplants. 19(5):659-666. \n\nEmrich LJ, Shlossman M, Genco RJ. 1991. Periodontal disease in non-insulin-dependent \ndiabetes mellitus. J Periodontol. 62(2):123-131. \n\nEsposito M, Grusovin MG, Willings M, Coulthard P, Worthington HV. 2007. The \neffectiveness of immediate, early, and conventional loading of dental implants: A \ncochrane systematic review of randomized controlled clinical trials. Int J Oral \nMaxillofac Implants. 22(6):893-904. \n\nExpert Committee on the D, Classification of Diabetes M. 2000. Report of the expert \ncommittee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 23 \nSuppl 1:S4-19. \n\nFeldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M. 1989. The direct \nexamination of three-dimensional bone architecture in vitro by computed tomography. \nJ Bone Miner Res. 4(1):3-11. \n\nFrantzis TG, Reeve CM, Brown AL, Jr. 1971. The ultrastructure of capillary basement \nmembranes in the attached gingiva of diabetic and nondiabetic patients with \nperiodontal disease. J Periodontol. 42(7):406-411. \n\n\n\nRefer\u00eancias  |  96 \n\nFu YX, Gu JH, Zhang YR, Tong XS, Zhao HY, Yuan Y, Liu XZ, Bian JC, Liu ZP. 2013. \nOsteoprotegerin influences the bone resorption activity of osteoclasts. Int J Mol Med. \n31(6):1411-1417. \n\nGiachelli CM, Steitz S. 2000. Osteopontin: A versatile regulator of inflammation and \nbiomineralization. Matrix Biol. 19(7):615-622. \n\nGiglio MJ, Giannunzio G, Olmedo D, Guglielmotti MB. 2000. Histomorphometric study of \nbone healing around laminar implants in experimental diabetes. Implant Dent. \n9(2):143-149. \n\nGil LF, Sarendranath A, Neiva R, Marao HF, Tovar N, Bonfante EA, Janal MN, Castellano \nA, Coelho PG. 2017. Bone healing around dental implants: Simplified vs conventional \ndrilling protocols at speed of 400 rpm. Int J Oral Maxillofac Implants. 32(2):329-336. \n\nGittens RA, McLachlan T, Olivares-Navarrete R, Cai Y, Berner S, Tannenbaum R, Schwartz \nZ, Sandhage KH, Boyan BD. 2011. The effects of combined micron-/submicron-scale \nsurface roughness and nanoscale features on cell proliferation and differentiation. \nBiomaterials. 32(13):3395-3403. \n\nGittens RA, Olivares-Navarrete R, Cheng A, Anderson DM, McLachlan T, Stephan I, Geis-\nGerstorfer J, Sandhage KH, Fedorov AG, Rupp F et al. 2013. The roles of titanium \nsurface micro/nanotopography and wettability on the differential response of human \nosteoblast lineage cells. Acta Biomater. 9(4):6268-6277. \n\nGonzalez-Garcia R, Monje F. 2013. The reliability of cone-beam computed tomography to \nassess bone density at dental implant recipient sites: A histomorphometric analysis by \nmicro-ct. Clin Oral Implants Res. 24(8):871-879. \n\nGooch HL, Hale JE, Fujioka H, Balian G, Hurwitz SR. 2000. Alterations of cartilage and \ncollagen expression during fracture healing in experimental diabetes. Connect Tissue \nRes. 41(2):81-91. \n\nGoodman WG, Hori MT. 1984. Diminished bone formation in experimental diabetes. \nRelationship to osteoid maturation and mineralization. Diabetes. 33(9):825-831. \n\nHarkness JE, Wagner JE. 1993. Biologia e cl\u00ednica de coelhos e roedores. S\u00e3o Paulo: Roca. \n\nHayashi M, Jimbo R, Lindh L, Sotres J, Sawase T, Mustafa K, Andersson M, Wennerberg A. \n2012. In vitro characterization and osteoblast responses to nanostructured \nphotocatalytic tio2 coated surfaces. Acta Biomater. 8(6):2411-2416. \n\n\n\nRefer\u00eancias  |  97 \n\nHe H, Liu R, Desta T, Leone C, Gerstenfeld LC, Graves DT. 2004. Diabetes causes decreased \nosteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic \ncells in bacteria stimulated bone loss. Endocrinology. 145(1):447-452. \n\nHoemann CD, El-Gabalawy H, McKee MD. 2009. In vitro osteogenesis assays: Influence of \nthe primary cell source on alkaline phosphatase activity and mineralization. Pathol \nBiol (Paris). 57(4):318-323. \n\nHoffler CE, Guo XE, Zysset PK, Goldstein SA. 2005. An application of nanoindentation \ntechnique to measure bone tissue lamellae properties. J Biomech Eng. 127(7):1046-\n1053. \n\nHoffler CE, Moore KE, Kozloff K, Zysset PK, Brown MB, Goldstein SA. 2000. \nHeterogeneity of bone lamellar-level elastic moduli. Bone. 26(6):603-609. \n\nHuang YH, Xiropaidis AV, Sorensen RG, Albandar JM, Hall J, Wikesjo UM. 2005. Bone \nformation at titanium porous oxide (tiunite) oral implants in type iv bone. Clin Oral \nImplants Res. 16(1):105-111. \n\nIyama S, Takeshita F, Ayukawa Y, Kido MA, Suetsugu T, Tanaka T. 1997. A study of the \nregional distribution of bone formed around hydroxyapatite implants in the tibiae of \nstreptozotocin-induced diabetic rats using multiple fluorescent labeling and confocal \nlaser scanning microscopy. J Periodontol. 68(12):1169-1175. \n\nJaved F, Almas K, Crespi R, Romanos GE. 2011. Implant surface morphology and primary \nstability: Is there a connection? Implant Dent. 20(1):40-46. \n\nJemt T, Lekholm U. 1993. Oral implant treatment in posterior partially edentulous jaws: A 5-\nyear follow-up report. Int J Oral Maxillofac Implants. 8(6):635-640. \n\nJemt T, Lekholm U, Adell R. 1989. Osseointegrated implants in the treatment of partially \nedentulous patients: A preliminary study on 876 consecutively placed fixtures. Int J \nOral Maxillofac Implants. 4(3):211-217. \n\nJiang H, Ma X, Zhou W, Dong K, Rausch-Fan X, Liu S, Li S. 2017. The effects of \nhierarchical micro/nano-structured titanium surface on osteoblast proliferation and \ndifferentiation under diabetic conditions. Implant Dent. 26(2):263-269. \n\nJiang P, Liang J, Song R, Zhang Y, Ren L, Zhang L, Tang P, Lin C. 2015. Effect of \noctacalcium-phosphate-modified micro/nanostructured titania surfaces on osteoblast \nresponse. ACS Appl Mater Interfaces. 7(26):14384-14396. \n\n\n\nRefer\u00eancias  |  98 \n\nJimbo R, Anchieta R, Baldassarri M, Granato R, Marin C, Teixeira HS, Tovar N, \nVandeweghe S, Janal MN, Coelho PG. 2013. Histomorphometry and bone mechanical \nproperty evolution around different implant systems at early healing stages: An \nexperimental study in dogs. Implant Dent. 22(6):596-603. \n\nJimbo R, Coelho PG, Bryington M, Baldassarri M, Tovar N, Currie F, Hayashi M, Janal MN, \nAndersson M, Ono D et al. 2012a. Nano hydroxyapatite-coated implants improve \nbone nanomechanical properties. J Dent Res. 91(12):1172-1177. \n\nJimbo R, Sotres J, Johansson C, Breding K, Currie F, Wennerberg A. 2012b. The biological \nresponse to three different nanostructures applied on smooth implant surfaces. Clin \nOral Implants Res. 23(6):706-712. \n\nJimbo R, Xue Y, Hayashi M, Schwartz-Filho HO, Andersson M, Mustafa K, Wennerberg A. \n2011. Genetic responses to nanostructured calcium-phosphate-coated implants. J Dent \nRes. 90(12):1422-1427. \n\nJinno Y, Jimbo R, Tovar N, Teixeira HS, Witek L, Coelho PG. 2017. In vivo evaluation of \ndual acid-etched and grit-blasted/acid-etched implants with identical macrogeometry \nin high-density bone. Implant Dent. 26(6):815-819. \n\nJohansson C, Albrektsson T. 1987. Integration of screw implants in the rabbit: A 1-year \nfollow-up of removal torque of titanium implants. Int J Oral Maxillofac Implants. \n2(2):69-75. \n\nJohansson CB, Gretzer C, Jimbo R, Mattisson I, Ahlberg E. 2012. Enhanced implant \nintegration with hierarchically structured implants: A pilot study in rabbits. Clin Oral \nImplants Res. 23(8):943-953. \n\nKayal RA, Tsatsas D, Bauer MA, Allen B, Al-Sebaei MO, Kakar S, Leone CW, Morgan EF, \nGerstenfeld LC, Einhorn TA et al. 2007. Diminished bone formation during diabetic \nfracture healing is related to the premature resorption of cartilage associated with \nincreased osteoclast activity. J Bone Miner Res. 22(4):560-568. \n\nKhang W, Feldman S, Hawley CE, Gunsolley J. 2001. A multi-center study comparing dual \nacid-etched and machined-surfaced implants in various bone qualities. J Periodontol. \n72(10):1384-1390. \n\nKhosla S. 2001. Minireview: The opg/rankl/rank system. Endocrinology. 142(12):5050-5055. \n\nKing H, Aubert RE, Herman WH. 1998. Global burden of diabetes, 1995-2025: Prevalence, \nnumerical estimates, and projections. Diabetes Care. 21(9):1414-1431. \n\n\n\nRefer\u00eancias  |  99 \n\nKing S, Klineberg I, Levinger I, Brennan-Speranza TC. 2016. The effect of hyperglycaemia \non osseointegration: A review of animal models of diabetes mellitus and titanium \nimplant placement. Arch Osteoporos. 11(1):29. \n\nKlokkevold PR, Nishimura RD, Adachi M, Caputo A. 1997. Osseointegration enhanced by \nchemical etching of the titanium surface. A torque removal study in the rabbit. Clin \nOral Implants Res. 8(6):442-447. \n\nKomori T, Kishimoto T. 1998. Cbfa1 in bone development. Curr Opin Genet Dev. 8(4):494-\n499. \n\nKubo K, Tsukimura N, Iwasa F, Ueno T, Saruwatari L, Aita H, Chiou WA, Ogawa T. 2009. \nCellular behavior on tio2 nanonodular structures in a micro-to-nanoscale hierarchy \nmodel. Biomaterials. 30(29):5319-5329. \n\nLalla E, Lamster IB, Drury S, Fu C, Schmidt AM. 2000. Hyperglycemia, glycoxidation and \nreceptor for advanced glycation endproducts: Potential mechanisms underlying \ndiabetic complications, including diabetes-associated periodontitis. Periodontol 2000. \n23:50-62. \n\nLang NP, Zitzmann NU, Working Group 3 of the VEWoP. 2012. Clinical research in implant \ndentistry: Evaluation of implant-supported restorations, aesthetic and patient-reported \noutcomes. J Clin Periodontol. 39 Suppl 12:133-138. \n\nLe Guehennec L, Soueidan A, Layrolle P, Amouriq Y. 2007. Surface treatments of titanium \ndental implants for rapid osseointegration. Dent Mater. 23(7):844-854. \n\nLee KL, Sobieraj M, Baldassarri M, Gupta N, Pinisetty D, Janal MN, Tovar N, Coelho PG. \n2013. The effects of loading conditions and specimen environment on the \nnanomechanical response of canine cortical bone. Mater Sci Eng C Mater Biol Appl. \n33(8):4582-4586. \n\nLian JB, Stein GS, Javed A, van Wijnen AJ, Stein JL, Montecino M, Hassan MQ, Gaur T, \nLengner CJ, Young DW. 2006. Networks and hubs for the transcriptional control of \nosteoblastogenesis. Rev Endocr Metab Disord. 7(1-2):1-16. \n\nLiu Y, de Groot K, Hunziker EB. 2004. Osteoinductive implants: The mise-en-scene for drug-\nbearing biomimetic coatings. Ann Biomed Eng. 32(3):398-406. \n\nLivak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time \nquantitative pcr and the 2(-delta delta c(t)) method. Methods. 25(4):402-408. \n\n\n\nRefer\u00eancias  |  100 \n\nLu H, Kraut D, Gerstenfeld LC, Graves DT. 2003. Diabetes interferes with the bone \nformation by affecting the expression of transcription factors that regulate osteoblast \ndifferentiation. Endocrinology. 144(1):346-352. \n\nManna S, Donnell AM, Kaval N, Al-Rjoub MF, Augsburger JJ, Banerjee RK. 2018. \nImproved design and characterization of plga/pla-coated chitosan based micro-\nimplants for controlled release of hydrophilic drugs. Int J Pharm. 547(1-2):122-132. \n\nMargonar R, Sakakura CE, Holzhausen M, Pepato MT, Alba j R, Marcantonio j E. 2003. The \ninfluence of diabetes mellitus and insulin therapy on biomechanical retention around \ndental implants: A study in rabbits. Implant Dent. 12(4):333-339. \n\nMarin-Pareja N, Salvagni E, Guillem-Marti J, Aparicio C, Ginebra MP. 2014. Collagen-\nfunctionalised titanium surfaces for biological sealing of dental implants: Effect of \nimmobilisation process on fibroblasts response. Colloids Surf B Biointerfaces. \n122:601-610. \n\nMarinho VC, Celletti R, Bracchetti G, Petrone G, Minkin C, Piattelli A. 2003. Sandblasted \nand acid-etched dental implants: A histologic study in rats. Int J Oral Maxillofac \nImplants. 18(1):75-81. \n\nMartin-Badosa E, Amblard D, Nuzzo S, Elmoutaouakkil A, Vico L, Peyrin F. 2003. Excised \nbone structures in mice: Imaging at three-dimensional synchrotron radiation micro ct. \nRadiology. 229(3):921-928. \n\nMartinez EF, Ishikawa GJ, de Lemos AB, Barbosa Bezerra FJ, Sperandio M, Napimoga MH. \n2018. Evaluation of a titanium surface treated with hydroxyapatite nanocrystals on \nosteoblastic cell behavior: An in vitro study. Int J Oral Maxillofac Implants. \n33(3):597-602. \n\nMcCracken M, Lemons JE, Rahemtulla F, Prince CW, Feldman D. 2000. Bone response to \ntitanium alloy implants placed in diabetic rats. Int J Oral Maxillofac Implants. \n15(3):345-354. \n\nMcMahon MM, Bistrian BR. 1995. Host defenses and susceptibility to infection in patients \nwith diabetes mellitus. Infect Dis Clin North Am. 9(1):1-9. \n\nMeirelles L, Arvidsson A, Albrektsson T, Wennerberg A. 2007. Increased bone formation to \nunstable nano rough titanium implants. Clin Oral Implants Res. 18(3):326-332. \n\nMeirelles L, Arvidsson A, Andersson M, Kjellin P, Albrektsson T, Wennerberg A. 2008. \nNano hydroxyapatite structures influence early bone formation. J Biomed Mater Res \nA. 87(2):299-307. \n\n\n\nRefer\u00eancias  |  101 \n\nMendes VC, Moineddin R, Davies JE. 2007. The effect of discrete calcium phosphate \nnanocrystals on bone-bonding to titanium surfaces. Biomaterials. 28(32):4748-4755. \n\nMichaeli E, Weinberg I, Nahlieli O. 2009. Dental implants in the diabetic patient: Systemic \nand rehabilitative considerations. Quintessence Int. 40(8):639-645. \n\nMiyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomi S. 1997. \nAdvanced glycation end products enhance osteoclast-induced bone resorption in \ncultured mouse unfractionated bone cells and in rats implanted subcutaneously with \ndevitalized bone particles. J Am Soc Nephrol. 8(2):260-270. \n\nMoraschini V, Poubel LA, Ferreira VF, Barboza Edos S. 2015. Evaluation of survival and \nsuccess rates of dental implants reported in longitudinal studies with a follow-up \nperiod of at least 10 years: A systematic review. Int J Oral Maxillofac Surg. \n44(3):377-388. \n\nNevins ML, Karimbux NY, Weber HP, Giannobile WV, Fiorellini JP. 1998. Wound healing \naround endosseous implants in experimental diabetes. Int J Oral Maxillofac Implants. \n13(5):620-629. \n\nNovaes AB, Jr., de Souza SL, de Barros RR, Pereira KK, Iezzi G, Piattelli A. 2010. Influence \nof implant surfaces on osseointegration. Braz Dent J. 21(6):471-481. \n\nOates TW, Huynh-Ba G, Vargas A, Alexander P, Feine J. 2013. A critical review of diabetes, \nglycemic control, and dental implant therapy. Clin Oral Implants Res. 24(2):117-127. \n\nOliver RC, Tervonen T. 1993. Periodontitis and tooth loss: Comparing diabetics with the \ngeneral population. J Am Dent Assoc. 124(12):71-76. \n\nPark HS, Lee YJ, Jeong SH, Kwon TG. 2008. Density of the alveolar and basal bones of the \nmaxilla and the mandible. Am J Orthod Dentofacial Orthop. 133(1):30-37. \n\nPark YS, Yi KY, Lee IS, Han CH, Jung YC. 2005. The effects of ion beam-assisted \ndeposition of hydroxyapatite on the grit-blasted surface of endosseous implants in \nrabbit tibiae. Int J Oral Maxillofac Implants. 20(1):31-38. \n\nPetri AD, Teixeira LN, Crippa GE, Beloti MM, de Oliveira PT, Rosa AL. 2010. Effects of \nlow-level laser therapy on human osteoblastic cells grown on titanium. Braz Dent J. \n21(6):491-498. \n\nPinholt EM. 2003. Branemark and iti dental implants in the human bone-grafted maxilla: A \ncomparative evaluation. Clin Oral Implants Res. 14(5):584-592. \n\n\n\nRefer\u00eancias  |  102 \n\nPjetursson BE, Tan K, Lang NP, Bragger U, Egger M, Zwahlen M. 2004. A systematic \nreview of the survival and complication rates of fixed partial dentures (fpds) after an \nobservation period of at least 5 years. Clin Oral Implants Res. 15(6):625-642. \n\nRetzepi M, Donos N. 2010. The effect of diabetes mellitus on osseous healing. Clin Oral \nImplants Res. 21(7):673-681. \n\nRothwell BR, Richard EL. 1984. Diabetes mellitus: Medical and dental considerations. Spec \nCare Dentist. 4(2):58-65. \n\nSafkan-Seppala B, Ainamo J. 1992. Periodontal conditions in insulin-dependent diabetes \nmellitus. J Clin Periodontol. 19(1):24-29. \n\nSantana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. 2003. A role for advanced \nglycation end products in diminished bone healing in type 1 diabetes. Diabetes. \n52(6):1502-1510. \n\nSarve H, Lindblad J, Borgefors G, Johansson CB. 2011. Extracting 3d information on bone \nremodeling in the proximity of titanium implants in srmuct image volumes. Comput \nMethods Programs Biomed. 102(1):25-34. \n\nSchlegel KA, Prechtl C, Most T, Seidl C, Lutz R, von Wilmowsky C. 2013. Osseointegration \nof slactive implants in diabetic pigs. Clin Oral Implants Res. 24(2):128-134. \n\nSchulz MC, Korn P, Stadlinger B, Range U, Moller S, Becher J, Schnabelrauch M, Mai R, \nScharnweber D, Eckelt U et al. 2014. Coating with artificial matrices from collagen \nand sulfated hyaluronan influences the osseointegration of dental implants. J Mater \nSci Mater Med. 25(1):247-258. \n\nSennerby L, Pagliani L, Petersson A, Verrocchi D, Volpe S, Andersson P. 2015. Two \ndifferent implant designs and impact of related drilling protocols on primary stability \nin different bone densities: An in vitro comparison study. Int J Oral Maxillofac \nImplants. 30(3):564-568. \n\nSennerby L, Thomsen P, Ericson LE. 1992. A morphometric and biomechanic comparison of \ntitanium implants inserted in rabbit cortical and cancellous bone. Int J Oral Maxillofac \nImplants. 7(1):62-71. \n\nStrietzel FP, Reichart PA, Kale A, Kulkarni M, Wegner B, Kuchler I. 2007. Smoking \ninterferes with the prognosis of dental implant treatment: A systematic review and \nmeta-analysis. J Clin Periodontol. 34(6):523-544. \n\n\n\nRefer\u00eancias  |  103 \n\nTakeshita F, Iyama S, Ayukawa Y, Kido MA, Murai K, Suetsugu T. 1997. The effects of \ndiabetes on the interface between hydroxyapatite implants and bone in rat tibia. J \nPeriodontol. 68(2):180-185. \n\nTomsia AP, Lee JS, Wegst UG, Saiz E. 2013. Nanotechnology for dental implants. Int J Oral \nMaxillofac Implants. 28(6):e535-546. \n\nWebster TJ, Ahn ES. 2007. Nanostructured biomaterials for tissue engineering bone. Adv \nBiochem Eng Biotechnol. 103:275-308. \n\nWeiss RE, Gorn AH, Nimni ME. 1981. Abnormalities in the biosynthesis of cartilage and \nbone proteoglycans in experimental diabetes. Diabetes. 30(8):670-677. \n\nWennerberg A, Albrektsson T. 2000. Suggested guidelines for the topographic evaluation of \nimplant surfaces. Int J Oral Maxillofac Implants. 15(3):331-344. \n\nWennerberg A, Albrektsson T. 2009. Effects of titanium surface topography on bone \nintegration: A systematic review. Clin Oral Implants Res. 20 Suppl 4:172-184. \n\nWennerberg A, Albrektsson T. 2010. On implant surfaces: A review of current knowledge \nand opinions. Int J Oral Maxillofac Implants. 25(1):63-74. \n\nWennerberg A, Albrektsson T. 2011. Current challenges in successful rehabilitation with oral \nimplants. J Oral Rehabil. 38(4):286-294. \n\nZhuang XM, Zhou B, Ouyang JL, Sun HP, Wu YL, Liu Q, Deng FL. 2014. Enhanced mc3t3-\ne1 preosteoblast response and bone formation on the addition of nano-needle and \nnano-porous features to microtopographical titanium surfaces. Biomed Mater. \n9(4):045001. \n\nZuo J, Huang X, Zhong X, Zhu B, Sun Q, Jin C, Quan H, Tang Z, Chen W. 2013. A \ncomparative study of the influence of three pure titanium plates with different micro- \nand nanotopographic surfaces on preosteoblast behaviors. J Biomed Mater Res A. \n101(11):3278-3284. \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAnexo \n\n  \n\n\n\nAnexo  |  105 \n\nANEXO \n\n \n \n\nAnexo 1. Certificado de aprova\u00e7\u00e3o do Comit\u00ea de \u00c9tica no Uso de Animais \n \n\n  \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nArtigos \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nArtigo 1 \n\n  \n\n\n\nArtigo 1  |  108 \n\nHistological and nanomechanical properties of a new nanometric hydroxiapatite \n\nimplant surface. AN in vivo study in diabetic rats.  \n\n \n\nPaula Gabriela Faciola Pess\u00f4a de Oliveira1,2, Paulo Guilherme Coelho2, Edmara Tatiely \n\nPedroso Bergamo2, Lukasz Witek2, Cristine D\u2019Almeida Borges1, F\u00e1bio Bezerra1, Arthur \n\nBel\u00e9m Novaes Jr1, S\u00e9rgio Lu\u00eds Scombatti de Souza1. \n\n \n\n1 Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of \n\nRibeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil. \n\n2 Department of Biomaterials and Biomimetics, New York University, New York, NY, USA. \n\n \n\nCorrespondence address: \n\nS\u00e9rgio Lu\u00eds Scombatti de Souza \n\nDepartament of Oral &amp; Maxillofacial Surgery and Periodontology \n\nSchool of Dentistry of Ribeirao Preto University of Sao Paulo \n\nAv do Caf\u00e9, s/n. Zip: 14040-904 Ribeirao Preto - SP - Brazil \n\nTel: +55 16 3315-3980 \n\nEmail: scombatti@forp.usp.br \n\n  \n\n\n\nArtigo 1  |  109 \n\nAbstract \n\nThe aim of this study was to evaluate, in healthy and diabetic rats the response of a \n\nnew topography implant surface (nano-hydroxyapatite coating), concerning to bone \n\nregeneration: bone to implant contact (%BIC) and bone area fraction occupancy (%BAFO); \n\nand nanomechanical properties: elastic modulus (EM) and hardness (H). Mini implants \n\n(machined, double acid etched (DAE) and with addition of nano-hydroxyapatite (NANO)) \n\nwere installed in tibias of healthy rats (n=36) and diabetic rats (n=36). The animals were \n\neuthanized at 7 and 30 days. NANO surface presented higher % BIC and % BAFO when \n\ncompared to machined and DAE (data evaluated as a function of implant surface). \n\nAdditionally, NANO surface presented higher % BIC and % BAFO than machined and DAE, \n\nwith statistically significant differences (data as a function of time and implant surface). \n\nNANO surface depicted higher EM and H values when compared to machined and DAE \n\nsurfaces, with statistically significant differences (data as a function of time and implant \n\nsurface). Nano-hydroxyapatite coated implants presented promising biomechanical results \n\nand can be considered an important tool to compensate impaired bone healing reported in \n\ndiabetics. \n\nKeywords: Diabetes Mellitus, dental implants, histology, hyperglycemia. osseointegration. \n\n  \n\n\n\nArtigo 1  |  110 \n\nIntroduction \n\nThe success of the dental implants is related to the osseointegration, that is defined as \n\na direct bone-to-implant contact without inter-position of any other tissue (1). In the recent \n\ndecade, the use of dental implants has been considered a favorable treatment modality to \n\nreplace missing and lost teeth because of proven biocompatibility, potential for esthetics, and \n\na good long-term prognosis (2, 3). According to Albrektson et al., 1981 some requisites are \n\ndecisive for achieving osseointegration, including the biocompatibility of the material, \n\nsurgical technique, implant design, condition of applied loads after implant placement, \n\nimplant surface quality and the site where the implants are installed (4). However, there are \n\nrisk factors that may affect and impair the osseointegration of the implant. \n\nDiabetes mellitus (DM) is defined as a \u2018\u2018group of metabolic diseases characterized by \n\nhyperglycemia resulting from defects in insulin secretion, insulin action or both\u2019\u2019 (5). It\u2019s one \n\nof the major health problems worldwide (6). Diabetes has been shown to significantly \n\nincrease the levels of periodontal disease and tooth loss (7-9), and has been considered a risky \n\ncondition for dental implants, with the fact that it is associated with delayed wound healing \n\n(10), prevalence of micro vascular disease (11), and impaired response to infection (12). \n\nTherefore, diabetes remains a relative contraindication for implant therapy (13); that is, well-\n\ncontrolled diabetic patients may be considered appropriate for implant therapy, while diabetic \n\npatients lacking good glycemic control may be denied the benefits of this treatment (14).  \n\nThe persistent hyperglycemia in diabetic individuals inhibit osteoblastic activity and alters \n\nthe response of parathyroid hormone that regulates metabolism of Ca and P (15), decreases \n\ncollagen formation during callus formation (16), induces apoptosis in lining cells of bone (17) \n\nand increases osteoclastic activity (18) due to persistent inflammatory response. It also \n\ninduces deleterious effect on bone matrix and diminishes growth and accumulation of \n\n\n\nArtigo 1  |  111 \n\nextracellular matrix (19). The consequent result is diminished bone formation during healing, \n\nwhich is observed in experimental animal studies (20). \n\nRecent developments in the surface of osseointegrated implants has been proposed to \n\nimprove osseointegration in individuals with metabolic disorders that can impair bone healing \n\n(21). Surface properties involved in the early phase of wound healing are surface topography \n\nand chemical composition known to affect cell behavior (22-24) and subsequent tissue \n\nattachment to the implanted material. The modification of the implant surface can thus bring \n\nbenefits to the response of the surrounding bone tissue, accelerating the healing process \n\nand/or improving the newly formed bone quality (25, 26). Osseointegration is directly related \n\nto microgeometric features, such as the degree of surface roughness, and can also depend on \n\nfactors as physical and chemical surface properties (27, 28).  \n\nFormation of a direct bone-to implant contact (BIC) is an important parameter, which \n\ninfluences the overall success and survival of dental implant therapy (29-31). It has been \n\nreported that osteoblastic attachment and collagen synthesis are significantly higher around \n\nrough-surfaced implants in contrast to implants with machined surfaces (32, 33). Jimbo et al., \n\n2012 evaluated 20 titanium implants, half prepared with a stable hydroxyapatite (HA) \n\nnanoparticle surface and half grit-blasted, acid-etched, and heat-treated, which were inserted \n\ninto rabbit femurs (34). After 3 weeks of healing, the samples were retrieved for \n\nhistomorphometry. The nanomechanical properties of the surrounding bone were evaluated \n\nby nanoindentation. While both implants revealed similar BIC, the nanoindentation \n\ndemonstrated that the tissue quality was significantly enhanced around the HA coated \n\nimplants. It can be said that the nanomechanical characterization provides a possibility to \n\npurely evaluate the bone mechanical properties in the reduced scale level without the \n\ndisturbance of other influential factors (35). \n\n\n\nArtigo 1  |  112 \n\nSome experimental studies in animals have demonstrated that DM could negatively \n\ninterfere with the process of implant osseointegration (36-38). Ajami et al., 2014 revealed that \n\nchronic hyperglycemia has an impact on early stages of peri-implant healing, specifically \n\nosteoconduction and new bone formation, which consequently affects long-term endosseous \n\nimplant stability and that compromised implant integration due to hyperglycemia could be \n\nabrogated by using nanotopographically complex implants (39). Additionally, newly formed \n\nbone around implants was reported immature and less organized in uncontrolled diabetic rats \n\nthan in non-diabetic controls, suggesting qualitative differences in newly formed bone (3, 36-\n\n38). Intriguingly, McCracken et al., 2000 even though supported these findings, reported very \n\nlow bone-to-implant contact for both diabetic (16.2%) and non-diabetic rats (24.5%) (37). \n\nThus, the aim of this study was to evaluate, in healthy and diabetic rats (as a model of \n\ndeficient bone repair) the response of a new topography implant surface (nano-hydroxyapatite \n\ncoating), concerning to bone regeneration: bone to implant contact (%BIC) and bone area \n\nfraction occupancy (%BAFO); and nanomechanical properties: elastic modulus (EM) and \n\nhardness (H), based on the hypothesis that the histological and mechanical aspect of the bone \n\nwould be improved due to the effect of the nanostructured HA. \n\n \n\nMaterials and Methods \n\nAnimals  \n\nSeventy-two adult male Wistar rats (250\u2013300 g) were included in the study. The \n\nanimals were treated according to the guidelines for animal care with free access to water and \n\na standard diet and were kept in plastic cages. Prior to the surgical procedures, all animals \n\nwere allowed to acclimatize to the laboratory environment for 7 days. The animals were \n\nrandomly allocated to diabetes mellitus group and control group. The protocol was approved \n\nby The Ethics Committee on Animal Experimentation at the school of Dentistry of Ribeirao \n\n\n\nArtigo 1  |  113 \n\nPreto, University of Sao Paulo \u2013 FORP/USP (protocol 2014.1.1083.58.4).  \n\n \n\nInduction of Diabetes Mellitus  \n\nDiabetes was induced by a single intraperitoneal (i.p.) injection of Streptozotocin \n\n(STZ, 60 mg/kg, Sigma, St. Louis, Missouri, USA), which was dissolved in 0.2 mL citrate \n\nbuffered solution (0.01 M, pH 4.5) (n=36). Healthy group received a vehicle i.p. injection at a \n\nvolume of 1mL/kg (n=36). Blood glucose levels were monitored at the day of implantation \n\nand euthanasia through a superficial puncture in the distal tail. Blood glucose was instantly \n\nmeasured with a glucometer (Accu-Check Active monitoring system, Roche Diagnostics, \n\nRotkreuz, Zug, Switzerland). Only animals with glucose levels higher than 300mg/dL were \n\nconsidered diabetic and included in the study (40). \n\n \n\nSurgical Procedures \n\nGeneral anesthesia was induced by administering an injection of 100\u2013130 \u00b5L/100g of \n\nanimal weight in a 4:3 combination of ketamine (74.1 mg/g of 10 % ketamine hydrochloride; \n\nAgener, Uni\u00e3o Qu\u00edmica Farmac\u00eautica Nacional S/A, Embu-Gua\u00e7u, Sao Paulo, Brazil) and \n\nxylazine (11.2 mg/kg dopaser; Calier Laboratories S/A, Catalonia, Barcelona, Spain). Next, \n\ntrichotomy and antisepsis with iodine solution 10% (Rioquimica Ind. Farmaceutica, Sao \n\nPaulo, Brazil) at the medial side of the left tibia were performed. \n\nA 15-mm incision was done using a type 15C scalpel blade (Swann-Morton, \n\nSheffield, England) on the medial side of the left tibia. After soft tissues dissection, bone was \n\nexposed, washed with copious sterile saline solution (0.9%) and drilled with a 2.0 mm pilot \n\ndrill (SIN implantes, Sao Paulo, Sao Paulo, Brazil) using an electric implant motor (Dentscler, \n\nRibeirao Preto, Sao Paulo, Brazil) at 1000rpm. The perforation was made under constant \n\nirrigation with sterile saline solution (0.9 %). A custom-made titanium implant (2.7 mm in \n\n\n\nArtigo 1  |  114 \n\nlength and 1.4 mm in diameter \u2013 SIN implantes, Sao Paulo, Sao Paulo, Brazil) was randomly \n\ninstalled in the left tibia using a hand driver key (SIN implantes, Sao Paulo, Sao Paulo, \n\nBrazil). Incisions were closed using 5-0 coated Vicryl- suture (Vicryl Ethicon 5.0, Johnson \n\nProd., S\u00e3o Jos\u00e9 dos Campos, Sao Paulo, Brazil). \n\nFollowing surgery, the animals were monitored daily for signs of pain, dehiscence, \n\ninfection, restricted movement, loss of appetite and weight loss. Post-operative analgesia was \n\nprovided with anti-inflammatory (ketoprofen 0,05mg/kg), and a single dose of antibiotic \n\n(penicillin 24.000 IU/kg) was administered. All animals recovered well form the surgery and \n\ndid not required additional doses of prescriptions.  \n\n \n\nExperimental Groups \n\nThe seventy-two rats were randomly divided into six experimental groups of twelve \n\nrats each, and the groups were defined as follows: G1 - machined mini implants installed in \n\nhealthy rats; G2 - double acid etched (DAE) mini implants installed in healthy rats; G3 - \n\nnano-hydroxyapatite (NANO HA) covered mini implants installed in healthy rats; G4 - \n\nmachined mini implants installed in diabetic rats; G5 - DAE mini implants installed in \n\ndiabetic rats; and G6 - NANO HA covered mini implants installed in diabetic rats.  \n\nThe animals were euthanized 7 and 30 days after implants placement (36 animals in \n\neach period, 18 healthy and 18 diabetic, 6 from each group) by the intraperitoneal \n\nadministration of a lethal dose (150 mg/kg) of sodium thiopental (Thiopentax, Cristalia, Sao \n\nPaulo, Brazil). The left tibia were removed and fixed in 10 % neutral formalin for 48 hours \n\nand the specimens were histologically processed. Histological parameters bone to implant \n\ncontact (%BIC) and bone area fraction occupancy (%BAFO); and nanomechanical properties: \n\nelastic modulus (EM) and hardness (H) were evaluated. \n\n \n\n\n\nArtigo 1  |  115 \n\nHistologic Sectioning and Histomorphometry \n\nBriefly, the tibia-implant blocks were fixed in 10% formalin buffered with 0.1 M \n\nsodium cacodylate, pH 7.3, for 48 hours and transferred to a solution of 70% ethanol for 72 \n\nhours. After dehydration, tibias were embedded in Hard Grade LR White resin (London Resin \n\nCompany, London, London, United Kingdom) and sectioned using Exakt Cutting System \n\n(Exakt, Norderstedt, Hamburg, Germany). The longitudinal sections obtained were polished \n\nand mounted on acrylic slides using Exakt Grinding System (Exakt). The resulting 40 \u00b5m \n\nthick sections were reduced to a thickness of 20 \u00b5m and stained with Stevenel\u2019s blue and \n\nAlizarin red and scanned via an automated slide scanning system and specialized computer \n\nsoftware (Aperio Technologies, Vista, California, USA).  \n\nFor histomorphometric evaluation, an imaging analysis software (ImageJ, NIH, \n\nBethesda, Maryland, USA) was used to quantify and evaluate osseointegration parameters \n\naround periimplant surface. The dependent variables of the present study were percentage of \n\nbone-to-implant contact (%BIC) and bone area fraction occupancy (%BAFO). %BIC was \n\nselected since it quantifies the degree of osseointegration derived from primary stability by \n\nmeasuring the percentage of bone along with implant surface perimeter. %BAFO evaluates \n\nthe degree of osseointegration derived from secondary stability by measuring the percentage \n\nof bone (newly formed and non-vital autografted/native bone due to instrumentation) within \n\nthe implant threads (41-43). All evaluations were performed in a blinded manner. \n\n \n\nNanoindentation assay \n\nThe nanoindentation test was performed as previously described by Coelho et al., \n\n2014 (35). In resume, the resin blocks were processed in the same manner as the histological \n\nsections; for scratch removal, further polishing was performed with diamond suspensions of 9 \n\nto 1 \u00b5m particle size (Buehler, Lake Bluff, Illinois, USA). Nanoindentation (n = 30 per \n\n\n\nArtigo 1  |  116 \n\nspecimen) were performed with a nanoindenter (Hysitron TI 950, Minneapolis, Minnesota, \n\nUSA) equipped with a Berkovich diamond three-sided pyramid probe (44). A loading profile \n\nwas developed with a peak load of 300 \u00b5N at a rate of 60 \u00b5N/sec, followed by a holding time \n\nof 10 seconds and an unloading time of 2 seconds. The extended holding period allowed bone \n\nto relax to a more linear response, so that no tissue creep effect occurred in the unloading \n\nportion of the profile (ISO 14577-4). Therefore, from each indentation, a load- displacement \n\ncurve was obtained (45). \n\nFor each specimen, mechanical testing was performed within the threaded regions \n\n(cortical area) between the first and second plateau or the initial set of inter-plateau spaces \n\ncontaining novel bone formation. If no cortical bone was presented within any of the inter-\n\nplateau regions, the specimen was discarded. Bone tissue within these regions was initially \n\ndetected via imaging through a light microscope (Hysitron) (46). Indentations (n = \n\n30/implant) were performed in the identified regions of interest within each plateau region. \n\nFrom each generated load\u2013displacement curve, the reduced modulus Er (GPa) and \n\nhardness H (GPa) of cortical bone tissue were computed via the Hysitron TriboScan software \n\nusing the following formulae, respectively: \n\n\t\t\t??\t? ? \n?!\"(#$)\n\n\u00d7\t%;\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t&amp;?\t'()*\t\"(#$) ;\n \n\nWhere S is the stiffness, hc is the contact depth, Pmax is the maximum applied force (300 \n\n\u00b5N), and A(hc) is the contact area computed from the TriboScan software utilizing the area \n\nfunction with respect to the contact depth. Through the reduced modulus Er, the \n\ncorresponding elastic modulus Eb (GPa) may be calculated using the following equation:  \n\n1\nE? =\n\n1 ?\tv??\nE? +\n\n1 ?\tv??\nE?  \n\nWhere vb (0.3) is the Poisson's ratio for cortical bone, Ei (1140 GPa) is the elastic modulus of \n\n\n\nArtigo 1  |  117 \n\nthe indenter, and vi (0.07) is the Poisson's ratio for the indenter (47, 48). This methodology \n\n(49) has been shown successful in determining the mechanical properties of bone through \n\nnanoindentation (34, 44, 50, 51). \n\n \n\nStatistical Analysis \n\nThe histomorphometric data (percentage of bone-to-implant contact = %BIC and bone \n\narea fraction occupancy = %BAFO) and nanomechanical properties (elastic modulus = EM \n\nand hardness = H) are presented as a function of mean values with the corresponding 95% \n\nconfidence interval (mean \u00b1 95% CI). Preliminary analyses of %BIC, %BAFO, EM and H \n\nhave shown indistinguishable variances (Levene test, all p> .25). %BIC, %BAFO, EM and H \n\ndata were collected and aligned along a linear mixed model with fixed factors of time (7 and \n\n30 days), systemic condition (healthy and diabetic) and surface chemistry/texture \n\nmodifications (machined, DAE and NANO) at a random intercept. After administering a \n\nsignificant omnibus test, post-hoc comparison of the experimental groups means was gathered \n\nusing Tukey test. The analysis was accomplished using SPSS (IBM SPSS 23, IBM Corp., \n\nArmonk, NY). \n\n \n\nResults \n\nThe surgical procedures and follow-up demonstrated no complications regarding to \n\ntechnical conditions or post-operative infections. All animals regained consciousness after 0.5 \n\nhours post-surgery and post-operative healing was uneventful. No clinical concerns or adverse \n\nevents, such as implant exposure, were detected, and a clinically healthy soft tissue aspect \n\nwas observed throughout the course of the study. \n\nA qualitative evaluation of the histologic micrographs of all groups is depicted in \n\nFigure 1 (A-L). All images confirmed successful osseointegration, irrespective of time, \n\n\n\nArtigo 1  |  118 \n\nimplant type and systemic condition. Overall, a notable difference was observed between 7 \n\nand 30 days. With regards to implant type, the NANO group demonstrated more intimate \n\nbone to implant interlocking when compared to machined and DAE. Also, at 30 days, NANO \n\ncoating implants micrographs depicted increased remodeling sites and new bone formation \n\ncompared to 7 days images.   \n\nCorrelating to histologic analysis, histomorphometric measurements of percentage of \n\nbone to implant contact (%BIC) as a function of time demonstrated statistic significant \n\ndifference between 7 (25,32 \u00b1 2,61) and 30 (59,69 \u00b1 2,61) days (p<0.001) (Figure 2A). No \n\nstatistical significant differences were found when healthy (43,03 \u00b1 2,61) and diabetic (41,96 \n\n\u00b1 2,61) groups were compared (data as function of systemic condition) (p=0.632) (Figure \n\n2B). When implant surfaces were considered, NANO group (57,39 \u00b1 3,20) exhibited higher \n\n%BIC relative to machined (32,35 \u00b1 3,20) and DAE (37,74 \u00b1 3,20) groups (data as a function \n\nof implant surface) (p<0.001) (Figure 2C). Data evaluation as a function of time and implant \n\nsurface highlighted the superiority of NANO group at 30 days (74,13 \u00b1 4,53) compared to \n\nothers (machined 7 days = 13,62 \u00b1 4,53, DAE 7 days = 21,62 \u00b1 4,53, NANO 7 days = 40,65; \n\nmachined 30 days = 51,07 \u00b1 4,53 DAE 30 days = 53,87 \u00b1 4,53) (p<0.001) (Figure 2D). When \n\n%BIC was evaluated as a function of systemic condition and surface, diabetic (62,58 \u00b1 4,53) \n\nNANO group depicted a significant statistical difference (p<0.001) (Figure 2E). Evaluating \n\nall factors: time, systemic condition and surface treatments, the results revealed that NANO \n\nsurface presented the best results in diabetic 7 (35,94 \u00b1 6,40) and 30 days (79,80 \u00b1 6,40) \n\n(p<0.001) (Figure 2F). \n\nPercentage of bone area fraction occupancy (%BAFO) as a function of time \n\ndemonstrated statistic significant difference between 7 (31,46 \u00b1 2,99) and 30 (52,87 \u00b1 2,99) \n\ndays (p<0.001) (Figure 3A). Healthy group (44,31 \u00b1 2,99) presented higher %BAFO when \n\ncompared to diabetic (40,02 \u00b1 2,99) (data as function of systemic condition) (p=0.048) \n\n\n\nArtigo 1  |  119 \n\n(Figure 3B). When implant surfaces were considered, NANO group (47,64 \u00b1 3,66) exhibited \n\nhigher %BAFO relative to machined (38,80 \u00b1 3,66) and DAE (40,05 \u00b1 3,66) groups (data as a \n\nfunction of implant surface) (p=0.002) (Figure 3C). Data evaluation as a function of time and \n\nimplant surfaces highlighted the superiority of NANO group at 30 days (56,95 \u00b1 5,18) \n\ncompared to others (machined 7 days = 26,83 \u00b1 5,18, DAE 7 days = 29,22 \u00b1 5,18, NANO 7 \n\ndays 38,34 \u00b1 5,18, machined 30 days = 50,77 \u00b1 5,18, DAE 30 days = 50,88 \u00b1 5,18) (p<0.001) \n\n(Figure 3D). No statistical significant differences were found when %BAFO was evaluated as \n\na function of systemic condition and surface (p=0.616) (Figure 3E). Evaluating all factors \n\n(time, systemic condition and surface treatment) the results revealed that NANO surface \n\npresented the best results at 7 days (healthy = 38,28 \u00b1 7,33 and diabetic = 38,39 \u00b1 7,33) \n\n(p<0.009) (Figure 3F). \n\nThe elastic modulus (EM) as a function of time demonstrated statistic significant \n\ndifference between 7 (8,94 \u00b1 1,36) and 30 (14,14 \u00b1 1,22) days (p<0.001) (Figure 4A). No \n\nstatistical significant differences were found when compared healthy (11,07 \u00b1 1,35) and \n\ndiabetic (12,01 \u00b1 1,24) groups (data as function of systemic condition) (p=0.308) (Figure 4B). \n\nWhen implant surfaces were considered, NANO group (14,89 \u00b1 1,59) exhibited higher EM \n\nrelative to machined (7,28 \u00b1 1,51) and DAE (12,45 \u00b1 1,65) groups (data as a function of \n\nimplant surface) (p<0.037) (Figure 4C). Data evaluation as a function of time and implant \n\nsurface highlighted the superiority of NANO group at 30 days (16,70 \u00b1 1,97) compared to \n\nothers (machined 30 days = 12,52 \u00b1 2,23, DAE 30 days = 13,20 \u00b1 2,16) (p<0.027) (Figure \n\n4D). When EM was evaluated as a function of systemic condition and surface, the diabetic \n\nNANO group (15,71 \u00b1 2,16) depicted higher values (p<0.001) (Figure 4E). Evaluating all \n\nfactors (time, systemic condition and surface treatment) the results revealed that surface \n\ntreated implants presented superior EM than machined (p<0.031) (Figure 4F).  \n\n\n\nArtigo 1  |  120 \n\nHardness (H) as a function of time demonstrated statistic significant difference \n\nbetween 7 (0,31 \u00b1 0,06) and 30 (0,64 \u00b1 0,05) days (p<0.001) (Figure 5A). Healthy group \n\n(0,53 \u00b1 0,06) presented higher H when compared to diabetic (0,42 \u00b1 0,05) (data as function of \n\nsystemic condition) (p=0.015) (Figure 5B). When implant surface were considered, NANO \n\ngroup (0,66 \u00b1 0,07) exhibited higher H relative to machined (0,34 \u00b1 0,07) and DAE (0,43 \u00b1 \n\n0,07) groups (data as a function of implant surface) (p<0.037) (Figure 5C). Data evaluation as \n\na function of time and implant surface highlighted the superiority of NANO group at 30 days \n\n(0,9 \u00b1 0,09) compared to others (machined 30 days = 0,55 \u00b1 0,10, DAE 30 days = 0,47 \u00b1 \n\n0,10) (p<0.027) (Figure 5D). When H was evaluated as a function of systemic condition and \n\nsurface, the healthy NANO group (0,79 \u00b1 0,11) depicted higher values (p<0.002) (Figure 5E). \n\nEvaluating all factors (time, systemic condition and surface treatment) the results revealed \n\nthat surface treated implants presented superior H than machined (p<0.025) and that NANO \n\nhealthy 30 days (1,25 \u00b1 0,14) presented the higher values of H (Figure 5F). \n\n \n\nDiscussion \n\nOsseointegration has been defined as the close contact between bone and biomaterials \n\nat the optical microscopic level (52, 53) and its success for oral rehabilitation is higher than \n\n90% (54-56). Over the previous 2 decades, significant attention has been devoted to \n\nimproving host-to-implant biocompatibility and biomechanical responses through implant \n\ndesign. Among design alterations, surface modification has been the most evaluated \n\nparameter, because it is the first part of the implant to interact with the host biofluids, thus \n\nhaving the potential of significantly altering the short-term interaction between bone and \n\nimplant (57-59). \n\nThe present study evaluated, in healthy and diabetic rats, the response of a new \n\ntopography implant surface (nano-hydroxyapatite coating), concerning to histomorphometric \n\n\n\nArtigo 1  |  121 \n\nbone regeneration (%BIC and %BAFO) and nanomechanical properties (elastic modulus and \n\nhardness). The postulated null hypothesis that histological and mechanical aspect of the bone \n\nwould be improved due to the effect of the nanostructured HA was accepted since \n\nhistomorphometric measurements and nanomechanical properties depicted statistical \n\nsignificant differences for NANO group in all evaluated parameters (data as a function of \n\nimplant surface).  \n\nThe basic osseointegration processes of hemostasis, inflammation, proliferation and \n\nremodeling are known to be impaired by metabolically compromised health conditions, such \n\nas diabetes mellitus (DM) (3, 36, 60, 61). In order to improve the rate and extend of \n\nosseointegration of dental implants in such challenging scenarios, implant surface \n\nchemistry/texture modifications have been suggested (62, 63). Nonetheless, studies \n\ncomparing their potential benefits are still not clear when used in a DM model (64). In the \n\npresent study, bone remodeling appeared to be at a more advanced stage around implants with \n\ntreated surfaces and to a lesser degree also around machined implants. These results suggest \n\nthat bone remodeling can start earlier around advanced, optimized, modified implant surfaces.  \n\nThe development of microscale surface topography, as dual acid-etched (DAE) \n\nimplants, enhanced bone formation along with implant surface when compared to machined \n\n(65-67). Additionally, the emergence of chemically/topographically complex surfaces, such as \n\nbioactive nano-hydroxyapatite coated implants (NANO), provided a more suitable \n\narrangement that better mimics natural tissue organization and facilitates interaction with \n\ntissues biomolecules and cell-cell communication during healing process (68-70). From the \n\nhistomorphometrical analysis, NANO surface presented higher %BIC and %BAFO when \n\ncompared with machined and DAE (regarding implant surface). Furthermore, through an \n\nimplant-specific healing mechanism, at 30 days, NANO surface presented higher %BIC and \n\n%BAFO than machined and DAE, with statistically significant differences (data evaluation as \n\n\n\nArtigo 1  |  122 \n\na function of time and implant surface). Literature findings support the evidence through \n\nprevious animal studies that demonstrated NANO complex surfaces outperforming \n\nmicrotopography surfaces in metabolically compromised subjects (21, 39, 71). \n\nThe noteworthy results evidenced for complex implant surface designs in challenging \n\nscenarios, such as low-density bone sites, motivated their use for compromised systemic \n\nconditions that affect bone metabolism and osseointegration (72). Nanoindentation of bone \n\naround implants has the potential to elucidate the qualitative aspects of osseointegration (34). \n\nIn our study, data evaluated as function of time depicted the superiority of EM and H at 30 \n\ndays compared to 7 days. When the data was evaluated as function of implant surface, NANO \n\ngroup presented higher EM and H than DAE and machined. Literature findings comparing the \n\nuse of NANO and DAE surfaces have confirmed the superiority of the former regarding to \n\nhistological parameters (72, 73).  \n\nHistological analysis is still considered as the \u201cgold standard\u201d to evaluate bone \n\nformation. However, this technique has some limitations. For instance, cutting and grinding \n\nthe implant in bone blocks may damage the interface and influence results. Two dimensional \n\nhistology may not have captured the actual process due to its limited scope of evaluation, \n\nsince it may depend on where the section was taken from (74). Therefore, the lack of a micro-\n\ntomographic investigation can be considered a limitation of this study. Additionally, gene \n\nexpression analysis could provide insights about normal cellular processes, such as osteoblast \n\ndifferentiation of some important bone markers, alkaline phosphatase protein expression, and \n\nextracellular matrix mineralization (75, 76). Finally, other periods of evaluation might \n\ncontribute for more reliable results. \n\nThis study demonstrates significant up-regulation of the mineralization process that \n\nwas detected with bone mechanical property assessment through nanoindentation and \n\nhistologic parameters. The conventional techniques such as the removal torque testing can be \n\n\n\nArtigo 1  |  123 \n\naffected not only by the micro-features, but also by the macro-features of the implant. It can \n\nbe said that the nanomechanical characterization provides a possibility to purely evaluate the \n\nbone mechanical properties in the reduced scale level without the disturbance of other \n\ninfluential factors. The nanoindentation technique is an appropriate method to take into \n\naccount the anisotropic organization of bone (48) and map the range of mechanical properties \n\nof bone around dental implants. With this technique, the process of bone mineralization \n\nrelative to implant design variations (e.g., instrumentation, bulk, and surface) can be \n\nevaluated. In the present study, it is evident that the degree of mineralization (elastic modulus \n\nand hardness) of the bone in the proximity of the implant was significantly enhanced for \n\nsurface treated implants, regardless systemic condition and time. Subsequently, the current \n\nresults and literature findings support the principle regarding to the use of bioactive nanoscale \n\nsurface modifications as a compensation for the negative influence of DM on \n\nosseointegration.  \n\n \n\nConclusions \n\nNano-hydroxyapatite coated implants presented promising biomechanical results and \n\ncan be considered an important tool to compensate impaired bone healing reported in \n\ndiabetics. These results suggest that this surface should be tested in human controlled trials, \n\nevaluating challenging clinical situations. \n\n \n\nAcknowledgements:  \n\nSebasti\u00e3o Carlos Bianco and Adriana Luisa Gon\u00e7alves de Almeida are acknowledged \n\nfor their technical assistance during the experiments. \n\n \n\n  \n\n\n\nArtigo 1  |  124 \n\nFunding:  \n\nThis research was supported by the State of Sao Paulo Research Foundation \n\n(FAPESP, Brazil) (grant numbers: 2015/09879-0 and 2016/14584-2) and the National \n\nCouncil of Scientific and Technological Development (CNPq, Brazil) (grant number: \n\n446840/2014-9).  \n\n \n\nConflict of interest  \n\nThe authors declare no conflict of interest associated with this study  \n\n  \n\n\n\nArtigo 1  |  125 \n\nReferences \n\n1. Branemark PI, Adell R, Breine U, Hansson BO, Lindstrom J, Ohlsson A. Intra-\n\nosseous anchorage of dental prostheses. I. Experimental studies. Scand J Plast Reconstr \n\nSurg. 1969;3(2):81-100. \n\n2. Geckili O, Bilhan H, Geckili E, Cilingir A, Mumcu E, Bural C. Evaluation of possible \n\nprognostic factors for the success, survival, and failure of dental implants. Implant Dent. \n\n2014;23(1):44-50. \n\n3. Nevins ML, Karimbux NY, Weber HP, Giannobile WV, Fiorellini JP. Wound healing \n\naround endosseous implants in experimental diabetes. Int J Oral Maxillofac Implants. \n\n1998;13(5):620-9. \n\n4. Albrektsson T, Branemark PI, Hansson HA, Lindstrom J. Osseointegrated titanium \n\nimplants. Requirements for ensuring a long-lasting, direct bone-to-implant anchorage in \n\nman. Acta Orthop Scand. 1981;52(2):155-70. \n\n5. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes \n\nCare. 2005;28 Suppl 1:S37-42. \n\n6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: \n\nprevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-31. \n\n7. Emrich LJ, Shlossman M, Genco RJ. Periodontal disease in non-insulin-dependent \n\ndiabetes mellitus. J Periodontol. 1991;62(2):123-31. \n\n8. Oliver RC, Tervonen T. Periodontitis and tooth loss: comparing diabetics with the \n\ngeneral population. J Am Dent Assoc. 1993;124(12):71-6. \n\n9. Safkan-Seppala B, Ainamo J. Periodontal conditions in insulin-dependent diabetes \n\nmellitus. J Clin Periodontol. 1992;19(1):24-9. \n\n10. Rothwell BR, Richard EL. Diabetes mellitus: medical and dental considerations. \n\nSpec Care Dentist. 1984;4(2):58-65. \n\n11. Frantzis TG, Reeve CM, Brown AL, Jr. The ultrastructure of capillary basement \n\nmembranes in the attached gingiva of diabetic and nondiabetic patients with \n\nperiodontal disease. J Periodontol. 1971;42(7):406-11. \n\n12. McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in \n\npatients with diabetes mellitus. Infect Dis Clin North Am. 1995;9(1):1-9. \n\n13. Michaeli E, Weinberg I, Nahlieli O. Dental implants in the diabetic patient: \n\nsystemic and rehabilitative considerations. Quintessence Int. 2009;40(8):639-45. \n\n14. Oates TW, Huynh-Ba G, Vargas A, Alexander P, Feine J. A critical review of \n\ndiabetes, glycemic control, and dental implant therapy. Clin Oral Implants Res. \n\n2013;24(2):117-27. \n\n15. Santana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. A role for \n\nadvanced glycation end products in diminished bone healing in type 1 diabetes. \n\nDiabetes. 2003;52(6):1502-10. \n\n16. Gooch HL, Hale JE, Fujioka H, Balian G, Hurwitz SR. Alterations of cartilage and \n\ncollagen expression during fracture healing in experimental diabetes. Connect Tissue \n\nRes. 2000;41(2):81-91. \n\n17. He H, Liu R, Desta T, Leone C, Gerstenfeld LC, Graves DT. Diabetes causes \n\ndecreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of \n\nosteoblastic cells in bacteria stimulated bone loss. Endocrinology. 2004;145(1):447-52. \n\n18. Kayal RA, Tsatsas D, Bauer MA, Allen B, Al-Sebaei MO, Kakar S, et al. Diminished \n\nbone formation during diabetic fracture healing is related to the premature resorption \n\nof cartilage associated with increased osteoclast activity. J Bone Miner Res. \n\n2007;22(4):560-8. \n\n\n\nArtigo 1  |  126 \n\n19. Weiss RE, Gorn AH, Nimni ME. Abnormalities in the biosynthesis of cartilage and \n\nbone proteoglycans in experimental diabetes. Diabetes. 1981;30(8):670-7. \n\n20. Lu H, Kraut D, Gerstenfeld LC, Graves DT. Diabetes interferes with the bone \n\nformation by affecting the expression of transcription factors that regulate osteoblast \n\ndifferentiation. Endocrinology. 2003;144(1):346-52. \n\n21. Schlegel KA, Prechtl C, Most T, Seidl C, Lutz R, von Wilmowsky C. \n\nOsseointegration of SLActive implants in diabetic pigs. Clin Oral Implants Res. \n\n2013;24(2):128-34. \n\n22. Boyan BD, Hummert TW, Dean DD, Schwartz Z. Role of material surfaces in \n\nregulating bone and cartilage cell response. Biomaterials. 1996;17(2):137-46. \n\n23. Chehroudi B, Gould TR, Brunette DM. Effects of a grooved titanium-coated \n\nimplant surface on epithelial cell behavior in vitro and in vivo. J Biomed Mater Res. \n\n1989;23(9):1067-85. \n\n24. Curtis A, Wilkinson C. Topographical control of cells. Biomaterials. \n\n1997;18(24):1573-83. \n\n25. Wennerberg A, Albrektsson T. Current challenges in successful rehabilitation \n\nwith oral implants. J Oral Rehabil. 2011;38(4):286-94. \n\n26. Novaes AB, Jr., de Souza SL, de Barros RR, Pereira KK, Iezzi G, Piattelli A. Influence \n\nof implant surfaces on osseointegration. Braz Dent J. 2010;21(6):471-81. \n\n27. Sul YT, Johansson C, Wennerberg A, Cho LR, Chang BS, Albrektsson T. Optimum \n\nsurface properties of oxidized implants for reinforcement of osseointegration: surface \n\nchemistry, oxide thickness, porosity, roughness, and crystal structure. Int J Oral \n\nMaxillofac Implants. 2005;20(3):349-59. \n\n28. Le Guehennec L, Soueidan A, Layrolle P, Amouriq Y. Surface treatments of \n\ntitanium dental implants for rapid osseointegration. Dent Mater. 2007;23(7):844-54. \n\n29. Javed F, Almas K, Crespi R, Romanos GE. Implant surface morphology and \n\nprimary stability: is there a connection? Implant Dent. 2011;20(1):40-6. \n\n30. Pinholt EM. Branemark and ITI dental implants in the human bone-grafted \n\nmaxilla: a comparative evaluation. Clin Oral Implants Res. 2003;14(5):584-92. \n\n31. Schulz MC, Korn P, Stadlinger B, Range U, Moller S, Becher J, et al. Coating with \n\nartificial matrices from collagen and sulfated hyaluronan influences the osseointegration \n\nof dental implants. J Mater Sci Mater Med. 2014;25(1):247-58. \n\n32. Jiang P, Liang J, Song R, Zhang Y, Ren L, Zhang L, et al. Effect of Octacalcium-\n\nPhosphate-Modified Micro/Nanostructured Titania Surfaces on Osteoblast Response. \n\nACS Appl Mater Interfaces. 2015;7(26):14384-96. \n\n33. Marin-Pareja N, Salvagni E, Guillem-Marti J, Aparicio C, Ginebra MP. Collagen-\n\nfunctionalised titanium surfaces for biological sealing of dental implants: effect of \n\nimmobilisation process on fibroblasts response. Colloids Surf B Biointerfaces. \n\n2014;122:601-10. \n\n34. Jimbo R, Coelho PG, Bryington M, Baldassarri M, Tovar N, Currie F, et al. Nano \n\nhydroxyapatite-coated implants improve bone nanomechanical properties. J Dent Res. \n\n2012;91(12):1172-7. \n\n35. Coelho PG, Takayama T, Yoo D, Jimbo R, Karunagaran S, Tovar N, et al. \n\nNanometer-scale features on micrometer-scale surface texturing: a bone histological, \n\ngene expression, and nanomechanical study. Bone. 2014;65:25-32. \n\n36. Giglio MJ, Giannunzio G, Olmedo D, Guglielmotti MB. Histomorphometric study of \n\nbone healing around laminar implants in experimental diabetes. Implant Dent. \n\n2000;9(2):143-9. \n\n\n\nArtigo 1  |  127 \n\n37. McCracken M, Lemons JE, Rahemtulla F, Prince CW, Feldman D. Bone response to \n\ntitanium alloy implants placed in diabetic rats. Int J Oral Maxillofac Implants. \n\n2000;15(3):345-54. \n\n38. Takeshita F, Iyama S, Ayukawa Y, Kido MA, Murai K, Suetsugu T. The effects of \n\ndiabetes on the interface between hydroxyapatite implants and bone in rat tibia. J \n\nPeriodontol. 1997;68(2):180-5. \n\n39. Ajami E, Mahno E, Mendes VC, Bell S, Moineddin R, Davies JE. Bone healing and \n\nthe effect of implant surface topography on osteoconduction in hyperglycemia. Acta \n\nBiomater. 2014;10(1):394-405. \n\n40. Margonar R, Sakakura CE, Holzhausen M, Pepato MT, Alba j R, Marcantonio j E. \n\nThe influence of diabetes mellitus and insulin therapy on biomechanical retention \n\naround dental implants: a study in rabbits. Implant Dent. 2003;12(4):333-9. \n\n41. Coelho PG, Marin C, Granato R, Giro G, Suzuki M, Bonfante EA. Biomechanical and \n\nhistologic evaluation of non-washed resorbable blasting media and alumina-\n\nblasted/acid-etched surfaces. Clin Oral Implants Res. 2012;23(1):132-5. \n\n42. Jinno Y, Jimbo R, Tovar N, Teixeira HS, Witek L, Coelho PG. In Vivo Evaluation of \n\nDual Acid-Etched and Grit-Blasted/Acid-Etched Implants With Identical Macrogeometry \n\nin High-Density Bone. Implant Dent. 2017;26(6):815-9. \n\n43. Gil LF, Sarendranath A, Neiva R, Marao HF, Tovar N, Bonfante EA, et al. Bone \n\nHealing Around Dental Implants: Simplified vs Conventional Drilling Protocols at Speed \n\nof 400 rpm. Int J Oral Maxillofac Implants. 2017;32(2):329-36. \n\n44. Baldassarri M, Bonfante E, Suzuki M, Marin C, Granato R, Tovar N, et al. \n\nMechanical properties of human bone surrounding plateau root form implants retrieved \n\nafter 0.3-24 years of function. J Biomed Mater Res B Appl Biomater. 2012;100(7):2015-\n\n21. \n\n45. Doerner MF, Nix WD. A method for interpreting the data from depth- sensing \n\nindentation instruments. . J Mater Res 1986;1:601 - 9. \n\n46. Butz F, Aita H, Wang CJ, Ogawa T. Harder and stiffer bone osseointegrated to \n\nroughened titanium. J Dent Res. 2006;85(6):560-5. \n\n47. Hoffler CE, Guo XE, Zysset PK, Goldstein SA. An application of nanoindentation \n\ntechnique to measure bone tissue Lamellae properties. J Biomech Eng. \n\n2005;127(7):1046-53. \n\n48. Hoffler CE, Moore KE, Kozloff K, Zysset PK, Brown MB, Goldstein SA. \n\nHeterogeneity of bone lamellar-level elastic moduli. Bone. 2000;26(6):603-9. \n\n49. Lee KL, Sobieraj M, Baldassarri M, Gupta N, Pinisetty D, Janal MN, et al. The effects \n\nof loading conditions and specimen environment on the nanomechanical response of \n\ncanine cortical bone. Mater Sci Eng C Mater Biol Appl. 2013;33(8):4582-6. \n\n50. Anchieta RB, Baldassarri M, Guastaldi F, Tovar N, Janal MN, Gottlow J, et al. \n\nMechanical property assessment of bone healing around a titanium-zirconium alloy \n\ndental implant. Clin Implant Dent Relat Res. 2014;16(6):913-9. \n\n51. Jimbo R, Anchieta R, Baldassarri M, Granato R, Marin C, Teixeira HS, et al. \n\nHistomorphometry and bone mechanical property evolution around different implant \n\nsystems at early healing stages: an experimental study in dogs. Implant Dent. \n\n2013;22(6):596-603. \n\n52. Albrektsson T, Wennerberg A. Oral implant surfaces: Part 1--review focusing on \n\ntopographic and chemical properties of different surfaces and in vivo responses to them. \n\nInt J Prosthodont. 2004;17(5):536-43. \n\n53. Albrektsson T, Wennerberg A. Oral implant surfaces: Part 2--review focusing on \n\nclinical knowledge of different surfaces. Int J Prosthodont. 2004;17(5):544-64. \n\n\n\nArtigo 1  |  128 \n\n54. Adell R, Lekholm U, Rockler B, Branemark PI. A 15-year study of osseointegrated \n\nimplants in the treatment of the edentulous jaw. Int J Oral Surg. 1981;10(6):387-416. \n\n55. Henry PJ, Laney WR, Jemt T, Harris D, Krogh PH, Polizzi G, et al. Osseointegrated \n\nimplants for single-tooth replacement: a prospective 5-year multicenter study. Int J Oral \n\nMaxillofac Implants. 1996;11(4):450-5. \n\n56. Jemt T, Chai J, Harnett J, Heath MR, Hutton JE, Johns RB, et al. A 5-year \n\nprospective multicenter follow-up report on overdentures supported by \n\nosseointegrated implants. Int J Oral Maxillofac Implants. 1996;11(3):291-8. \n\n57. Mendes VC, Moineddin R, Davies JE. The effect of discrete calcium phosphate \n\nnanocrystals on bone-bonding to titanium surfaces. Biomaterials. 2007;28(32):4748-55. \n\n58. Berglundh T, Abrahamsson I, Albouy JP, Lindhe J. Bone healing at implants with a \n\nfluoride-modified surface: an experimental study in dogs. Clin Oral Implants Res. \n\n2007;18(2):147-52. \n\n59. Buser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, et al. \n\nEnhanced bone apposition to a chemically modified SLA titanium surface. J Dent Res. \n\n2004;83(7):529-33. \n\n60. King S, Klineberg I, Levinger I, Brennan-Speranza TC. The effect of \n\nhyperglycaemia on osseointegration: a review of animal models of diabetes mellitus and \n\ntitanium implant placement. Arch Osteoporos. 2016;11(1):29. \n\n61. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, et al. Advanced \n\nglycation end products enhance osteoclast-induced bone resorption in cultured mouse \n\nunfractionated bone cells and in rats implanted subcutaneously with devitalized bone \n\nparticles. J Am Soc Nephrol. 1997;8(2):260-70. \n\n62. Burgos PM, Rasmusson L, Meirelles L, Sennerby L. Early bone tissue responses to \n\nturned and oxidized implants in the rabbit tibia. Clin Implant Dent Relat Res. \n\n2008;10(3):181-90. \n\n63. Cochran DL, Schenk RK, Lussi A, Higginbottom FL, Buser D. Bone response to \n\nunloaded and loaded titanium implants with a sandblasted and acid-etched surface: a \n\nhistometric study in the canine mandible. J Biomed Mater Res. 1998;40(1):1-11. \n\n64. Jiang H, Ma X, Zhou W, Dong K, Rausch-Fan X, Liu S, et al. The Effects of \n\nHierarchical Micro/Nano-Structured Titanium Surface on Osteoblast Proliferation and \n\nDifferentiation Under Diabetic Conditions. Implant Dent. 2017;26(2):263-9. \n\n65. Coelho PG, Bonfante EA, Pessoa RS, Marin C, Granato R, Giro G, et al. \n\nCharacterization of five different implant surfaces and their effect on osseointegration: a \n\nstudy in dogs. J Periodontol. 2011;82(5):742-50. \n\n66. Coelho PG, Jimbo R, Tovar N, Bonfante EA. Osseointegration: hierarchical \n\ndesigning encompassing the macrometer, micrometer, and nanometer length scales. \n\nDent Mater. 2015;31(1):37-52. \n\n67. Khang W, Feldman S, Hawley CE, Gunsolley J. A multi-center study comparing \n\ndual acid-etched and machined-surfaced implants in various bone qualities. J \n\nPeriodontol. 2001;72(10):1384-90. \n\n68. Hayashi M, Jimbo R, Lindh L, Sotres J, Sawase T, Mustafa K, et al. In vitro \n\ncharacterization and osteoblast responses to nanostructured photocatalytic TiO2 coated \n\nsurfaces. Acta Biomater. 2012;8(6):2411-6. \n\n69. Tomsia AP, Lee JS, Wegst UG, Saiz E. Nanotechnology for dental implants. Int J \n\nOral Maxillofac Implants. 2013;28(6):e535-46. \n\n70. Webster TJ, Ahn ES. Nanostructured biomaterials for tissue engineering bone. \n\nAdv Biochem Eng Biotechnol. 2007;103:275-308. \n\n\n\nArtigo 1  |  129 \n\n71. Ajami E, Bell S, Liddell RS, Davies JE. Early bone anchorage to micro- and nano-\n\ntopographically complex implant surfaces in hyperglycemia. Acta Biomater. \n\n2016;39:169-79. \n\n72. Coelho PG, Teixeira HS, Marin C, Witek L, Tovar N, Janal MN, et al. The in vivo \n\neffect of P-15 coating on early osseointegration. J Biomed Mater Res B Appl Biomater. \n\n2014;102(3):430-40. \n\n73. Coelho PG, Freire JN, Granato R, Marin C, Bonfante EA, Gil JN, et al. Bone mineral \n\napposition rates at early implantation times around differently prepared titanium \n\nsurfaces: a study in beagle dogs. Int J Oral Maxillofac Implants. 2011;26(1):63-9. \n\n74. Vandeweghe S, Coelho PG, Vanhove C, Wennerberg A, Jimbo R. Utilizing micro-\n\ncomputed tomography to evaluate bone structure surrounding dental implants: a \n\ncomparison with histomorphometry. J Biomed Mater Res B Appl Biomater. \n\n2013;101(7):1259-66. \n\n75. Beck GR, Jr., Sullivan EC, Moran E, Zerler B. Relationship between alkaline \n\nphosphatase levels, osteopontin expression, and mineralization in differentiating \n\nMC3T3-E1 osteoblasts. J Cell Biochem. 1998;68(2):269-80. \n\n76. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M. Transcriptional control of \n\nosteoblast growth and differentiation. Physiol Rev. 1996;76(2):593-629. \n \n\n \n\n \n\n  \n\n\n\nArtigo 1  |  130 \n\nFigures and legends  \n\n \n\n \n\nFigure 01. Histologic micrographs of all experimental groups (A-L). Stevenel\u2019s blue Alizarin \n\nred stained histologic micrographs of healthy (A, B, C, G, H and I) and diabetic (D, E, F, J, K \n\nand L) groups for machined (A, D, G and E), DAE (B, E, H and K) and NANO coated (C, F, I \n\nand L) implant surface treatments. All images confirmed successful osseointegration, \n\nirrespective of time, implant type and systemic condition. Overall, a notable difference was \n\nobserved between 7 and 30 days. With regards to implant type, the NANO group \n\ndemonstrated more intimate bone to implant interlocking when compared to machined and \n\nDAE. Also, at 30 days, NANO coating implants micrographs depicted increased remodeling \n\nsites and new bone formation compared to 7 days images.  \n\n \n\n\n\nArtigo 1  |  131 \n\n \n\nFigure 2. A-F. Graphs representing the percentage of bone to implant contact (%BIC) \n\ndifferently arranged as a function of study factors (mean and 95%CI). Significant difference \n\nwas seen between 7 and 30 days in vivo (A). No statistical significant differences were found \n\nwhen compared healthy and diabetic group (data as function of systemic condition) (B). \n\nWhen implant surface were considered, NANO group exhibited higher %BIC relative to \n\nmachined and DAE groups (data as a function of implant surface) (C). Data evaluation as a \n\nfunction of time and implant surface highlighted the superiority of NANO group at 30 days \n\ncompared to others (D). When %BIC was evaluated as a function of systemic condition and \n\nsurface, diabetic NANO group depicted a significant statistical difference (E). Evaluating all \n\nfactors: time, systemic condition and surface treatment the results revealed that NANO \n\nsurface presented the best results in diabetic group (7 and 30 days) (F). Identical letters \n\nindicate no significant difference among groups.  \n\n\n\nArtigo 1  |  132 \n\n \n\nFigure 3. A-F. Graphs representing the percentage of bone area fraction occupancy \n\n(%BAFO) differently arranged as a function of study factors (mean and 95%CI). Significant \n\ndifference was seen between 7 and 30 days in vivo (A). Statistical significant difference was \n\nfound when compared healthy and diabetic group (data as function of systemic condition) (B). \n\nWhen implant surface were considered, NANO group exhibited higher %BAFO relative to \n\nmachined and DAE groups (data as a function of implant surface) (C). Data evaluation as a \n\nfunction of time and implant surface highlighted the superiority of NANO group at 30 days \n\ncompared to others (D). No statistical significant differences were found when %BAFO was \n\nevaluated as a function of systemic condition and surface (E). Evaluating all factors (time, \n\nsystemic condition and surface treatment) the results revealed that NANO surface presented \n\nthe best results at 7 days (healthy and diabetic group) (F). Identical letters indicate no \n\nsignificant difference among groups.   \n\n  \n\n \n\n\n\nArtigo 1  |  133 \n\n \n\nFigure 4. A-F. Graphs representing elastic modulus (EM) differently arranged as a function \n\nof study factors (mean and 95%CI). Significant difference was seen between 7 and 30 days in \n\nvivo (A). No statistical significant difference were found when compared healthy and diabetic \n\ngroup (data as function of systemic condition) (B). When implant surface were considered, \n\nNANO group exhibited higher EM relative to machined and DAE groups (data as a function \n\nof implant surface) (C). Data evaluation as a function of time and implant surface highlighted \n\nthe superiority of NANO group at 30 days compared to others (D). When EM was evaluated \n\nas a function of systemic condition and surface, diabetic NANO group depicted higher values \n\n(E). Evaluating all factors: time, systemic condition and surface treatment the results revealed \n\nthat surface treated implants presented superior EM than machined (F). Identical letters \n\nindicate no significant difference among groups.   \n\n \n\n\n\nArtigo 1  |  134 \n\n \n\nFigure 5. A-F. Graphs representing hardness (H) differently arranged as a function of study \n\nfactors (mean and 95%CI). Significant difference was seen between 7 and 30 days in vivo \n\n(A). Healthy group presented higher H when compared to diabetic (data as function of \n\nsystemic condition) (B). When implant surface were considered, NANO group exhibited \n\nhigher H relative to machined and DAE groups (data as a function of implant surface) (C). \n\nData evaluation as a function of time and implant surface highlighted the superiority of \n\nNANO group at 30 days compared to others (D). When H was evaluated as a function of \n\nsystemic condition and surface, healthy NANO group depicted depicted higher values (E). \n\nEvaluating all factors: time, systemic condition and surface treatment the results revealed that \n\nsurface treated implants presented superior H than machined and that NANO healthy 30 days \n\npresented the higher values of H (F). Identical letters indicate no significant difference among \n\ngroups. \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nArtigo 2 \n\n  \n\n\n\nArtigo 2  |  136 \n\nInfluence of nano-hydroxyapatite coating implants on gene expression of osteogenic \n\nmarkers and micro-CT parameters. An in vivo study in diabetic rats.  \n\n \n\nPaula Gabriela Faciola Pess\u00f4a de Oliveira1, Mariana Sales de Melo Soares1, M\u00e1rio Taba Jr.1, \n\nDaniela Bazan Palioto1, Michel Reis Messora1, Bruna Ghiraldini2, Felipe Anderson de Sousa \n\nNunes1, S\u00e9rgio Lu\u00eds Scombatti de Souza1.  \n\n  \n\n1Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of \n\nRibeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil. \n2Paulista University, School of Dentistry, Sao Paulo, SP, Brazil. \n\n \n\nCorrespondence address: \n\nS\u00e9rgio Lu\u00eds Scombatti de Souza \n\nDepartament of Oral &amp; Maxillofacial Surgery and Periodontology \n\nSchool of Dentistry of Ribeirao Preto University of Sao Paulo \n\nAv do Caf\u00e9, s/n. Zip: 14040-904 Ribeirao Preto - SP - Brazil \n\nTel: +55 16 3315-4141 \n\nEmail: scombatti@forp.usp.br \n\n  \n\n\n\nArtigo 2  |  137 \n\nAbstract \n\nThe aim of this study was to evaluate, in healthy and diabetic rats, the response of a \n\nnew topography implant surface (nano-hydroxyapatite coating) throught gene expression \n\nanalysis (runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), osteopontin \n\n(Opn), osteocalcin (Oc), receptor activator of nuclear factor-kappa B (Rank), receptor \n\nactivator of nuclear factor-kappa B ligand (Rank-L), and osteoprotegerin (Opg)) and a three-\n\ndimensional (3D) evaluation using micro-CT (percent bone volume (BV/TV, %); percent \n\nintersection surface (BIC, %); bone surface/volume ratio (BS/BV, mm); and total porosity \n\n(To.Po, %)). Mini implants (machined, double acid etched (DAE) and with addition of nano-\n\nhydroxyapatite (NANO)) were installed in tibias of healthy rats and diabetic rats. The animals \n\nwere euthanized at 7 and 30 days. Evaluating all factors the relative expression of Rank \n\nshowed that NANO surface presented the best results at 7 days (diabetic rats). Furthermore \n\nthe levels of Runx2, Alp, Oc and Opn suggest an increase in osteoblasts proliferation, \n\nespecially in early stages of osseointegration. %BIC in healthy and diabetic (7 days) depicted \n\nstatistically significant differences for NANO HA when compared to machined and DAE. \n\nBV/TV (%), BS/BV (mm) and To.Po (%) demonstrated higher values for NANO group in all \n\nevaluated time point and irrespective of systemic condition, but BS/BV 30 days (healthy rat) \n\nand 7 and 30 days (diabetic rat). Microtomographic and gene expression analyses have shown \n\nthe benefits of nano-hidroxyapatite coating implants in promote new bone formation in \n\ndiabetic rats.  \n\nKeywords: Diabetes Mellitus, dental implants, gene expression, microtomography.  \n\n \n\n  \n\n\n\nArtigo 2  |  138 \n\nIntroduction  \n\nOsseointegration has been described as the intimate contact between bone and \n\nbiomaterials occurring at the optical microscopy level, and this phenomenon allows implants \n\nto replace load-bearing organs, restoring their form and function (1). Implant dentistry has \n\nbecome one of the most successful dental specialties, with success rates often reported at \n\ngreater than 90 % (2). \n\nDiabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia \n\nyielded by abnormalities in the secretion or response of cells to insulin, which is a hormone, \n\nproduced by beta cells in the pancreatic islets of Langerhans (3). Type 1 diabetes is an \n\nautoimmune disease associated to pancreatic ?-cell destruction and therefore requires insulin \n\ntherapy, while type 2 diabetes is characterized by a relative rather than absolute insulin \n\ndeficiency and is usually a multi-factorial disease (4). Chronic hyperglycemia, \n\npathognomonic of DM, is known to have a significant impact on bone healing. Nevertheless, \n\nthe increasing success of dental implants, along with the realized benefits of implant therapy, \n\nhave accommodated patients with controlled diabetes as candidates for treatment (5-7). \n\nHowever, for those who fail to control their glucose levels, the attendant uncontrolled \n\nhyperglycemia is considered a contra-indication for dental implant placement. \n\nIt has been demonstrated that alterations in implant topography, energy, wettability, \n\nchemistry or an association of them affect cell adhesion, migration, proliferation, \n\ndifferentiation, messenger ribonucleic acid (mRNA) expression, protein synthesis, and \n\nsecretion, which may have a beneficial effect on interfacial tissue formation (8-10). A large \n\nnumber of studies have shown that increasing the implant surface texture by a variety of \n\nprocesses, such as acid etching and various forms of grit-blasting, positively affected early \n\nhealing, leading to greater degrees of integration and biomechanical fixation (11). In addition \n\nto texture alterations, chemistry modifications, such as the incorporation of hydroxyapatite \n\n\n\nArtigo 2  |  139 \n\n(HA) as a surface coating through a variety of processes, resulted in highly osseoconductive \n\nsurfaces (11).  \n\nNano-scale roughness may be a decisive factor for osteogenesis, because the size of \n\nproteins and cell membrane receptors corresponds to surface topography on this length scale. \n\nGittens et al., 2011 reported that nano-scale modifications considerably enhanced the \n\ndifferentiation of pre-osteoblasts, which showed significantly higher levels of osteocalcin and \n\nosteoprotegerin expression in vitro (12). Furthermore, Meirelles et al., 2007 conducted an \n\nanimal study with implants containing nanostructures and polished implants deliberately \n\nlacking them, and found that the former had higher bone-to-implant contact than the latter \n\nimplant surfaces (13). These reports suggest that cells, particularly osteoblasts, respond to \n\ntopographical alterations at the nanometer scale. Additionally, reduced osteoid formation, \n\ndelayed osteoid mineralization, and reduced overall bone volume and maturation in \n\nhyperglycemia were reported by Goodman and Hori, 1984 (14). \n\nMicro-computed tomography (micro-CT) has become a powerful tool in dental \n\nresearch and is promising for qualitative and quantitative analyses of implant osseointegration \n\n(15-17). It\u2019s widely used for observing and analyzing the internal structure of hard tissue due \n\nto its advantages of rapidity, reproducibility, and nondestructiveness (18). Additionally, \n\nmicro-CT also allows for accurate three-dimensional (3D) measurements of bone-to-implant \n\ncontact (BIC), and is used to measure several variables, including bone volume (BV), total \n\nvolume (TV), bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular \n\nnumber (Tb.N), and trabecular separation (Tb.Sp) (19).  \n\nAjami et al., 2014 perfomerd a microtomography and histologic study using \n\neuglycemic and hyperglycemic rats and conclude that compromised implant integration in \n\nhyperglycemia is abrogated by the addition of nanotopographical features to an underlying \n\nmicrotopographically complex implant surface (20). Thus, the aim of this study was to \n\n\n\nArtigo 2  |  140 \n\nevaluate, in healthy and diabetic rats, the response of a new topography implant surface \n\n(nano-hydroxyapatite coating) throught gene expression analysis (evaluating runt-related \n\ntranscription factor 2 (Runx2), alkaline phosphatase (Alp), osteopontin (Opn), osteocalcin \n\n(Oc), receptor activator of nuclear factor-kappa B (Rank), receptor activator of nuclear factor-\n\nkappa B ligand (Rank-L), and osteoprotegerin (Opg)) and a three-dimensional (3D) \n\nevaluation using micro-CT (evaluating the percent bone volume (BV/TV, %); percent \n\nintersection surface (BIC, %); bone surface/volume ratio (BS/BV, mm); and total porosity \n\n(To.Po, %)), in order to investigate the surface modifications at the nano-scale in a \n\ncompromise model of bone healing at two different time points (7 and 30 days).  \n\n \n\nMaterials and Methods \n\n \n\nAnimals  \n\nThis study was approved by The Ethics Committee on Animal Experimentation at the \n\nschool of Dentistry of Ribeirao Preto, University of Sao Paulo \u2013 FORP/USP (protocol \n\n2014.1.1083.58.4).  \n\nSeventy-two adult male Wistar rats (250\u2013300 g) were included in the study. The \n\nanimals were treated according to the guidelines for animal care with free access to water and \n\na standard diet and were kept in plastic cages. Prior to the surgical procedures, all animals \n\nwere allowed to acclimatize to the laboratory environment for 7 days. The animals were \n\nrandomly allocated to diabetes mellitus group or control group.  \n\n \n\nInduction of Diabetes Mellitus  \n\nDiabetes was induced by a single intraperitoneal (i.p.) injection of Streptozotocin \n\n(STZ, 60 mg/kg, Sigma, St. Louis, Missouri, USA), which was dissolved in 0.2 mL citrate \n\n\n\nArtigo 2  |  141 \n\nbuffered solution (0.01 M, pH 4.5) (n = 36). Healthy group received a vehicle i.p. injection at \n\na volume of 1 mL/kg (n = 36). Blood glucose levels were monitored at the day of \n\nimplantation and before euthanasia through a superficial puncture in the distal tail, and \n\ninstantly measured with a glucometer (Accu-Check Active monitoring system, Roche \n\nDiagnostics, Rotkreuz, Zug, Switzerland). Only animals with glucose levels higher than 300 \n\nmg/dL were considered diabetic and included in the study (21). \n\n \n\nSurgical Procedures \n\nGeneral anesthesia was induced by administering an injection of 100\u2013130 \u00b5L/(100 g \n\nanimal weight) in a 4:3 combination of ketamine (74.1 mg/g of 10 % ketamine hydrochloride; \n\nAgener, Uni\u00e3o Qu\u00edmica Farmac\u00eautica Nacional S/A, Embu-Gua\u00e7u, Sao Paulo, Brazil) and \n\nxylazine (11.2 mg/kg dopaser; Calier Laboratories S/A, Catalonia, Barcelona, Spain). Next, \n\ntrichotomy and antisepsis with iodine solution 10 % (Rioquimica Ind. Farmaceutica, Sao Jose \n\ndo Rio Preto, Sao Paulo, Brazil) at the medial side of the right and left tibia were performed. \n\nUsing a type 15C scalpel blade (Swann-Morton, Sheffield, England), a 15-mm \n\nincision was done on the medial side of the right and left tibias. After dissection with a \n\nperiosteum separator, bone was exposed, washed with copious sterile saline solution (0.9 %) \n\nand drilled with a 2.0 mm length pilot drill (SIN implantes, Sao Paulo, Sao Paulo, Brazil) \n\nusing an electric implant motor (Dentscler, Ribeirao Preto, Sao Paulo, Brazil) at 1000 rotation \n\nper minute (rpm). The perforation was made under constant irrigation with sterile saline \n\nsolution (0.9 %). A custom-made titanium implant (2.7 mm in length and 1.4 mm in diameter \n\n\u2013 SIN implantes, Sao Paulo, Sao Paulo, Brazil) was randomly installed in the left or right tibia \n\nusing a hand driver key (SIN implantes, Sao Paulo, Sao Paulo, Brazil). Incisions were closed \n\nusing 5-0 coated Vicryl suture (Vicryl Ethicon 5.0, Johnson Prod., S\u00e3o Jos\u00e9 dos Campos, Sao \n\nPaulo, Brasil). \n\n\n\nArtigo 2  |  142 \n\nFollowing surgery, the animals were monitored daily for signs of pain, dehiscence, \n\ninfection, restricted movement, loss of appetite and weight loss. Post-operative analgesia was \n\nprovided with anti-inflammatory (ketoprofen 0,05mg/kg), and a single dose of antibiotic \n\n(penicillin 24.000 IU/kg) was also administered. All animals recovered well form the surgery \n\nand did not require additional doses of prescriptions.  \n\n \n\nExperimental Groups \n\nThe seventy-two rats were randomly divided into six experimental groups of twelve \n\nrats each, and the groups were defined as follows: G1 - machined mini implants installed in \n\nhealthy rats; G2 - double acid etched (DAE) mini implants installed in healthy rats; G3 - \n\nnano-hydroxyapatite (NANO) covered mini implants installed in healthy rats; G4 - machined \n\nmini implants installed in diabetic rats; G5 - DAE mini implants installed in diabetic rats; and \n\nG6 - NANO covered mini implants installed in diabetic rats.  \n\nThe animals were euthanized 7 and 30 days after implants placement (36 animals in \n\neach period, 18 healthy and 18 diabetic, 6 from each group) by the intraperitoneal \n\nadministration of a lethal dose (150 mg/kg) of sodium thiopental (Thiopentax, Cristalia, Sao \n\nPaulo, Brazil). The implant and surrounding bone from right tibia were carefully collected \n\nwith the use of a ?3.0 mm trephine bur (Alpha instruments, Ribeirao Preto, Sao Paulo, \n\nBrazil); thereafter, the samples were frozen at -80\u00b0C until analysis. The left tibia was removed \n\nand fixed in 10 % neutral formalin for 48 hours for micro-CT analysis. Gene expression of \n\nRunx2, Alp, Opn, Oc, Rank, Rankl and Opg, and micro-CT parameters of percent bone \n\nvolume (BV/TV, %), percent intersection surface (BIC, %), bone surface/volume ratio \n\n(BS/BV, mm), and total porosity (To.Po, %), were evaluated. \n\n \n\n  \n\n\n\nArtigo 2  |  143 \n\nQuantitative real-time polymerase chain reaction assay \n\nQuantitative real-time polymerase chain reaction (qRT-PCR) was carried out at 7 and \n\n30 days to evaluate the gene expression of Runx2, Alp, Oc, Op, Rank, RankL and Opg. The \n\nimplants were removed and bone fragments of two specimens of the same group were pooled \n\nand immediately crushed, and the total RNA was extracted with Trizol reagent (Life \n\nTechnologies \u2013 Invitrogen, Carlsbad, CA) followed by SV Total RNA Isolation System \n\n(Promega, Madison, Wisconsin, USA) according to the manufacturer\u2019s instructions. The \n\nconcentration and purity were determined using NanoVue spectrophotometer (GE Healthcare, \n\nLittle Chalfont, Buckinghamshire, United Kingdom) by optical density at a wavelength of \n\n260 and 260:280 nm, respectively, and only samples presenting 260:280 ratios higher than 1.8 \n\nwere analyzed. The integrity of ribosomal RNA was evaluated using the 2100 Bioanalyzer \n\n(Agilent Technologies, Stockport, Manchester, United Kingdom). Samples with RNA \n\nIntegrity Number (RIN) values equal or higher than 7 were used to synthesize complementary \n\nDNA (cDNA) from 1 \u00b5g of total RNA, using cDNA High-Capacity cDNA Reverse \n\nTranscription Kit (Applied Biosystems, Foster City, California, USA), according to \n\nmanufacturer\u2019s instructions. Real-time PCR was carried out in triplicate and performed in a \n\nStepOnePlus Real-Time PCR System (Thermo Fisher Scientific, Waltham, Massachusetts, \n\nUSA); the thermal cycling conditions were 50\u00b0C (2?min), 95\u00b0C (20 s), and 40 cycles of 95\u00b0C \n\n(3?s) and 60\u00b0C (30?s) in a 10 \u00b5l reaction volume, using 5 \u00b5l of TaqMan universal PCR master \n\nmix AmpErase UNG 2X (Life Technologies-Invitrogen), 0.5 \u00b5l of TaqMan probes (20X \n\nTaqMan gene expression assay mix) and 1.125 \u00b5g/\u00b5l of cDNA. The relative gene expression \n\nwas calculated in reference to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) \n\nexpression and the real changes were expressed relative to the gene expression of the healthy \n\nmachined 7 days group, using the comparative delta-Ct method (22).  \n\n \n\n\n\nArtigo 2  |  144 \n\nComputed microtomographic analysis \n\nThe samples were fixed in 10 % buffered formalin solution (pH = 7) for 2 days. \n\nSequentially, the micro-CT analysis was performed using a Skyscan 1172 micro-CT scanner \n\n(Bruker, Kontich, Antwerp, Belgium). All scans were obtained at 100 kV and 100 ?A, using \n\nan aluminum\u2013copper filter to optimize the contrast, and set at 5.87 mm pixel size, 360 \n\nrotation, 4 frames averaging, a rotation step of 0.40. The reconstruction software (NRecon \n\nv.1.6.10.4, Bruker, Kontich, Antwerp, Belgium) was used to create the images, which were \n\npositioned according to the implant long axis.  \n\nThe 3D analysis was performed using the CTAn software (CTAn., v. 1.15.4.0, Bruker, \n\nKontich, Antwerp, Belgium) and the following parameters were analyzed: percent bone \n\nvolume (BV/TV, %), percent intersection surface (BIC, %), bone surface/volume ratio \n\n(BS/BV, mm), and total porosity (To.Po, %). \n\nA task list was created (custom processing) to automatically obtain the values of the \n\nselected parameters for inter-group comparisions. The measurements were performed 1 mm \n\nfrom the top of the implant, reaching its entire length. This process involved the \n\ndetermination of the region of interest (ROI). The collective sum of all ROIs over a \n\ncontiguous set of cross-sectional image slices was used to determine the volume of interest \n\n(VOI), representing the selected 3D volume. The binarization was performed using the gray \n\nscale defined by a density of 35\u2013150 for bone, and 150\u2013255 for implant. All micro-CT \n\nanalyzes were done by a single examiner, blinded to the experimental groups. \n\n \n\nStatistical Analysis \n\nAll variables are presented as a function of mean values with the corresponding 95 % \n\nconfidence interval (mean \u00b1 95 % CI). Preliminary analyses have shown indistinguishable \n\nvariances (Levene test, all p> .25). Additionally, data were collected and aligned along a \n\n\n\nArtigo 2  |  145 \n\nlinear mixed model with fixed factors of time (7 and 30 days), systemic condition (healthy \n\nand diabetic) and surface chemistry/texture modifications (machined, DAE and NANO HA) \n\nat a random intercept. After administering a significant omnibus test, post-hoc comparison of \n\nthe experimental groups means was gathered using Tukey test. The analysis was \n\naccomplished using SPSS (IBM SPSS 23, IBM Corp., Armonk, New York, USA). \n\n \n\nResults  \n\nNo postoperative infections and/or other immediate clinical concerns accompanied the \n\nsurgical procedures or follow-up. All animals regained consciousness after 30 minutes post-\n\nsurgery and post-operative healing was uneventful. No clinical concerns or adverse events, \n\nsuch as implant exposure, were detected, and a clinically healthy soft tissue aspect was \n\nobserved throughout the course of the study. \n\nFigure 1 shows the blood glucose (mg / dL) of healthy and diabetic groups at surgery \n\nday and before euthanasia. The values for the healthy (surgery: 89.55 \u00b1 8.88 and euthanasia: \n\n92.19 \u00b1 9.67) and diabetic (surgery: 499.88 \u00b1 62.27 and euthanasia: 544.63 \u00b1 57.07) rat \n\nconfirm the establishment of diabetic model. \n\nFigures 2 and 3 showed the relative gene expression of osteogenic markers, including \n\nRunx2 (2A), Alp (2B), Opn (2C), Oc (2D), Rank (3A), RankL (3B) and Opg (3C), detected \n\nby qRT-PCR after 7 and 30 days. Diabetic NANO 7 days and healthy NANO 30 days \n\npresented for Runx2 (figure 2A)(diabetic NANO 7 days: 1.78 and healthy NANO 30 days: \n\n4.59) (p<0.035), Alp (figure 2B) (diabetic NANO 7 days: 2.57 and healthy NANO 30 days: \n\n2.44) (p<0.001) and Opn (figure 2C) (diabetic NANO 7 days: 1.55 and healthy NANO 30 \n\ndays: 0.20) (p<0.001) statistically significant differences when compared to machined and \n\nDAE. Additionally, diabetic NANO 7 days depicted statistically significant differences for Oc \n\n(3.38) (p<0.001) (figure 2D) and Rank (1.84) (p<0.001) (figure 3A) related to other \n\n\n\nArtigo 2  |  146 \n\nexperimental groups. No statistically significant differences were found for Rankl (figure 3B) \n\nand Opg (figure 3C) however the values of diabetic NANO 7 days were equivalent to healthy \n\nDAE 7 days.  \n\nWhen data were evaluated as a function of implant surface, Runx2 (NANO: 2.23, \n\nDAE: 1.52 and machined: 0.58), Alp (NANO: 1.70, DAE: 1.03 and machined: 0.48), and Opn \n\n(NANO: 1.13, DAE: 0.77 and machined: 0.49) showed higher gene expression in NANO \n\ngroup when compared to machined and DAE (p<0.001) (figure 4 A-C). \n\nThe percentage of BV/TV showed statistically significant differences for NANO \n\ngroup irrespective of systemic condition and time point (healthy NANO 7 days: 18,51 %, \n\nhealthy NANO 30 days: 23,20 %, diabetic NANO 7 days: 18,20 %, and diabetic NANO 30 \n\ndays: 23,95 %) (p<0.001) (figure 5A). At 7 days, BIC (healthy: 32,34 % and diabetic: 29,47 \n\n%) (p<0.046) (figure 5B), BS/BV (healthy: 109,87 mm) (p=0.003) (figure 5C) and Po.To \n\n(healthy: 86,90 % and diabetic: 83,87 %) (p<0.022) (figure 5D) depicted statistically \n\nsignificant differences for NANO HA when compared to machined and DAE. At 30 day time \n\npoint NANO surface revealed statistically significant differences for BIC (healthy: 49,30 %) \n\n(p<0.046) and Po.To (diabetic: 83,87 %) (p<0.022) related to machined and DAE (Figures 5B \n\nand 5D). \n\nWhen data were evaluated as a function of implant surface, all micro-CT parameters: \n\nBV/TV (NANO: 20,97 %, DAE: 18,36 % and machined: 16,60 %), BIC (NANO: 38,52 %, \n\nDAE: 32,69 % and machined: 26,60 %), BS/BV (NANO: 95,28 mm, DAE: 86,55 mm and \n\nmachined: 85,25 mm) and Po.To (NANO: 84,39 %, DAE: 80,57 % and machined: 80,22 %) \n\npresented statistically significant differences for NANO surface when compared to machined \n\nand DAE (p<0.001) (Figure 6 A-C). \n\nThe representative 3D reconstructed images with a focus on the interfacial bone \n\nformation on the implants surface in machined, DAE and NANO groups, at 7 and 30 days, \n\n\n\nArtigo 2  |  147 \n\nand in healthy and diabetic rats is shown in Figure 7. From the image, significant bone \n\nformation can be observed at the implant interface in the NANO group in all time point \n\nevaluations and systemic condition.  \n\n \n\nDiscussion \n\nToday, dental implants are one of the restorative methods to replace missing teeth. \n\nImprovements in implant design, surface characteristics, and surgical protocols made \n\nimplants a secure and highly predictable procedure, with a mean survival rate of 94.6 % and a \n\nmean success rate of 89.7 % after more than 10 years (23). In this study, the effects of \n\nnanostructured hydroxyapatite coated implant surface were observed after 7 and 30 days, in \n\nhealthy and diabetic rats (as a model of impaired bone healing). \n\nPrevious studies have also confirmed the influence of diabetes mellitus on implant \n\nosseointegration in experimental diabetic models (24-26). These studies have shown that \n\ndiabetes leads to less bone\u2013implant contact and bone density (27, 28). The values found in the \n\npresent study for healthy (surgery: 89.55 \u00b1 8.88 and euthanasia: 92.19 \u00b1 9.67) and diabetic \n\n(surgery: 499.88 \u00b1 62.27 and euthanasia: 544.63 \u00b1 57.07) rats were in agreement with \n\nliterature (21). Margonar et al., 2003 used the same parameter (blood glucose levels at or \n\nabove 300 mg/dL), and they suggested that more elevated blood glucose levels could lead to \n\nmore severe alterations on osseointegration (21). Newly formed bone around implants was \n\nreported immature and less organized in uncontrolled diabetic rats than in non-diabetic \n\ncontrols, suggesting qualitative differences in newly formed bone (29).  \n\nBecause the surface is the first part of the implant to interact with the host, its texture \n\nand chemical configuration have been widely investigated (11, 30, 31). Changes in surface \n\ntopography of materials with similar chemical compositions may affect cell\u2013matrix\u2013substrate \n\ninteractions by a) altered protein adsorption, fibrin clot formation, and integrin expression, b) \n\n\n\nArtigo 2  |  148 \n\nthe topography itself, and/or c) changes in surface wettability/energy. Indeed, such aspects \n\nhave been implicated as major mechanisms for controlling selective cell adhesion, signaling, \n\ndifferentiation, and eventual tissue formation on biomaterial surfaces (32, 33). In the present \n\nstudy, gene expression (Runx2, Alp and Opn) and micro-CT (BV/TV, BIC, BS/BV and \n\nPo.To) analysis revealed the superiority of NANO surface when compared to machined and \n\nDAE (data as a function of implant surface).  \n\nSurface topography structuring at the micron and nanoscale level has been developed \n\nin the field of implant research aiming to promote bone formation adjacent to, or in contact \n\nwith, implant surfaces. Moreover, micron- and nanostructured commercially pure titanium \n\nsurfaces may promote enhanced osteoblast adhesion, functions, bone nodule formation, and \n\nbone-to-implant contact (32-34). \n\nZuo et al., 2013 also pointed out that surface topography, particularly nanotopography \n\nrather than surface chemistry, played a relatively more important role in cell adhesion and \n\nproliferation (35). Previous studies depicted that biomaterial surfaces with microscale \n\nroughness can depress osteoblast proliferation however nanoscale topography tends to help \n\nthe proliferation processes (36-38). In the present study, in a diabetic rat model, the nano-\n\nhydroxyapatite coating implant surface outperformed the micro- and machined surfaces, \n\nsuggesting that the addition of particles of nano-hydroxyapatite significantly influenced on \n\nosseointegration. \n\nThe gene expression of Runx2, Alp, Opn and Oc, key markers of bone tissue, was \n\nused to evaluate the development of osteoblast phenotype. As extensively reported, Runx2 is \n\nthe master transcriptional factor that initiates bone formation (39) and osteoblast \n\ndifferentiation (40). ALP is known to be a regulatory factor for matrix mineralization, and it\u2019s \n\nexpressed at the early stages of osteogenesis (41). Opn is generally regarded as a \n\nmultifunctional extracellular matrix protein involved in cell adhesion and migration and in the \n\n\n\nArtigo 2  |  149 \n\nregulation of mineral deposition (42, 43). Oc is an osteoblast-specific gene that regulates bone \n\nmineralization (44). The Opg/Rankl/Rank system plays a central role in the paracrine \n\nregulation and osteoclast function (45). Opg binds to Rankl, both secreted by osteoblasts, and \n\nprevent the Rankl binding to Rank, that is present in the osteoclast membrane, inhibiting bone \n\nresorption (46). \n\nIn the present study, a reduction in the expression of Opg at 7 days healthy NANO \n\ngroup was observed. This result suggests that osteoblastic cells from NANO-HA coating \n\ncould increase the osteoclastic activity. However, it should not be interpreted as a possible \n\nincrease in bone resorption, since several cytokines released by osteoblastic cells exert \n\nregulatory functions on osteoclasts (47). Probably, the resorption activity of osteoclasts was \n\nsuppressed by high concentrations of Opg, at the molecular level, and Opg decreased the \n\nexpression of osteoclastic bone resorption- related genes. This result is in agreement with the \n\nstudy performed by Fu et al., 2013 (48). No statistically significant differences were found for \n\nRankl however the values of diabetic NANO 7 days were equivalent to healthy DAE 7 days.  \n\nIt has been hypothesized that high levels of glucose in the blood can lead to formation \n\nof irreversible advanced glycation end product (AGEs) that can bind to receptor for advanced \n\nglycation end products (RAGE) and can accumulate on fibroblasts (49). When this occurs, \n\nthere can be more destruction of connective tissue and bone because of a decrease in collagen \n\nsynthesis and increase in inflammatory mediators (49). He et al., 2004 suggested that diabetes \n\nmay exhibit more bone resorption because of the prolonged apoptosis of osteoblasts and \n\ndecrease in bone formation (50). In the present study, some results indicated that NANO-HA \n\nsurface may be less affected by these adverse effects of the high glucose environment: the \n\nlevels of Runx2 (DN7d: 1.78), Alp (DN7d: 2.57), Opn (DN7d: 1.55) and Oc (DN7d: 3.38) \n\nsuggests an enhancement of osteoblast proliferation, mainly at early stages of \n\nosseointegration.  \n\n\n\nArtigo 2  |  150 \n\nFurthermore, the highly active mineralization cascade of the interfacial bone around \n\nthe NANO HA coated implants can be explained from a genetic perspective. It has been \n\nreported that alkaline phosphatase expression in bone around nanostructured HA-coated \n\nimplants was significantly higher when compared to non-coated surfaces (9) Since high \n\nalkaline phosphatase activity enhances osteopontin expression, which is known to be a \n\ncohesive factor for mineralization, we can suggested that HA coating was partly responsible \n\nfor the enhanced bone properties. \n\n3D evaluation with micro-CT has received considerable attention in recent years \n\nbecause it facilitates the observation and quantification of bone formation surrounding \n\nimplants or bone substitutes in a 3D plane (51). High-resolution 3D imaging techniques, such \n\nas micro-CT, directly measure bone microarchitecture. The current study evaluated by micro-\n\nCT analysis the percent bone volume (BV/TV, %), percent intersection surface (IS/TS, %), \n\nbone surface/volume ratio (BS/BV, mm), and total porosity (To.Po, %). \n\nIn this study, the percentage of IS/TS results showed that NANO HA coating \n\npresented statistical significant difference when compared to machined and DAE, irrespective \n\nof time and systemic condition. This evidence can suggest that the new implant surface could \n\ncompensate the limitations of an impaired bone-healing model. The results of this study were \n\nin agreement with other studies that demonstrate nano-scale modified titanium surface \n\ninhibited the effect of high glucose concentrations (20, 52, 53). Additionally, the hierarchical \n\nmicro/nano-structured titanium surface has a favorable biocompatibility on simultaneously \n\nimproving osteoblast proliferation and differentiation in diabetic serum (54).  \n\nThe micro-CT analysis of BV/TV (%), BS/BV (mm) and Po.To (%) showed higher \n\nvalues, more organized bone patterns and higher volume densities for NANO group in all \n\nevaluated time point and irrespective of systemic condition compared to other experimental \n\ngroups, but BS/BV (30 days heathy group and 7 and 30 days diabetic group), implying a more \n\n\n\nArtigo 2  |  151 \n\nfavorable bone response in these groups. Our results are in agreement with Ajami et al., 2014 \n\nthat perfomerd a microtomography and histologic study using euglycemic and hyperglycemic \n\nrats and conclude that compromised implant integration in hyperglycemia is abrogated by the \n\naddition of nanotopographical features to an underlying microtopographically complex \n\nimplant surface (20). \n\nThe 3D evaluation is a reliable method and is more accurate than histological analysis, \n\nsince the evaluation includes all the acquired data (16). Vandeweghe et al., 2013 suggested \n\nthat micro-CT has a strong potential to become an alternative for histological examination \n\n(16). On the other hand, is important to understand the biological responses by combining \n\ninformation from 2D histomorphometry and 3D evaluation. Since there exist certain \n\nbiological events that cannot be observed by micro-CT, e.g. cell alignment, cell shape, \n\nlocalization of proteins or enzyme detection (10). Furthermore, Schouten et al., 2009 reported \n\nhigh discrepancy between micro-CT and histomorphometry regarding the bone volume \n\naround implants (55). In additional, the limitations of this study include the lack of a \n\nhistological analysis and other periods of evaluation. \n\nThe amount of bone surrounding implants surface differed across different implant \n\ntreatments, systemic condition and time. Bone formation at the implant interface was found to \n\nbe higher (i.e. direct bone contact to the implant) in NANO groups irrespective of systemic \n\ncondition and time. Along with image reconstruction, it was easy to observe the state of \n\ntrabecular bone formation to the implant surface, which provides additional information from \n\nboth qualitative and quantitative perspectives. \n\n \n\nConclusion \n\nMicrotomographic and gene expression analyses have shown the benefits of nano-\n\nhidroxyapatite coating implants in promote new bone formation in diabetic rats when \n\n\n\nArtigo 2  |  152 \n\ncompared to machined and double acid etched surfaces. Thus, this surface may represent a \n\npromising alternative for replacing missing teeth in compromise subjects. Clinical studies are \n\nwarranted to better confirm this benefits in humans.  \n\n \n\nAcknowledgements  \n\nFab\u00edola Singaretti de Oliveira, Adriana Luisa Gon\u00e7alves de Almeida, Milla Sprone \n\nTavares and Roger Rodrigo Fernandes are acknowledged for their technical assistance during \n\nthe experiments. \n\n \n\nFunding \n\nThis research was supported by the State of Sao Paulo Research Foundation \n\n(FAPESP, Brazil) (grant numbers: 2015/09879-0 and 2016/14584-2) and the National \n\nCouncil of Scientific and Technological Development (CNPq, Brazil) (grant number: \n\n446840/2014-9).  \n\n \n\nConflict of interest  \n\nThe authors declare no conflict of interest associated with this study. \n\n \n\n \n  \n\n\n\nArtigo 2  |  153 \n\nReferences \n \n1. Albrektsson T, Branemark PI, Hansson HA, Lindstrom J. Osseointegrated titanium \n\nimplants. Requirements for ensuring a long-lasting, direct bone-to-implant anchorage in \n\nman. Acta Orthop Scand. 1981;52(2):155-70. \n\n2. Chuang SK, Tian L, Wei LJ, Dodson TB. Kaplan-Meier analysis of dental implant \n\nsurvival: a strategy for estimating survival with clustered observations. J Dent Res. \n\n2001;80(11):2016-20. \n\n3. Expert Committee on the D, Classification of Diabetes M. Report of the Expert \n\nCommittee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. \n\n2000;23 Suppl 1:S4-19. \n\n4. Retzepi M, Donos N. The effect of diabetes mellitus on osseous healing. Clin Oral \n\nImplants Res. 2010;21(7):673-81. \n\n5. Courtney MW, Jr., Snider TN, Cottrell DA. Dental implant placement in type II \n\ndiabetics: a review of the literature. J Mass Dent Soc. 2010;59(1):12-4. \n\n6. Farzad P, Andersson L, Nyberg J. Dental implant treatment in diabetic patients. \n\nImplant Dent. 2002;11(3):262-7. \n\n7. Fiorellini JP, Nevins ML. Dental implant considerations in the diabetic patient. \n\nPeriodontol 2000. 2000;23:73-7. \n\n8. Papalexiou V, Novaes AB, Jr., Grisi MF, Souza SS, Taba M, Jr., Kajiwara JK. \n\nInfluence of implant microstructure on the dynamics of bone healing around immediate \n\nimplants placed into periodontally infected sites. A confocal laser scanning microscopic \n\nstudy. Clin Oral Implants Res. 2004;15(1):44-53. \n\n9. Jimbo R, Xue Y, Hayashi M, Schwartz-Filho HO, Andersson M, Mustafa K, et al. \n\nGenetic responses to nanostructured calcium-phosphate-coated implants. J Dent Res. \n\n2011;90(12):1422-7. \n\n10. Jimbo R, Coelho PG, Vandeweghe S, Schwartz-Filho HO, Hayashi M, Ono D, et al. \n\nHistological and three-dimensional evaluation of osseointegration to nanostructured \n\ncalcium phosphate-coated implants. Acta Biomater. 2011;7(12):4229-34. \n\n11. Coelho PG, Granjeiro JM, Romanos GE, Suzuki M, Silva NR, Cardaropoli G, et al. \n\nBasic research methods and current trends of dental implant surfaces. J Biomed Mater \n\nRes B Appl Biomater. 2009;88(2):579-96. \n\n12. Gittens RA, McLachlan T, Olivares-Navarrete R, Cai Y, Berner S, Tannenbaum R, et \n\nal. The effects of combined micron-/submicron-scale surface roughness and nanoscale \n\nfeatures on cell proliferation and differentiation. Biomaterials. 2011;32(13):3395-403. \n\n13. Meirelles L, Arvidsson A, Albrektsson T, Wennerberg A. Increased bone formation \n\nto unstable nano rough titanium implants. Clin Oral Implants Res. 2007;18(3):326-32. \n\n14. Goodman WG, Hori MT. Diminished bone formation in experimental diabetes. \n\nRelationship to osteoid maturation and mineralization. Diabetes. 1984;33(9):825-31. \n\n15. Swain MV, Xue J. State of the art of Micro-CT applications in dental research. Int J \n\nOral Sci. 2009;1(4):177-88. \n\n16. Vandeweghe S, Coelho PG, Vanhove C, Wennerberg A, Jimbo R. Utilizing micro-\n\ncomputed tomography to evaluate bone structure surrounding dental implants: a \n\ncomparison with histomorphometry. J Biomed Mater Res B Appl Biomater. \n\n2013;101(7):1259-66. \n\n17. Li Z, Kuhn G, von Salis-Soglio M, Cooke SJ, Schirmer M, Muller R, et al. In vivo \n\nmonitoring of bone architecture and remodeling after implant insertion: The different \n\nresponses of cortical and trabecular bone. Bone. 2015;81:468-77. \n\n\n\nArtigo 2  |  154 \n\n18. Feldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M. The direct \n\nexamination of three-dimensional bone architecture in vitro by computed tomography. J \n\nBone Miner Res. 1989;4(1):3-11. \n\n19. Odgaard A. Three-dimensional methods for quantification of cancellous bone \n\narchitecture. Bone. 1997;20(4):315-28. \n\n20. Ajami E, Mahno E, Mendes VC, Bell S, Moineddin R, Davies JE. Bone healing and \n\nthe effect of implant surface topography on osteoconduction in hyperglycemia. Acta \n\nBiomater. 2014;10(1):394-405. \n\n21. Margonar R, Sakakura CE, Holzhausen M, Pepato MT, Alba j R, Marcantonio j E. \n\nThe influence of diabetes mellitus and insulin therapy on biomechanical retention \n\naround dental implants: a study in rabbits. Implant Dent. 2003;12(4):333-9. \n\n22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time \n\nquantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. \n\n23. Moraschini V, Poubel LA, Ferreira VF, Barboza Edos S. Evaluation of survival and \n\nsuccess rates of dental implants reported in longitudinal studies with a follow-up period \n\nof at least 10 years: a systematic review. Int J Oral Maxillofac Surg. 2015;44(3):377-88. \n\n24. Takeshita F, Iyama S, Ayukawa Y, Kido MA, Murai K, Suetsugu T. The effects of \n\ndiabetes on the interface between hydroxyapatite implants and bone in rat tibia. J \n\nPeriodontol. 1997;68(2):180-5. \n\n25. McCracken M, Lemons JE, Rahemtulla F, Prince CW, Feldman D. Bone response to \n\ntitanium alloy implants placed in diabetic rats. Int J Oral Maxillofac Implants. \n\n2000;15(3):345-54. \n\n26. Iyama S, Takeshita F, Ayukawa Y, Kido MA, Suetsugu T, Tanaka T. A study of the \n\nregional distribution of bone formed around hydroxyapatite implants in the tibiae of \n\nstreptozotocin-induced diabetic rats using multiple fluorescent labeling and confocal \n\nlaser scanning microscopy. J Periodontol. 1997;68(12):1169-75. \n\n27. Sennerby L, Thomsen P, Ericson LE. A morphometric and biomechanic \n\ncomparison of titanium implants inserted in rabbit cortical and cancellous bone. Int J \n\nOral Maxillofac Implants. 1992;7(1):62-71. \n\n28. Johansson C, Albrektsson T. Integration of screw implants in the rabbit: a 1-year \n\nfollow-up of removal torque of titanium implants. Int J Oral Maxillofac Implants. \n\n1987;2(2):69-75. \n\n29. Nevins ML, Karimbux NY, Weber HP, Giannobile WV, Fiorellini JP. Wound healing \n\naround endosseous implants in experimental diabetes. Int J Oral Maxillofac Implants. \n\n1998;13(5):620-9. \n\n30. Albrektsson T, Wennerberg A. Oral implant surfaces: Part 2--review focusing on \n\nclinical knowledge of different surfaces. Int J Prosthodont. 2004;17(5):544-64. \n\n31. Albrektsson T, Wennerberg A. Oral implant surfaces: Part 1--review focusing on \n\ntopographic and chemical properties of different surfaces and in vivo responses to them. \n\nInt J Prosthodont. 2004;17(5):536-43. \n\n32. Boyan BD, Lossdorfer S, Wang L, Zhao G, Lohmann CH, Cochran DL, et al. \n\nOsteoblasts generate an osteogenic microenvironment when grown on surfaces with \n\nrough microtopographies. Eur Cell Mater. 2003;6:22-7. \n\n33. de Oliveira PT, Nanci A. Nanotexturing of titanium-based surfaces upregulates \n\nexpression of bone sialoprotein and osteopontin by cultured osteogenic cells. \n\nBiomaterials. 2004;25(3):403-13. \n\n34. Huang YH, Xiropaidis AV, Sorensen RG, Albandar JM, Hall J, Wikesjo UM. Bone \n\nformation at titanium porous oxide (TiUnite) oral implants in type IV bone. Clin Oral \n\nImplants Res. 2005;16(1):105-11. \n\n\n\nArtigo 2  |  155 \n\n35. Zuo J, Huang X, Zhong X, Zhu B, Sun Q, Jin C, et al. A comparative study of the \n\ninfluence of three pure titanium plates with different micro- and nanotopographic \n\nsurfaces on preosteoblast behaviors. J Biomed Mater Res A. 2013;101(11):3278-84. \n\n36. Kubo K, Tsukimura N, Iwasa F, Ueno T, Saruwatari L, Aita H, et al. Cellular \n\nbehavior on TiO2 nanonodular structures in a micro-to-nanoscale hierarchy model. \n\nBiomaterials. 2009;30(29):5319-29. \n\n37. Zhuang XM, Zhou B, Ouyang JL, Sun HP, Wu YL, Liu Q, et al. Enhanced MC3T3-E1 \n\npreosteoblast response and bone formation on the addition of nano-needle and nano-\n\nporous features to microtopographical titanium surfaces. Biomed Mater. \n\n2014;9(4):045001. \n\n38. Gittens RA, Olivares-Navarrete R, Cheng A, Anderson DM, McLachlan T, Stephan I, \n\net al. The roles of titanium surface micro/nanotopography and wettability on the \n\ndifferential response of human osteoblast lineage cells. Acta Biomater. 2013;9(4):6268-\n\n77. \n\n39. Lian JB, Stein GS, Javed A, van Wijnen AJ, Stein JL, Montecino M, et al. Networks \n\nand hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord. \n\n2006;7(1-2):1-16. \n\n40. Komori T, Kishimoto T. Cbfa1 in bone development. Curr Opin Genet Dev. \n\n1998;8(4):494-9. \n\n41. Hoemann CD, El-Gabalawy H, McKee MD. In vitro osteogenesis assays: influence \n\nof the primary cell source on alkaline phosphatase activity and mineralization. Pathol \n\nBiol (Paris). 2009;57(4):318-23. \n\n42. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling \n\nand toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723-49. \n\n43. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and \n\nbiomineralization. Matrix Biol. 2000;19(7):615-22. \n\n44. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased bone \n\nformation in osteocalcin-deficient mice. Nature. 1996;382(6590):448-52. \n\n45. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, \n\nRANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol. \n\n2006;3(1):41-9. \n\n46. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. \n\n2001;142(12):5050-5. \n\n47. Petri AD, Teixeira LN, Crippa GE, Beloti MM, de Oliveira PT, Rosa AL. Effects of \n\nlow-level laser therapy on human osteoblastic cells grown on titanium. Braz Dent J. \n\n2010;21(6):491-8. \n\n48. Fu YX, Gu JH, Zhang YR, Tong XS, Zhao HY, Yuan Y, et al. Osteoprotegerin \n\ninfluences the bone resorption activity of osteoclasts. Int J Mol Med. 2013;31(6):1411-7. \n\n49. Lalla E, Lamster IB, Drury S, Fu C, Schmidt AM. Hyperglycemia, glycoxidation and \n\nreceptor for advanced glycation endproducts: potential mechanisms underlying diabetic \n\ncomplications, including diabetes-associated periodontitis. Periodontol 2000. \n\n2000;23:50-62. \n\n50. He H, Liu R, Desta T, Leone C, Gerstenfeld LC, Graves DT. Diabetes causes \n\ndecreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of \n\nosteoblastic cells in bacteria stimulated bone loss. Endocrinology. 2004;145(1):447-52. \n\n51. Sarve H, Lindblad J, Borgefors G, Johansson CB. Extracting 3D information on \n\nbone remodeling in the proximity of titanium implants in SRmuCT image volumes. \n\nComput Methods Programs Biomed. 2011;102(1):25-34. \n\n\n\nArtigo 2  |  156 \n\n52. Ajami E, Bell S, Liddell RS, Davies JE. Early bone anchorage to micro- and nano-\n\ntopographically complex implant surfaces in hyperglycemia. Acta Biomater. \n\n2016;39:169-79. \n\n53. Ma XY, Feng YF, Wang TS, Lei W, Li X, Zhou DP, et al. Involvement of FAK-\n\nmediated BMP-2/Smad pathway in mediating osteoblast adhesion and differentiation on \n\nnano-HA/chitosan composite coated titanium implant under diabetic conditions. \n\nBiomater Sci. 2017;6(1):225-38. \n\n54. Jiang H, Ma X, Zhou W, Dong K, Rausch-Fan X, Liu S, et al. The Effects of \n\nHierarchical Micro/Nano-Structured Titanium Surface on Osteoblast Proliferation and \n\nDifferentiation Under Diabetic Conditions. Implant Dent. 2017;26(2):263-9. \n\n55. Schouten C, Meijer GJ, van den Beucken JJ, Spauwen PH, Jansen JA. The \n\nquantitative assessment of peri-implant bone responses using histomorphometry and \n\nmicro-computed tomography. Biomaterials. 2009;30(27):4539-49. \n \n  \n\n\n\nArtigo 2  |  157 \n\nFigures and legends  \n\n \n\n \n\nFigure 1. Blood glucose (mg/dL) of healthy and diabetic groups at surgery day and before \n\neuthanasia.  \n\n \n\n \n\n89,55 92,19\n\n499,88\n544,63\n\n0\n\n100\n\n200\n\n300\n\n400\n\n500\n\n600\n\nSurgery Euthanasia Surgery Euthanasia\n\nHealthy Diabetic\n\nm\ng\n\n/\nd\n\nL\n\nBlood Glucose \n\n\n\nArtigo 2  |  158 \n\n \n\nFigure 2. A-D. Relative gene expression of osteogenic markers: Runx2, Alp, Opn and Oc \n\nwhen all factors were collapsed. Identical letters indicate no significant difference among \n\ngroups.  \n\n \n\n\n\nArtigo 2  |  159 \n\n \n\nFigure 3. A-C. Relative gene expression of osteogenic markers: Rank, Rankl and Opg when \n\nall factors were collapsed. Identical letters indicate no significant difference among groups.  \n\n\n\nArtigo 2  |  160 \n\n \n\nFigure 4. A-C. Runx2, Alp and Opn as a function of implant surface. Identical letters indicate \n\nno significant difference among groups. \n\n \n\n \n\n\n\nArtigo 2  |  161 \n\n \n\nFigure 5. A-D. Microtomography evaluated parameters (BV/TV, BIC, BS/BV and Po.To) \n\nwhen all factors were collapsed. Identical letters indicate no significant difference among \n\ngroups.  \n\n \n\n\n\nArtigo 2  |  162 \n\n \n\nFigure 6. A-C. BV/TV, BIC, BS/BV and Po.To as a function of implant surface. Identical \n\nletters indicate no significant difference among groups. \n\n \n\n\n\nArtigo 2  |  163 \n\n \n\nFigure 7. (A-L). The representative 3D reconstructed images with a focus on the interfacial \n\nbone formation on implants surface of machined (A, D, G, J), DAE (B, E, H, K) and NANO \n\n(C, F, I, L) groups in healthy (A-C and G-I) and diabetic (D-F and J-L) rats at 7 (A-F) and 30 \n\n(G-L) days. From the images, significant bone formation can be observed at the implant \n\ninterface in the NANO group in all time point evaluation and systemic condition."}]}}}